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3PREFACE
Nanotechnology powers enormous resources to impact at various 
field of science and industry. All aspect of involvement of NT is hard 
to cover at the same moment. 
Opportunities of NT often outpace our imaginations and resemble 
science fiction. However even more incredible accomplishment are 
achieved, due to outstanding inventions in physics, chemistry and 
material sciences. From contemporary vision NT represents not only 
single discipline, but outreaches abilities of each fields of S&T and 
overlapped utilities enable NanoS&T more versatile. We should 
distinguish extent of hype, accompanying this novel sphere of 
technology on it’s way of maturation. In the chapter one is revised 
attitudes towards this intriguing discipline and discovered what is 
realistic versus  fanciful.   
Realistic landscape will be uncovered  if we’ll  delve in the search of 
indicators and denominators of  research activities in the field of 
NanoS&T. By proper selection of the exact type for investigational 
method at the starting stage of our research, will give the tool to 
determine the extent of interest into nano innovation. In the chapter 
two then suggested sources to determine “leading indicators” that can 
be helpful and  that might provide early hints of change. To highlight 
the certain type of innovation it is important to choose appropriate 
type of evaluation method. In the case of nanotechnology bibliometric 
and patent application analysis will be helpful, as these are the most 
indicative methods for pursuance the scale of implication of 
nanotechnology in science, technology and industry. 
In the chapter three  are represented some assumptions about 
technology assessment of nanotechnology, as emerging technology, 
to highlight present goals for socio-economic and ethical implications 
of nanotechnology.  
Finally, overview of nano medical applications is presented, focused 
on novel drag delivery systems, which  reside on their inceptive 
stages of development. Most of drugs are at preclinical or starting 
phases of clinical investigations.
4NANOTECHNOLOGY – BRIDGE TO THE FUTURE
• 'Nano" is a term creeping into our vocabulary and our culture 
these days, and it's likely to be one of the buzzwords of the future, 
the way "cyber" was in the '90s.1
•Nanotechnology is widely expected to be one of the most 
important industrial innovations of the 21st century. U.S. Senator 
Ron Wyden, Democrat from Oregon, said, "My own judgment is 
that the nanotechnology revolution has the potential to change the 
world on a scale equal to, if not greater than, the computer 
revolution.
• Nanotechnology is the science of building things or devices at the 
molecular and atomic level - at the nanometer scale, usually 100 
nanometers or less in size. For example, a single data bit might be 
represented by only one atom some time in the future. 
National Nanotechnology Initiative (NNI) 
• The term "nano" refers to the measurement of a nanometer - one 
nanometer equals one thousandth of a micrometer, or one 
millionth of a millimeter, or one billionth of a meter.  
source: CERN http://microcosm.web.cern.ch/microcosm
• Nanotechnology is expected to produce an immense new wave of 
novel products and improved versions of what we have now. 
Scientists envision materials with several times the strength of steel 
but a fraction of its weight. Developments in data storage could 
put nearly all the world's information on a single tiny chip.
A swatch of NanoCare fabric, for example, resists stains and 
liquids because it is layered with billions of microscopic hairs that 
1 Chapman, G., (2005) Nanotechnology looks like the next big thing. Nanotech. 
5act like the fur on a seal. But these hairs are so small that 
NanoCare fabric looks no different than plain cotton. 
•  Nanotechnology is providing a critical bridge between the 
physical sciences and engineering, on the one hand, and modern 
molecular biology on the other. Materials scientists are learning 
the principles of the nanoscale world by studying the behavior of 
biomolecules and biomolecular assemblies. 
In return, engineers are creating a host of nanoscale tools that are 
required to develop the systems biology models of malignancy 
needed to better diagnose, treat, and ultimately prevent cancer. 
Going Small for Big Advances 
Using Nanotechnology to Advance 
Cancer Diagnosis, Prevention 
and Treatment 
U.S. DEPARTMENT OF 
HEALTH AND HUMAN SERVICES 
National Institutes of Health 
National Cancer Institute 
July 2004 
• There should be major advances in medical technology. 
Beyond being used in computers and communications devices, 
nanotechnology could be used extensively in biotechnology to 
build devices, fight disease, and change the properties of 
materials. There should be major advances in medical technology. 
6CHAPTER ONE
FINE LINE BETWEEN REALITY AND SCIENCE FICTION
Science fiction has played a powerful role in creating 
excitement and fascination for nanotechnology in society. It 
envisions fictitious scenarios of both the meritorious and the dark 
side of nanotechnology. The public perception of the power of 
nanotechnology in medicine is still dominated by scenarios 
described in movies and science fiction literature. In the movie 
“Fantastic Voyage” from the 1960s, for example, macroscopic 
design principles were scaled down to the nanoscale to create 
nanobots — nanoscale robots — that travel through the blood 
stream equipped with intelligently controlled arms and sensors. In 
Star Trek, the blind wear goggles that transmit visual images 
directly to the brain; and with the command “Energize” people are 
transported across space, disassembled and reassembled in an 
instant. Robots are often indistinguishable from humans, able to 
rationalize, argue and perform intelligent tasks. And the endless 
dream  of immortality is portrayed by some to become reality once 
society fully exploits its new nanotech toys. In fact, scientists must 
play a vital role in drawing the line between realistic predictions 
and futuristic dreams, to prevent the public podium from remaining 
occupied by scientifically unsubstantiated optimists or worriers 
(Vogel, 2001).
It no longer seems a question of whether nanotechnology 
will become a reality. No one knows how much of 
nanotechnology’s promise will prove out. Technology prediction 
has never been too reliable.  “Nanotechnology is the builder's final 
frontier,” remarked Nobel laureate Richard Smalley (Amato, 
1999).
Richard Smalley, in the introductory part of a public speech 
about his very specific work on the use of carbon nanotubes for 
energy storage, claims: ‘The list of things you could do with such a 
7technology [nanotechnology] reads like much of the Christmas 
Wish List of our civilization’ (Smalley, 1995). 
The prefix “nano” has begun diffusing into popular culture. 
It’s getting into screenplays and scripts for TV shows like the 
Xfiles and Star Trek: The Next Generation. Companies are using it 
in their names. It’s a favorite topic of science fiction writers. For 
many years futurists steeped in the culture of science fiction and 
prone to thinking in time frames that reach decades ahead have 
been dreaming up a fantastic future built using nanotechnologies. 
(Amato, 1999). 
Organization and process professionals like those from 
ITRI and the Institute for Alternative Futures can coordinate 
experts who would typically not relate to each other. Technology 
assessment professionals like those with Coates & Jarratt, Inc. can 
apply time-tested tools to estimate a range of possible 
circumstances and assess the secondary and tertiary effects of 
incremental and radical changes (Smith, 2001). Joe Coates is a 
world-renowned thinker, writer, and speaker on the future. After
leading Coates & Jarratt, Inc. through more than two decades of 
designing and delivering studies on the future of technology, 
business and government. In the course of his pioneering future 
studies, Joe has consulted with 45 of the Fortune 500 companies 
and numerous smaller firms, scores of professional, trade and 
public interest groups, and with all levels of government. 
The history of predictions about the societal and economic 
impacts of promising new technologies is replete with predictions 
that incipient advances will amount to little, only to have them 
substantially transform daily life, and those about major advances 
that subsequently fizzle. Here are some brief examples from The 
Experts Speak, compiled by Cerf and Navasky (1984)2:
2 Cerf, C. and Navasky, V. (1984), The Experts Speak. New York: Pantheon 
Books. 
8Failing to See the Future: 
“When the Paris Exhibition closes, the electric light will 
close with it and no more will be heard of it.” (Erasmus 
Wilson, Oxford University, 1878) 
“I think there is a world market for about five computers.” 
(Attributed to Thomas Watson, 1943) 
“There is no reason for any individual to have a computer 
in their home.” (Ken Olson, 1977) 
Seeing a Future that Wasn’t: 
“(A) few decades hence, energy may be free — just like the 
unmetered air.” (John von Neuman, 1956) 
“(I)t can be taken for granted that before 1980 ships, 
aircraft, locomotives and even automobiles will be 
atomically fueled.” (General David Sarnoff, 1955). 
These quotes point to fundamental difficulties in predicting 
the what, where, when, and how of asserted major scientific and 
technological advances, however carefully and thoughtfully crafted 
the projections (Feller, 2001).
Technology pessimists can probe areas of risk that might 
escape a less vigorous review. Technology optimists from 
organizations like the Foresight Institute can provide insights into 
the kinds of systems that seem to be within the realm of the 
possible if assemblers can be made to work. Public education may 
be needed to balance the views expressed by anti-technology 
writers and press (Smith, 2001). 
NANOVISION THROUGH  THE SOCIETY
Types of  attitudes to nanotechnology among different 
groups of society are dividing in three main groups, which may 
consist several subgroups.
9A least three categories of public presented3 (Wilsdon, J. & 
Willis, R.  2005): 
» NANO-RADICALS see nanotechnology as profoundly 
disruptive of economies and societies. In his 1986 book Engines of 
Creation, Eric Drexler, the so-called “father of nanotechnology”, 
predicted a world in which nanoscale machines – “molecular 
assemblers” - would be capable of arranging atoms to build almost 
anything from the bottom up. Because it would take millions of 
these assemblers to build anything, Drexler argued that assemblers 
would also need to be capable of replicating themselves, hence his 
famous - and now disowned - scenario of self-replicating nanobots 
smothering the world in “grey goo”. 
» NANO-REALISTS emphasize the incremental 
innovations and commercial returns that the technology will 
provide in sectors such as manufacturing, IT and healthcare. They 
aren’t interested in the hypothetical possibilities of bottom-up 
molecular manufacture. Theirs is a venture-capitalized, research-
council approved version of nanotechnology, focused on practical 
applications and economic returns. It is this vision that has excited 
policymakers and unleashed a cascade of government funding 
across the industrialized world.  
» NANO- SKEPTICS count Prince Charles and Michael 
Crichton amongst their number, but their most active and articulate 
representatives are the ETC Group, a small Canadian NGO. It’s 
not grey goo that worries them, so much as the immediate risks 
posed by nanoparticles to human health and the environment. They 
also have some pretty serious questions about who is controlling 
the technology and whose interests it will ultimately serve. 
(Wilsdon, J. & Willis, R.  2005) 
The vision of few intelligent nanometer robots mentioned 
in science fiction literature (for example, the novel Prey by Michel 
3 Wilsdon, J. & Willis, R. (2004). See-Through Science: Why Public 
Engagement Needs to Move Upstream. London: Demos.  
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Crichton) leads to immediate criticism by some groups that are 
concerned that such robots would take over the world and damage 
the environment. This criticism ignores input from researchers who 
note that basic laws of mass and energy conservation may not lead 
to infinitely multiplying material objects, and that only a complex 
systems of presumably already known living systems may be able 
to multiply and be intelligent (Roco, 2003). 4
Nanobots are often on top of the list of nanotechnological 
creations that cause deep concern to the public. Eric Drexler and 
followers postulate that it will soon be possible to create nanoscale, 
addressable robots that have the ability to move in space, recognize 
the environment and self-replicate. Will it indeed be possible to 
create another form of life at the nanoscale? When it comes to the 
engineering of nanoscale machinery, nature is still far superior in 
its ability to integrate synergistically operating nanoscale systems 
of high complexity. Yet, even nature has not been able to engineer 
nanoscale creatures that combine all of the above-mentioned 
attributes of nanobots. Viruses are amazing nanoscale systems, but 
even they do not have the finesse of the hypothetical nanobots. 
Viruses are not capable of self-replication. Future man-made 
nanosystems will certainly be able to perform a variety of 
functions, but a robot that is proficient in all three functions — 
movement in space, recognition of a chemically complex 
environment and self-replication - will remain the fabric of dreams 
(Vogel, 2001). 
NANOTECHNOLOGY INSPIRATION FROM RICHARD FEYNMAN’S
1959 TALK
Usually, though, the credit for inspiring nanotechnology 
goes to a lecture by Richard Phillips Feynman, a brilliant Caltech 
4 Roco M.C. (2003), NNI after three years (2001-2003): Setting  new targets for 
responsible nanotechnology, in the Report of the NNI Workshop. 
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physicist who later won a Nobel Prize for “fundamental work in 
quantum electrodynamics.” (Toumey, 2005).5
 He is best remembered today for his clear and quirky 
classroom lectures and for his critical role on the presidential 
commission that investigated the Challenger accident. On the 
evening of December 29, 1959, Feynman delivered an after-dinner 
lecture at the annual meeting of the American Physical Society; in 
that talk, called “There’s Plenty of Room at the Bottom,” Feynman 
proposed work in a field “in which little has been done, but in 
which an enormous amount can be done in principle.” (Keiper, 
2003).
In his speech he predicted that physicists would eventually 
be able to manipulate matter at the molecular or even atomic scale, 
and would thus usher in a new technological revolution. “It doesn’t 
cost anything for materials, you see. So I want to build a billion 
tiny factories, models of each other, which are manufacturing 
simultaneously, stamping parts, and so on. As we go down in size, 
there are a number of interesting problems that arise. . . . But I am 
not afraid to consider the final question as to whether, ultimately—
in the great future—we can arrange the atoms the way we want; 
the very atoms, all the way down!” (Feynman, 1960). The tools to 
begin to pursue Feynman’s playful predictions started to come on 
line in the coming decades. In 1980, IBM scientists used a 
scanning tunneling microscope to directly image individual atoms 
for the first time  (Binnig & Rohrer 1982). The development of the 
atomic force microscope in the mid 1980s further advanced 
imaging capabilities, and in 1990, again at IBM, scientists actually 
manipulated individual Xenon atoms to write their company logo 
(Eigler & Schweitzer, NSTC,1990; 2000). A giant step had been 
taken toward confirming Feynman’s assertion that it should be 
5 Toumey, C. (2005), Does nanotechnology descend from Richard Feynman’s 
1959 talk? J. Engineering & Science No. 1/2, P.16-23. 
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possible to print the entire Encyclopedia Britannica on the head of 
a pin.6
“What I want to talk about,” Feynman said, “is the problem 
of manipulating and controlling things on a small scale. As soon as 
I mention this, people tell me about miniaturization, and how far it 
has progressed today … But that’s nothing; that’s the most 
primitive, halting step in the direction I intend to discuss.” 
(Feynman, 1960). 
He was talking about nanotechnology before the word 
existed. Feynman regaled his audience with a technological vision 
of extreme miniaturization in 1959, several years before the word 
“chip” became part of the lexicon. Extrapolating from known 
physical laws, Feynman argued it was possible (with, say, an 
electron beam that could form lines in materials) to write all 
25,000 pages of the 1959 edition of the Encyclopedia Britannica in 
an area the size of a pin head! He calculated that a million such 
pinheads would amount to an area of about a 35 page pamphlet. 
Said Feynman: “All of the information which all of mankind has 
ever recorded in books can be carried in a pamphlet in your hand–
and not written in code, but a simple reproduction of the original 
pictures, engravings and everything else on a small scale without 
loss of resolution.” (Amato, 1999). 
Feynman himself didn’t use the word “nanotechnology” in 
his lecture; in fact, the word didn’t exist until 15 years later in 
1974, when Japanese engineer Norio Taniguchi of the Tokyo 
University of Science suggested it to describe technology that 
strives for precision at the level of about one nanometer (Klaes, 
2004 )7. In his lecture, Feynman pointed out several avenues for 
research that would later come to define nanotechnology, such as 
6 Bennett, I. and Sarewitz, D. (2005), Too Little, Too Late?: Research Policies 
on the Societal Implications of Nanotechnology in the United States, 
Consortium for science, Policy, and Outcomes, Arizona State University.  
7 Klaes, L. (2004) What is Nanotechnology? Well, It's Very, Very, Very Small. 
The Ithaca Journal, No 4.  
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making computers much smaller and therefore faster, and making 
“mechanical surgeons” that could travel to trouble spots inside the 
body. Feynman admitted that he didn’t have a clear conception of 
how such tiny machines might be used or created, but to help get 
things going, he offered two prizes: $1,000 to the first person to 
make a working electric motor that was no bigger than one sixty-
fourth of an inch on any side, and another $1,000 to the first person 
to shrink a page of text to 1/25,000 its size—the dimension 
necessary to fit the Encyclopedia Britannica on the head of a pin. 
(He awarded the former prize in 1960, the latter in 1985.) (Keiper, 
2003).
And that’s just how his talk began. He outlined how, with 
proper coding, all the world’s books at the time actually could be 
stored in something the size of a dust speck, with each of the 
million billion bits in those books requiring a mere 100 atoms to 
store. How about building computers using wires, transistors, and 
other components that were that small? “They could make 
judgements,” Feynman predicted. He spoke about using big tools 
to make smaller tools suitable for making yet smaller tools, and so 
on, until researchers had tools sized just right for directly 
manipulating atoms and molecules. (Amato, 1999). 
“And what might that mean?,” asked Feynman. Chemistry 
would become a matter of literally placing atoms one by one in 
exactly the arrangement you want. “Up to now,” he added, “we 
have been content to dig in the ground to find minerals. We heat 
them and we do things on a large scale with them, and we hope to 
get a pure substance with just so much impurity, and so on. But we 
must always accept some atomic arrangement that nature gives 
us...I can hardly doubt that when we have some control of the 
arrangement of things on a small scale we will get an enormously 
greater range of possible properties that substances can have, and 
of different things that we can do.” Repeatedly, during this famous 
lecture, Feynman reminded his audience that he wasn’t joking. “I 
am not inventing anti-gravity, which is possible someday only if 
14
the laws are not what we think,” he said. “I am telling you what 
could be done if the laws are what we think; we are not doing it 
simply because we haven’t yet gotten around to it.” (Feynman, 
1960).
SCIENCE  FICTION AUTHORS IN NANOTECHNOLOGY
Within the genre of science fiction, nano-science fiction is 
certainly one of the most flourishing fields nowadays. An online 
bibliography on Nanotechnology in Science Fiction lists 189 
books, novels and anthologies, published between the mid-1980s 
and November 2003 in the English language only (Napier 2004). 
Milburn has identified many nano-science fiction stories in the 
1940s and 1950s and argues that these stories already inspired 
Richard Feynman's 1959 visionary speech "There is plenty of room 
at the bottom", which later became the posthumous founding myth 
of nanotechnology (Milburn 2002)8. Invisibly small devices or the 
manipulation of the "ultimate building blocks of nature" have been 
a favorite topic ever since the genre of science fiction emerged and 
appear throughout the works of Jules Verne and H.G. Wells. In 
addition, 'manipulating-nature' was the pivotal theme in all the 
19th-century 'mad scientist' stories, which in turn go back to 
medieval and early modern satires of alchemy (Schummer, 2006). 
Thus, the vagueness of nanotechnology definitions is passed on to 
the vagueness of what is nano-science fiction. (Schummer, 2005).9
Although the primary goal of science fiction is 
entertainment, the genre is frequently divided up according to 
different moral messages expressed by optimistic or pessimistic 
prospects of technology for society. Many of the stories that are 
8 Milburn, C.: 2002 ‘Nanotechnology in the Age of Posthuman Engineering: 
Science Fiction as Science’, Configurations, 10, 261-295.
9 Schummer, J. (2005), "Societal and Ethical Implications of  nanotechnology": 
Meanings, Interest Groups, and Social Dynamics, Techné: Journal of the Society 
for Philosophy and Technology, Vol. 8, No 2. 
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today called nano-science fiction, including for instance Neal 
Stephenson's The Diamond Age (1995), also run under the insider 
labels of 'Cyberpunk' and 'Postcyberpunk', depending on whether 
they focus on a radically computerized society or additionally 
employ fictional biotechnology. “Now nanotechnology had made 
nearly anything possible, and so the cultural role in deciding what 
should be done with it had become far more important than 
imaging what could be done with it.” Instead of conveying a 
simple moral message, it is rather up to readers to make their own 
positive or negative judgment on the fictional technology's impacts 
on society. While many readers might feel uncomfortable with 
such visions, Cyberpunk has, as a matter of fact, inspired many, if 
not all, visions of transhumanist utopia. (Schummer, 2005). 
Few nano-science fiction stories directly prompt moral 
questions about technology. An example is Michael Flynn's 
Nanotech Chronicles (1991). There are exceptional cases, 
however, like Michael Crichton's nanotechcatastrophe book Prey
(2002) that employs Drexler's gray goo fiction. In the tradition of 
19th-century mad scientist horror stories, Crichton retells the old 
fable of scientists (here, software engineers) who loose control 
over their work to the extent that they are threatened and finally 
controlled by their own creations. (Schummer, 2005). 
For the majority of nano-science fiction authors, "societal 
and ethical implications of nanotechnology" is an experimental 
field of composing social contexts with visionary technologies 
(mostly computer technology) that more or less radically change 
humans and society, from using new tools to achieving a state of 
transcendence. Apart from making a living and from entertaining 
readers, their major interest seems to be to make readers think 
about general social and moral issues, about the place of 
technology in society, and about radical change, without providing 
simple answers or moral messages. Many have taken visionary 
ideas from SF authors, e.g. on the release of the movie version of 
Michel Crichton’s novel, Prey. (Schummer, 2005). 
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DEALING WITH THE LANDSCAPES OF NANOHYPERBOLE
Nano-radical like K. Eric Drexler, whose 1986 book, 
Engines of Creation, popularized the vivid and exciting 
possibilities of “the coming era of nanotechnology” as his subtitle 
put it (Drexler 1986). Subsequently he institutionalized his 
enthusiasm in the form of the Foresight Institute in Palo Alto, 
California. In his book and elsewhere, Drexler has emphasized one 
form of nanotech more than any other, namely, nano-size 
machines, commonly called nanobots. It is generally agreed that if 
these devices are to be realized, they must be preceded by some 
kind of machines which can reliably manufacture nanobots in very 
large quantities. Thus the controversy that surrounds Drexler’s 
vision is centered not on the desirability of nanobots per se, but 
rather on the feasibility of the process of producing them. 
Extremely nanophilic hyperbole includes excitement about 
nanobots and the assemblers that make them, as anticipated by Eric 
Drexler and his supporters, and it also comprises a pair of 
contradictory theories about the interface of technology with 
human anatomy. One is the expectation that medical 
nanotechnology will cure diseases and repair human anatomy so 
quickly and successfully that the normal human lifespan will be 
extended indefinitely. The other is the hope that all human 
consciousness can be uploaded into machines, thus making human 
anatomy unnecessary. So our bodies can stay healthy for enormous 
lengths of time; but, our bodies are irrelevant to knowledge, 
thought, or spirituality. Extreme nanophilia is also represented in 
some works of science fiction, especially the novels of Kathleen 
Ann Goonan (1994; 1997; 2000). (Toumey, 2004). 10
Nano-realistic approach is characteristic for the U.S. 
government’s optimism, which is much more concerned with 
10 Toumey, C. (2004), Narratives for Nanotech: Anticipating Public Reactions to 
Nanotechnology, Techné 8:2, Narratives for Nanotech, pp. 88-116. 
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immediate and near-future events, especially in materials science, 
medicine, information technology, and other areas in which 
commercial products can be delivered fairly soon. It distances 
itself from Drexler’s agenda of nanobots and assemblers (Roco & 
Bainbridge 2001, p. 14). In 1998, the U.S. government organized 
the Interagency Working Group on Nanotechnology (IWGN). Two 
years later, starting funded at $270 million, president Clinton’s 
Clinton administration gathered its various nanotech projects under 
the umbrella of the National Nanotechnology Initiative (Amato, 
1999).11 In the January 2000 President Clinton’s program speech 
at Caltech unveiled the initiative, saying “Caltech is no stranger to 
the idea of nanotechnology. . . . Over forty years ago, Caltech’s 
own Richard Feynman asked, ‘What would happen if we could 
arrange the atoms, one by one, the way we want them?’ The 
National Nanotechnology Initiative’s brochure reminds us that 
“one of the first to articulate a future rife with nanotechnology was 
Richard Feynman.” (Toumey, 2005). 
 In the detailed blueprint for the NNI, it was said that 
“developments in…(nanotechnology) are likely to change the way 
almost everything - from vaccines to computers to automobile tires 
to objects not yet imagined—is designed and made” (NSTC 2000, 
p. 13). The next major NNI text told us that “The effect of 
nanotechnology on the health, wealth, and standard of living for 
people in this century could be at least as significant as the 
combined influences of microelectronics, medical imaging, 
computer-aided engineering, and man-made polymers developed 
in the past century” (Roco & Bainbridge 2001, p. 2.). 
My next category is that of measured skepticism. This 
genre comes from a group of science writers who recognize that 
important work is being done at the nanoscale, and that this work 
will generate profound consequences for science and society. But 
11 Amato, I. (1999),  Nanotechnology: Shaping The World Atom By Atom, 
National Science & Technology Council, Washington, D.C. 
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they also express disdain, almost contempt, for the hyperbole of 
extreme nanophilia. Scientific American is their principal venue, 
and the epitome of this kind of writing is Gary Stix’s 1996 profile 
of Eric Drexler, wherein Drexler and his followers are comic 
eccentrics (Stix 1996)12. Stix’s next article on nanotech was 
slightly kinder to Drexler, but still found ways to diminish him 
(Stix 2001). When Scientific American reported on carbon 
nanotubes (Minsky 2000) and molecular computing (Reed & Tour 
2000), it found it necessary to suggest that stories of “microscopic 
robots rearranging atoms on command” might be “moonshine.” 
“The hype,” said John Rennie, “outruns the reality” (Rennie 2000). 
The September 2001 special issue on nanotechnology gave Drexler 
a chance to present his vision of nanobots (Drexler 2001), but the 
following article by Richard E. Smalley explained why nanobots 
were preposterous (Smalley 2001). And a facetious opinion piece 
in the same issue by Michael Shermer (Shermer, 2001) ridiculed 
the idea that “nanocryonics” will banish death (Toumey, 2004). 
The genre of measured skepticism  is continued by other 
authors as well. Peter Vettiger & Gerd Binnig clearly aspire to 
create nanoscale computers, but they emphasize how difficult it 
will be do so (Vettiger & Binnig 2003). Adam Keiper writes a 
lucid introduction to nanotech which bifurcates all the talk of a 
“nanotechnology revolution.” On the one hand there are solid 
advances, incrementally achieved by hard-working scientists, and 
on the other there are the vivid fantasies of Drexler and such 
(Keiper 2003). Military applications from nanotech will be 
remarkable, says Jurgen Altmann, but they involve so many risks 
that we need a series of preventive measures to prevent them from 
creating disasters (Altmann, 2004). 
12 Stix, G. (1996), Trends in Nanotechnology: Waiting for Breakthroughs, 
Scientific American, 274(4), 94-99. 
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Measured skepticism final stance is an extreme nanophobic 
counter-hyperbole, approximately as intense as that of the 
visionary nanophiles or nano-radicalism.
The most sustained commentary in this genre comes from 
the ETC Group of Winnipeg, Manitoba, an activist organization 
that during the 1980s and 90s played a central role in opposition to 
genetically modified foods, especially to Monsanto’s “terminator” 
technologies. Following several angry denunciations of the dangers 
of nanotech (ETC Group 2002; 2003a; 2003b), this organization 
called for a moratorium on commercial development of nanotech 
(ETC Group 2003c; 2003d; 2003e; see also Brown 2003), after 
which it published additional denunciations of nanotech (ETC 
Group 2003f; 2003g; see also Thomas 2003). The Big Down, an 
extended polemic on the potential evils of nanotechnology, 
published at the start of this year by an organization called ETC, a 
pressure group based in Canada. The ETC perspective focused on 
a combination of equity issues (who would benefit socially and 
economically from nanotechnology?) and a more traditional risk 
framework (what are the environmental and health risks associated 
with nanotechnology?) (Bennett and  Sarewitz, 2005). 
Lord May, president of the Royal Society and former 
government chief scientist, said that advances in science and 
technology have made life better in both the developed and 
developing worlds. Lifespan have increased, from a global life 
expectancy at birth 50 years ago of 46 years, to 64 years today, he 
said. World food production has doubled over the past 35 years, 
using only 10 per cent more land (Highfield, 2003). 
The Greenpeace report on nanotech (Arnall 2003) relied 
very heavily on the ETC Group’s position papers but, after briefly 
flirting with the idea of a moratorium, it recommended instead a 
balance of industrial self-restraint and government oversight 
(Arnall 2003,40-41). The Chemical Market Reporter expressed a 
sense of alarm in the business community that popular hostility to 
nanotech, regardless whether it had its basis in fact or in fiction, 
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could poison the future of this kind of research (Lerner 2003). The 
dark view of nanotech is also represented in a recent series of 
science fiction films, particularly The Hulk, Agent Cody Banks,
Jason X and Cowboy BeBop. A group of novels, the best known of 
which is Michael Crichton’s Prey (Crichton 2002), present visions 
of a world radically altered for the worse by nanotechnology. (For 
recent commentaries on nano in science fiction, see Collins 2001; 
Hayles 2004; Miksanek 2001; Milburn 2002, Johnston, 2001). 
Another form of dramatic nanophobia comes from Bill Joy (2000; 
2001) and Bill McKibben (2003). This subgenre indicates that 
nanotech is the centerpiece of a so-called convergence of 
technologies which will diminish human nature so much, in 
relation to high-performance machines, that our human qualities 
will become irrelevant: the end of humanity, so to speak. Vicki 
Colvin and others have instigated good questions about nanorisk 
(Rotman 2003; Tenner 2001), while Doug Brown, Barnaby J. 
Feder and Candace Stuart have chronicled these discourses (Brown 
2001; 2002a; 2002b; 2002c; Feder 2003a; 2003b; Stuart 2002; 
2003a; 2003b).
Fears by the Prince of Wales that armies of microscopic 
robots could turn the face of the planet into an uninhabitable 
wasteland have prompted the nation's top scientists and engineers 
to launch an inquiry. Having attacked GM foods in the past, Prince 
Charles has more recently turned his attention to nanotechnology, 
the ability to manipulate matter at scales of billionths of a metre. 
Concerned by claims by environmentalists that swarms of rogue 
"nanomachines" could one day reduce all in their path to "grey 
goo", the prince has asked the Royal Society to help him to weigh 
up the risks. (Highfield, R. 2003).13
13 Highfield, R. (2003), Prince asks scientists to look into 'grey goo', in online 
magazine Telegraph, http://www.telegraph.co.uk/ 
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Table 1. Two opposite (political) visions on nano-bio-info-
cogno technologies (NBIC) convergence (based on Garreau 
2004, Hughes 2004). 
Scenarios -
Political ideology 
Optimistic Pessimistic - 
BioLuddism
Development
technology
Technology develops exponentially 
Determining factor Technology determines history 
(technological determinism)
Outcome
technological
development
Progress Disasters and 
catastrophes
Development
humankind
Human nature is 
‘under construction’ 
Intelligent machines 
(Übermensch) win 
the evolutionary 
struggle with humans 
Technology changes 
the principle 
characteristics of 
human nature 
Humans as a species 
are threatened by 
technology
People and parties Eric Drexler (1986) 
Ray Kurzweil (1999) 
Gregory Stock 
(2002)
Roco & Bainbridge 
(2002(a)) -NSF-
workshop
Transhumanists, such 
as James Hughes 
(2004) and Nick 
Bostrom (2006) 
Bill Joy (2000) 
Francis Fukuyama 
(2002)
Bill McKibben 
(2003)
President´s Council 
on Bioethics (2003) 
Susan Greenfield 
(2003)
ETC Group (2003) 
Martin Rees (2003)
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Lord May at the Cheltenham Festival of Science announced 
that the Society and the Royal Academy of Engineering are to 
launch a study into nanotechnology. But Lord May stressed: 
"There is nothing inherently sinister about nanoscience or 
nanotechnology, it just refers to the study of things on the scale of 
one-millionth of a millimetre." He said the prince should be 
reassured that the "grey goo" scenario, which is raised by various 
sources, notably Michael Crichton's book Prey, is even less likely 
to come true than cloning dinosaurs. "The nightmare scenario of 
self-replicating nanobots destroying everything is about as likely to 
come true as Jurassic Park, another product of Michael Crichton's 
fertile imagination," said Lord May. Compared with the real threat 
from nuclear weapons, Sir Martin said that the "grey goo" scenario 
"might become a concern 50 years from now but is science fiction 
for the moment". (Highfield, 2003). 
Polarizes discussions of nanotech between extreme 
nanophilic and extreme nanophobic hyperbole thereby erases the 
more nuanced ideologies in between. The Economist has noted 
that, unfortunately, common images of nanotech tend to arrange 
themselves into a bipolar division of love-nano-or-hate-nano 
positions (Economist 2002).  
SCIENCE FICTION RATHER THAN REALITY
By sketching extreme future versions the political 
discussion about the present and future of our information society 
gains meaning and new demarcation lines for politics in the 21st 
century appear. On the one side of this new political dimension 
transhumanism (quasi religious organization) sees itself as a 
progressive emancipation movement which fights for the right of 
people to improve themselves (via technology), and which tries to 
enthuse the present-day culture for their utopian vision. On the 
other side, the bioLuddites accept the cultural analysis of the 
transhumanists, but oppose the utopia that they sketch because they 
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experience this as a dystopia. (European Parliament’s Department 
of Economic and Scientific Policy, 2005).14 The popular press has 
often aired heated discussions by the author Ray Kurzweil and 
others about the idea that it will soon be possible to scan the 
human brain and essentially transfer its neural activity to a 
computer designed to simulate billions and billions of human 
neurons (Kurzweil 1999).15 Raymond Kurzweil is the author of 
several books on health, artificial intelligence, transhumanism, 
technological singularity, and futurism. 
This fantastic thought is based on a series of assumptions, 
some of which are reasonable extrapolations of future 
technological abilities. If Moore’s law can be extrapolated, 
computers will achieve the memory capacity and computing speed 
of the human brain by around the year 2020. Computer experts 
claim, it will be possible to simulate the brain and its function and 
eventually the state of the human mind, complete with its 
memories, emotions and creativity (Vogel, 2001). 
Two pioneers in molecular electronics, Mark A. Reed and 
James M. Tour (2000), pose the question: “Will it be possible 
someday to create artificial 'brains' that have intellectual 
capabilities comparable - or even superior - to those of human 
beings?”  - which they answer in a review of their own research as 
follows: ”…scientists have achieved revolutionary advances that 
may very well radically change the future of computing. And 
although the road from here to intelligent machines is still rather 
long and might turn out to have unbridgeable gaps, the fact that 
there is a potential path at all is something of a triumph. The recent 
advances were in molecular-scale electronics…By pushing 
Moore's Law past the limits of the tremendously powerful 
14 European Parliament’s Department of Economic and Scientific Policy (2005), 
Technology Assessment on Converging Technologies, Report of European 
Parliament. 
15 Kurzweil, R. 1999. The Age of Spiritual Machines. Penguin Books. 
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technology we already have, these researchers will take electronics 
into vast, uncharted terrain. If we can get to that region, we will 
almost certainly find some wondrous things - maybe even the 
circuitry that will give rise to our intellectual successor.” 
Bill Joy’s recent article, “Why the Future Doesn’t Need 
Us” in Wired is a widely read example. His article, though 
intriguing, misses a most critical point. Virtually every 
“millennium survey” of the future poses some social, ethical, or 
legal questions about nanotechnology. But there is little so far in 
the way of serious study (Smith, 2001). 
Expanding on scenarios already published by Drexler, as 
well as the ideas of the inventor technological visionary Ray 
Kurzweil (1998), Joy wrote: “robotics, genetic engineering, and 
nanotechnology . . . pose a different threat than the technologies 
that have come before. Specifically, robots, engineered organisms, 
and nanobots share a dangerous amplifying factor: They can self-
replicate. A bomb is blown up only once - but one bot can become 
many, and quickly get out of control.” While Drexler had devoted 
a chapter to the possible dangers of self-replication, he had also 
considered it to be a manageable problem. Joy saw it as 
intrinsically uncontrollable. His solution?: “relinquishment: to 
limit development of the technologies that are too dangerous, by 
limiting our pursuit of certain kinds of knowledge.” Joy’s position 
as one of the chief architects of the world’s high technology 
information infrastructure meant that he could not be dismissed as 
a fringe voice or Luddite. Advocates of the benefits of 
nanotechnology thus sought from the outset to discredit the 
plausibility of Joy’s ideas on either the scientific grounds that self-
replicating “nanobots,” as originally described by Drexler, were 
impossible (e.g., Armstrong, 2001; also see discussion in Sarewitz 
and Woodhouse, 2003), so there was nothing to worry about 
(Bennett and Sarewitz, 2005). 
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PROFESSIONAL FUTURISTS – REALISTIC VISIONARIES
As early as 1990 the popular journal ‘The Futurist’ 
published an article entitled “Nanotechnology and Human Values” 
(Wrubleski, 1991); during the 1990s business magazines such as 
‘Forbes’ and ‘Futures’ also featured occasional coverage of the 
implications of nanotechnology, and academic journals such as 
‘Scientometrics’ and ‘Research Policy’ began to track scientific 
and technical trends (Bennett and Sarewitz, 2005). 
Futurists is a term used to describe management science 
consultants who practice systems thinking to advise private and 
public organizations on diverse global trends, risk management 
and emerging market opportunities. Some countries call these 
interdisciplinary practitioners Futurologists. A key element of all 
management is being able to anticipate what competitors, 
employees and customers are likely to do next, in the context of a 
rapidly changing wider world. Thus it is true that to some extent all 
effective leaders are futurists. All serious futurists have 
demonstrated their professionalism in the field of future studies 
and the application of trends knowledge and insights. 
To meet the challenges of the future, we need to find out 
about what we can plausibly expect in the years ahead so we can 
understand what our options are. We can then set reasonable goals 
and develop effective strategies for achieving them. A key part of 
futuring is managing uncertainty and risk. Every crisis should be a 
reminder to us of the importance of thinking now about the future. 
A crisis almost always results from earlier failures to deal with an 
emerging problem or to anticipate a likely eventuality. In 
retrospect, we often recognize that the crisis was perfectly 
preventable. The importance of thinking ahead is growing rapidly 
because the pace of change is accelerating. New technologies are 
producing a cascade of economic and social changes in our lives 
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and raising serious questions for politicians and ethicists (World 
Future Society, 2002).16
In 1999 the Institute for Global Futures deployed a 
privately funded study to assess the general awareness and 
readiness of the business community regarding the economic and 
business impact of nanotechnology. A series of interviews with a 
broad range of business executives in health care, manufacturing, 
medicine, real estate, information technology, consumer goods, 
entertainment and financial services was conducted, and is still 
being conducted at this time. The Institute for Global Futures, a 
ten-year-old San Francisco organization advises the Fortune 1000 
and government on the impact of leading-edge technology on 
markets, society, customers and the economy. The Institute covers 
telecommunications, robotics, computers, life sciences, the 
Internet, software, artificial intelligence and a host of other 
technologies and forecasts trends.(Canton, J., 2001, Institute for 
Global Futures). 
Governments rely to a considerable extent on technology 
foresight studies in their long-term science and technology policy 
planning. These exercises provide governments with estimates 
about future technological developments and the implications they 
might have for society. Some of these studies also addressed NST. 
We shall have a closer look at them in the following section 
(Meyer.M., 2001, Technopolis Ltd.). 
16 World Future Society, (2002), The Future: An Owner's Manual.  
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SOCIETAL INNOVATION REGARDING NANOINNOVATION
THEORETICAL INTERFACE OF  SOCIO-ECONOMIC IMPLICATIONS 
IN NANOINNOVATION
Nanotechnology, if even partially realized, over the next few 
decades has the potential to realign society, change business and 
affect economics at the structural level. New business models, 
design tools and manufacturing strategies may emerge at price 
points much reduced and highly efficient.  
Nanotechnology will touch all aspects of economics: wages, 
employment, purchasing, pricing, capital, exchange rates, 
currencies, markets, supply and demand. Nanotechnology may 
well drive economic prosperity or at the least be an enabling factor 
in shaping productivity and global competitiveness (Canton, 2001). 
Social scientists and economists should be encouraged to address 
six main research questions, in support of the NanoInitiative 
(Darby and Newlon, 2003). 
¾ First, what policies increase or determine the transfer of 
nanoscale science and engineering knowledge from academe to 
industry? Issues to be examined include licensing intellectual 
property to inventor-affiliated companies under the Bayh-Dole 
Act and concerns about conflict of interest or commitment. 
The issues could be framed in terms of the optimal assignment 
of property rights for university research, developing ideas of 
Aghion and Tirole (1994) and Jensen and Thursby (2001).
 The Bayh-Dole Act is one of the most important 20th century pieces of 
legislation in the field of intellectual property in the US, along with the creation 
in 1982 of the Court of Appeals for the Federal Circuit. Perhaps the most 
important contribution of Bayh-Dole is that it reversed the presumption of title. 
Bayh-Dole permits a university, small business, or non-profit institution to elect 
to retain title first. 
 P. Aghion. J. Tirole. The management of innovation. The  Quarterly Journal of 
Economics, 109,1185-l209 (1994). 
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¾ Second,  what are the returns from nanotechnology 
investment? This question addresses why government should 
be investing in nanotechnology. An interesting alternative 
question is: How much should government and industry invest, 
given a reference rate of return? 
¾ Third research question, with both economic and social 
dimensions, concerns how longer, healthier lives will change 
work patterns. If people are able to work far into their 
seventies, will they and the labor market around them become 
segmented by age? How will the activity of older people be 
distributed across entertainment, paid labor and volunteer 
contributions to the well-being of others? 
¾ Fourth, what skill biases are associated with major 
nanotechnology applications and what do they imply for wages 
and returns to education? 
¾ Fifth, should there be a research exemption for patents? At 
present, there is much debate about the conditions under which 
scientists should have a free license to employ patented 
inventions in non-profit research for example, in their 
instrumentation and other research tools. Traditionally. 
technological inventions can be patented, whereas scientific 
discoveries cannot. Yet, the line between nanotechnology and 
nanoscience is unclear, and the economic benefits of progress 
be diminished if intellectual properly rights prevent rather that 
stimulate innovation. 
¾ Finally, what are the most efficient and effective forms of 
government-industry cooperation? NSI‘s  Grant Opportunities 
for Academic Liaison with Industry (GOALI) and the 
Microelectronics Advanced Research Corporation/Department 
of Defense Focus Center Research Program are examples that 
deserve considerations. 
 R. Jensen, M. Thursby, Proofs and prototypes for sale: The tale of university 
licensing. American Economic Review; 91.240-259 (200l). 
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The research methods that are most likely to result in usable, 
credible answers to these questions are; major data collection 
(firms, products, people); Nanobank.org and studies of NNI grant 
awardees; Center for Economic Studies/Research Data Series: case 
studies (e.g.. industry, cross-cutting tech); surveys (e.g., 
technology transfer job skills, Delphi) economic models, dynamic 
adjustment); and input-output analysis of impact on sectoral 
productivity (Darby & Newlon). 
EMPIRICAL INTERFACE OF  SOCIO-ECONOMIC IMPLICATIONS IN  
NANOINNOVATION
As nanotechnology moves from the theoretical, through the 
empirical, to the practical, as many of us believe it shall do faster 
than is expected, then the possible impact on business, society and 
the economy will become evident over time. But we have a new 
opportunity today. Given the recent history of digital technology 
and access to better models of socio-economic analysis, we must 
 Most NSF (nanoscale science and technology) supported work on the public 
understanding of sciences focuses on attitudes toward science and knowledge 
about science rather than the ends to which science could or should be put. 
Several modes of identifying social needs on which to base justifications for 
advances in S&T have been outlined. These include Foresight and Delphi 
techniques, Charettes in city planning, as well as public discussion models from 
the philosophy of science. The identification of technology goals could also 
process from social science research on human needs, e.g. Maslow’s hierarchy 
of goals. Foresight studies attempt to depict an image of a possible future using 
a variety of  techniques. An important foresight method is the Delphi survey. A 
Delphi survey basically is a tool to create consensus and detect areas of 
conflicting expert opinions. In a first round, experts are confronted with a 
number of topics they have to evaluate with respect to time of realization, 
implication on wealth creation, quality of life, and similar issues. In another 
round the results of the previous round are introduced to the experts who then 
have a chance to re-evaluate the topic.  
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consider growing readiness a social responsibility. We must 
consider readiness as part of our social policy (Canton, 2001).  
1. Nanoscience and nanotechnology provide an excellent 
testbed case to study the speed at which new scientific 
findings are transformed into commercially important 
technological innovations? (Feller, 2001). 
2. Current developments at the frontiers of research in these 
domains also provide a natural experiment to assess 
alternative models (e.g., linear, pipeline models; chain-link 
models; Pasteur’s Quadrants, soccer games) of 
relationships between scientific and technological 
advances. (Feller, 2001).
3. Why is the potential economic impact of nanotechnology 
so important to consider? The risks in not preparing for and 
examining the economic and business impact are too large 
to ignore (Canton, 2001). 
4. There would be a dramatic impact on lifestyles, jobs, and 
economics. Most value chains, supportive linkages, 
alliances and channels of distribution will be altered. 
Institutions of learning, financial services and certainly 
manufacturing will be reshaped. What if the fabrication 
lines for making computers are reduced in costs by 50%? 
What if drug development and manufacturing costs are 
reduced by 70%? What if energy sources were not 
dependent upon fossil fuels? What then might the impact 
be if nanotechnology were applied to real cost reductions 
for essential goods and services that affect quality of life, 
health, habitat and transportation? (Canton, 2001). 
5. We must learn to ask the questions now about how 
nanotechnology may change our choices, affect our 
lifestyles, shape our careers, influence our communities — 
we must ask now and prepare so we may examine the 
implications that may shape the future we will live in 
together. Readiness is always a wise choice. Though one 
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could question at this time, when nanotechnology is still in 
its infancy, largely theoretical, why should anyone care and 
why would we even expect readiness? (Canton, 2001). 
6. Must we interested in readiness and awareness prior to the 
accelerated changes that may lie ahead, not so far ahead as 
we might think? (Canton, 2001). 
7. The issues that remain are to consider in what timeline 
what actions might be taken. How might we prepare as a 
society for these changes? Will there be radical dislocations 
or a smooth coordinated adaptation? (Canton, 2001). 
8. Is there any reason to expect that nanotechnology would 
impact a wide range of industries—creating entirely new 
industries, increasing demand for some goods and lowering 
demand for others? (Darby and Newlon, 2003). 
9. What might the economic impact on the computer industry 
be overnight? (Canton, 2001). 
10. Imagine a super-strong and inexpensive material to be used 
for construction and manufacturing that would eliminate 
the market for steel and plastics. How might that influence 
the economy? (Canton, 2001).  
11. In an era of prosperity it is difficult to consider the lack of 
global leadership that might occur with a nation such as the 
United States. How might the United Kingdom have better 
prepared for its 19th century challenges if it had known 
what was to come at the height of its global leadership in 
the last century? We might well ask the same questions 
today. (Canton, 2001). 
12. If NT would develop in the way it ought, might or not poor 
and sick in the developing world equally benefit  from 
advances in NT? Furthermore, if developing countries were 
to see the potential of NT and became early players in the 
field (China increase expenditure on NT R&D), NT might 
have an impact on their economic development and obviate 
the need quite soon for these countries to become net 
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importers of NT. This is similar to what is happening in 
biotechnology, a field in which countries such as India, 
China, Brazil, and Cuba have already begun to invest in. 
(Maclurcan, 2005). 
APPLICATION INTERFACE  OF SOCIO-ECONOMIC IMPLICATIONS 
IN NANOINNOVATION
In addressing future economic and societal effects, researchers 
need to take a number of different but ultimately complementary 
viewpoints.
One point of view addresses the macroeconomic effects in terms of 
effects of economic growth, productivity, real wages, and the 
standard of living. 
Another industrial organization approach focuses on the particular 
industries that will be most directly affected by nanotechnology 
and attempts to assess how they will be transformed.  
Labor economists take a similar point of departure, but instead 
focus on the movement of labor among industries, the acquisition 
by some workers of new skills, the obsolescence of other skills, 
and the necessary wage signals to accomplish both labor 
movement and training. 
We must plan for multiple scenarios. The value of these scenarios 
may be viewed as a catalyst for mapping future impact on an 
economy and society (Darby and Newlon, 2003). 
1. For each of these viewpoints, the first step is framing the 
“counter-factual question”- what is the effect of the 
nanotechnology we are going to see compared to what 
alternative? (Darby and Newlon, 2003). Nanotechnology 
provides a stimulating and somewhat awesome challenge to 
meet. If we had the knowledge in the 1960s and 1970s to 
prepare for the impact of computers or telecom in the 1990s, 
how might we have prepared the nation? Today we have real-
time examples and a history of rapid accelerated economic 
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change due to new technology to learn from, in preparing for 
the future (Canton, 2001).
2. What might the potential scenarios be, given the contrasting 
readiness factors of a society? Many of the necessary factors 
are in place to drive this scenario: widespread potential cross-
industry applications; fast track R&D; government 
investment (Canton, 2001).  
3. The evolution of a nano-economy, as contrasted with the 
petro-economy of today, is an intriguing idea. How might an 
economy not dependent on oil realign itself? More study will 
be need to be conducted in order to understand and map these 
scenarios. Fundamental nanotechnology innovations yet to 
come will set the timeline for this economic transformation. 
Or, nanotechnology may just become integrated into 
industries such as health care, manufacturing and energy 
much like artificial intelligence became an embedded 
component of new products (Canton, 2001). 
4. A nanotechnology revolution would have implications for 
education and infrastructure. Real wages and the standard of 
living are closely tied to growth in labor productivity 
resulting from both increasing levels of education and from 
innovations. The first  point is that the top scholars and 
doctoral students are the scarce resource around which 
industries will be formed and transformed (Darby and 
Newlon, 2003).
5. Business schools should offer courses to familiarize both 
MBA students and mid-career executives with the basic ideas 
and the potential of nanotechnology. Promote NT education 
in secondary schools and universities. To emphasize that this 
multidisciplinary subject is gaining priority. Schools and 
universities could discuss the issue in depth: as well, could 
include exhibits on NT; Conversely,  there is an important 
niche in facilitating the aspirations of scientists attempting to 
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become or work with entrepreneurs in order to bring their 
discoveries to market (Darby and Newlon, 2003). 
6. In conclusion, the readiness of a nation to prepare for large-
scale socio-economic change is a challenging task. 
Nevertheless, the future wealth of nations, certainly the 
economic sustainability of nations, will be shaped by the 
preparations we make today. Coordinated large-systems 
strategic planning efforts may well shape our ability to adapt. 
Strategically important decisions will need to be made. 
Vastly important national security and economic issues lay 
yet unexamined. Huge cultural issues related to managing 
large-scale change will need to be better understood and 
plans formulated (Canton, 2001).  
ACTION RECOMMENDATIONS
The research questions in theoretical part listed above depicted the 
important role that socio-economic research can play in resolving 
major issues in how much government should invest in nanoscale 
research and how to make those investment have the greatest 
return to the national welfare. 
The accumulated research to date makes a strong and clear case for 
one recommendation that is most important for maximizing the 
benefits from investment in nanoscale science and engineering:
¾ research should be broadly funded primarily based on 
peer-reviewed investigator-initiated proposals: research 
grants, career awards, increased funding, etc; 
¾ benefits of nanoscalɟ science and engineering are so 
broad that funding should not be driven by a few specific 
top-down priorities;
 Nanotechnology is often represented by two fundamentally different 
approaches: ‘top-down’ and ‘bottom-up’. ‘Top-down’ refers to making 
nanoscale structures by machining, templating and lithographic techniques, 
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¾ short-term and long-term priorities should be indicated; 
¾ global opinion-leaders network for socio-economic and 
ethical implications ought to be established so that third 
world countries may be involved (Darby and Newlon, 
2003).
It is too trite to state no one can know the future. The future may 
indeed be unpredictable. But we do know that without asking the 
hard questions, without speculating on the possibilities, without 
preparing the nation by building readiness, we may do ourselves 
a disservice that will be difficult to repair. We might well consider 
the possible futures that will result from our collective actions. 
We must have the courage to speculate on the possible nanotech 
futures we may shape as a nation (Canton, 2001). 
whereas ‘bottom-up’, or molecular nanotechnology, applies to building organic 
and inorganic materials into defined structures, atom-by-atom or molecule-by-
molecule, often by self-assembly or self-organisation. Biologists/chemists are 
involved in the synthesis of inorganic, organic and hybrid nanomaterials for the 
use in nanodevices, the development of novel nanoanalytical techniques, and the 
manipulation of biological molecules such as DNA and the evolution of 
molecular machines. 
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CHAPTER TWO
ESSENTIAL INDICATORS OF R&D EXCELLENCE IN NANOS&T:
PUBLICATIONS AND PATENTS ANALYSIS
NANOTECHNOLOGY PATENTS ON THE INCREASE
Main quantifiable indicators of scientific and technological 
excellence are patents and publications (Hullmann, 2006). 
Statistics produced by Thomson Derwent show that whilst 
there was a sudden rise in journal papers on nanotechnology 
beginning in the mid-1990s, patent applications did not start to 
accelerate until 1998. From that time, however, huge yearly jumps 
have been recorded, from around 500 in 1998 to nearly 1,300 in 
2000. All of which is putting patent offices under strain. Nowhere 
more so than the United States Patent and Trademark Office 
(USPTO), which has to deal with the majority of applications 
(Wild, 2002). 
PATENT APPLICATIONS AS AN INDICATOR OF 
NANOTECHNOLOGY EXCELLENCE 
Patents are generally regarded as output indicator of 
technology development (Schmoch, 1999). They represent 
intellectual property rights and are thus legal documents. A patent 
application has to fulfill various criteria to be granted: 
1) The described invention has to be new on a worldwide 
level.
2) The new product or process must be distinctly different 
compared to the state-of-the art; it must imply an inventive 
step.
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3) The invention has to be exploitable in commercial terms. 
Scientific discoveries without a practical purpose are not 
patentable.
The third criterion implies that most patent applicants are 
industrial companies. This is reinforced by the fact that patent 
applications are expensive so that their issuance is only reasonable 
if a commercial exploitation is aimed at. With North American 
universities increasingly filing patents (mainly as a result of the 
Bayh-Dole Act 1980) in the last two decades, such an approach 
allows the identification of patenting activity of public research 
organizations. However, the situation in Europe is different. A 
recent study of the Organization for Economic Cooperation and 
Development (“OECD”) concludes that public research 
organizations are presently not active patent applicants (Org. for 
Econ. Cooperation & Dev., 2003). Traditionally, the ownership has 
remained in the hands of individual employees (mainly university 
professors). Although several countries, among them Germany and 
Austria, transferred the property rights to the universities by 
modifying their patent law in the last couple of years, until recently 
universities did not frequently file patents. An inventor law, valid 
in the past period, which allowed university professors to exploit 
their intellectual property on their private account; whereas the 
universities did not appear as applicants in the patent documents 
(Heinze, 2004).
An assessment of 2003 figures from the U.S. Patent and 
Trademark Office (USPTO) highlighted the commanding lead held 
by the U.S. in nanoscale science and engineering patenting, with 
42% of the overall share. Germany followed with 15.3%, and 
Japan was placed 3
rd
, with 12.6%. Fast growth was said to be 
occurring in South Korea, the Netherlands, Ireland and China 
(Huang et al, 2003). A report later that year claimed China was 
ranked 3rd in general nanotechnology patents behind the U.S. and 
Japan (Xinhua News Agency, 2003).
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Furthermore, of all the U.S. patent applications in 
nanotechnology, about 90% of the applications came from private 
corporations, while universities filed roughly 7%, and about 3% 
were filed by government agencies and collaborative research 
centers.  The number of issued patents involving nanotechnology 
has increased by more than 600% in the last five year period, from 
370 in 1997 to 2,650 in 2002. While only 2% of all patents issued 
in 2002 involved nanotechnology, that was much higher than the 
0.3% in 1997. Nanotechnology-related patent applications are 
evenly split between process and product inventions. Most of the 
inventions are refinements to known technology, but a significant 
number can be considered "revolutionary" or pioneering in nature 
(Heines, 2003). 
A BIBLIOMETRIC ANALYSIS OF ON-GOING R&D ACTIVITIES IN 
NANOSCIENCE AND TECHNOLOGY
The scientific publications and citations represent scientific 
basis of nanotechnology. Scientific publications are the most 
appropriate indicator for measuring scientific excellence by 
quantifying the output (Hullmann, 2006). 
Heinze (2004) pointed out, that worldwide rise both in 
nanopublications and nanopatents is remarkable. Since the 
discovery and development of the Scanning Tunnel Microscope 
(“STM”) in the early 1980s and later Atomic Force Microscope 
(“ATM”), research on nanoscale phenomena has burgeoned, 
particularly since the early 1990s, only when the expensive STM 
and ATM become available at reasonable prices. The stark 
increase in publications in the year 1991 has continued ever since 
and has led to a lagged but similar development in patenting 
activity. The number of SCI publications (Science Citation Index 
(“SCI”), the world’s largest publication and citation database in the 
natural and medical sciences) in 2002 is six times the number it 
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was 1992. Over the whole 20-year period, an annual growth rate of 
37% in the number of publications.  
The results are consistent with other bibliometric studies on 
nanoscience and nanotechnology published since the late 1990s. In 
the most recent study, however, Meyer (2001) reports far fewer 
worldwide nano patent applications because he used the official 
EPO database instead of DWPI. Derwent World Patents Index 
(“DWPI”) is the database. Searching with DWPI titles and 
abstracts proves to be a major advantage for the proper 
identification of nanotechnology patents. The staff of Thomson 
Derwent prepares new titles and abstracts that describe the 
technological content of each patent application in more detail and 
depth. A search of “nano” with right-hand truncation in DWPI 
titles and abstracts yields about three to four times as many 
documents as a search in official databases of the U.S. Patent and 
Trademark Office or the European Patent Office (Heinze, 2004). 
Figure 1. Evidence from Nanopublications. Source: 
Bonaccorsi and Thoma (2005). 
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Whenever a new product or process emerges, patent offices 
are under pressure to ensure that they understand the parameters 
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within which development work is taking place. It is crucial to be 
able to differentiate between what is already established 
knowledge and what is new when assessing a patent application for 
novelty and non-obviousness. The problem is that when you are 
dealing with something that has not been around for very long, it is 
not easy to find examiners who have experience of working in the 
field or to track down all references to prior art. The risk is that the 
granting of patents can be too broad and give the successful 
applicant a stranglehold on huge areas within the technology, so 
making it far harder for other companies to operate in that field 
(Wild, 2002).  
Nanotechnology first gained recognition after Nobel 
Laureate, Richard Feynman, presented his talk, "There's Plenty of 
Room at the Bottom" to the American Physical Society in 1959 
(Coleman, 2003). 
Heinze et al (2006) had examined the relationships between 
nominated creative researchers (obtained through their expert 
survey and prize winner data bases) and bibliometric assessments 
of highly cited researchers. They found that combining two data 
sources – the nominations of creative research and the databases of 
scientific prizewinners – was complementary and offered 
additional validation, particularly in identifying researchers who 
were recognized for their creativity through multiple nominations 
and prizes. Authors delineated types of scientific research 
creativity: e.g. Invention of novel instruments that opened up new 
search perspectives and research domains, e.g. Scanning tunneling 
microscopy (STM), a powerful research instrument (Hessenbruch 
2004) by physicists Gerd Binnig and Heinrich Rohrer (Binnig & 
Rohrer 1982). Binnig and Rohrer were awardees of the 1986 Nobel 
Prize in Physics “for their design of the scanning tunneling 
microscope”. STM opened up new research avenues in 
semiconductor physics, microelectronics, and surface chemistry. 
Most significantly, STM is recognized as an important tool in the 
emergence of nanotechnology (mid-1980s to present), giving rise 
43
to the promise of assembling materials, structures, and systems at 
atomic and molecular scales. 
Donald Eigler of IBM’s Alden Research Center remembers 
the day in 1990 when he and Erhard K. Schweitzer, who was 
visiting from the Fritz-Haber Institute in Berlin, moved individual 
atoms for the first time. Using one of the most precise measuring 
and manipulating tools the world had ever seen, the researchers 
slowly finessed thirty-five xenon atoms to spell out the three-letter 
IBM logo atop a crystal of nickel. To be sure, it only worked in a 
vacuum chamber kept at a temperature that makes the North Pole 
seem tropical (Sarewitz and Woodhouse, 2003). 
In 1988, Eric Drexler taught the first course on 
NanoTechnology. In that  program, he suggested the possibility of 
nanosized objects that were self-replicating. The next major 
milestone was when Rice University Professor Richard Smalley 
won the 1996 Nobel Prize for discovering a new form of carbon: a 
molecule of sixty carbon atoms (referred to as C60).Today C60 has 
become one of a growing number of building blocks for a new 
class of nanosized materials. The advancements in 
NanoTechnology really began to accelerate in the late 1990s 
(Coleman, 2003). 
NANOSCIENCE AND NANOTECHNOLOGY LINKAGES
Nanoscience and nanotechnology provide an excellent 
testbed case to study increasingly commonplace statements about 
the blurring of distinctions between science and technology and the 
speed at which new scientific findings are transformed into 
commercially important technological innovations. Current 
developments at the frontiers of research in these domains also 
provide a natural experiment to assess alternative models (e.g., 
linear, pipeline models; chain-link models; Pasteur’s Quadrants, 
soccer games) of relationships between scientific and technological 
advances (Feller, 2001). 
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Mehta, M. D. (2002). denotes that developments in 
nanoscience and nanotechnology will provide social scientists with 
a unique opportunity to examine how different models of 
innovation may explain how the knowledge-based economy is 
being shaped by radically new approaches to science. Nanoscience 
and developments in nanotechnology are expensive and require 
cooperation between universities, governments and industry. Not 
too long ago, the linear model of innovation dominated.  
Traditionally, knowledge transfer within innovation processes is 
considered a one-way flow of scientific or technological 
knowledge from academic research (university) to industrial 
development. Several other actors play important roles in 
innovation processes, such as government (Leydesdorff & 
Etzkowitz, 1996), investors (Coehoorn, 1995), and end users 
(Bobrowski, 2000;  Bunders, Broerse, & Zweekhorst, 1999; von 
Hippel, (1988); Kline and Rosenberg, (1986)), criticized the linear 
model and launched the so-called chain-linked model of
innovation processes. In this model, the “central chain of 
innovation” begins with design and moves toward development 
and production to marketing. Each step is linked together via 
feedback loops and all are side-linked to research. It is assumed 
that scientific research is not a source of inventive ideas but is used 
to solve problems along the chain of innovation.  
Stokes (1997) introduced an alternative innovation model 
in his book Pasteur’s Quadrant. This model rejects the traditional 
distinction made between basic and applied research. Stokes 
outlines how basic science could be oriented toward improving 
simultaneously an understanding of fundamental principles and 
stimulating improvements in technology by formalizing the links 
between science and technology. Another innovation model is the 
“triple helix” of Leydesdorff (2000) and Leydesdorff and 
Etzkowitz (1996). This model focuses on the overlay of 
communications and interactions between the three institutional 
spheres (three helices) of industry, university and government.
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Each sphere produces its own knowledge, engages in marketplace 
activity and attempts to control external influences. Through 
information exchange and shared expertise, internal 
transformations in each of the helices facilitate the generation of 
new ideas and stimulate innovation.  
The last type of innovation model the author of this article 
would like to mention is called “national systems of innovation”
(Niosi, 2000) and has been defined by Lundvall (1992) as “the 
elements and relationships which interact in the production, 
diffusion and use of new, and economically useful, knowledge 
either located within or rooted inside the borders of a nation state”. 
Such a system creates, stores and transfers information, 
knowledge, skills and artifacts related to technologies and 
innovations. Although scholars and policymakers apply different 
definitions and perspectives to this concept, in general the basic 
premise is that understanding the linkages between actors involved 
in innovation is central to improving technology performance 
(Organization for Economic Cooperation and Development, 1996).  
Understanding the roles and relations between academia, 
government, and industry could be the basis for assessing and 
anticipating the likely trajectories of technology-induced social 
change and help answer the following question: What model or 
models of innovation best explain the changes being ushered in by 
the revolution in nanotechnology?
Darby, M. R. and Newlon, D. H., (2003) stated several 
research and evaluation methodologies which are encouraged 
economists to address several main research questions, in support 
of the National Nanotechnology Initiative. One question is, what
policies increase or determine the transfer of nanoscale science and 
engineering knowledge from academe to industry? Issues to be 
examined include licensing intellectual property to inventor-
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affiliated companies under the Bayh-Dole Act18 and concerns 
about conflict of interest or commitment. The issues could be 
framed in terms of the optimal assignment of property rights for 
university research, developing ideas of Aghion and Tirole (1994) 
and Jensen and Thursby (2001).
Other issue is, should there be a research exemption for 
patents? At present, there is much debate about the conditions 
under which scientists should have a free license to employ 
patented inventions in non-profit research for example, in their 
instrumentation and other research tools. Traditionally. 
technological inventions can be patented, whereas scientific 
discoveries cannot. Yet, the line between nanotechnology and 
nanoscience is unclear, and the economic benefits of progress be 
diminished if intellectual properly rights prevent rather that 
stimulate innovation. The fear lies where potentially devastating 
effects of being excluded from a market because of a rival's over-
broad patent means extra expense for companies who could do 
without it. It is not cheap to challenge an examiner's decision 
within the USPTO, let alone through the courts, whilst delays in 
obtaining protection could make the difference between securing 
funding and going out of business. When Todd Dickinson former 
Commissioner of the USPTO was made aware of difficulties in 
handling business method patent applications, he undertook a 
period of extensive consultation with industry. As a result new 
examination guidelines were drawn up. Companies and investors, 
who are pouring billions of dollars into the nascent 
nanotechnology industry, are expectant of a similar approach 
(Wild, 2002). 
18
The Bayh-Dole Act is one of the most important 20th century pieces of 
legislation in the field of intellectual property in the US, along with the creation 
in 1982 of the Court of Appeals for the Federal Circuit. Perhaps the most 
important contribution of Bayh-Dole is that it reversed the presumption of title. 
Bayh-Dole permits a university, small business, or non-profit institution to elect 
to retain title first. 
47
BAYH-DOLE’S ACT IMPLIED DUTY TO COMMERCIALIZE 
The Bayh-Dole Act can be seen to impose a duty on the 
part of all researchers who contract with the government, referred 
to as grantees or contractors, to pursue the commercialization of 
government-funded scientific inventions. Recognizing an implied 
duty to commercialize under Bayh-Dole begins with the Act’s 
enumerated objectives, contained in Section 200. Directly 
implicating utilization of the patent system for the purpose of 
effectuating its goals, Congress identifies seven objectives which 
form the basis of its policy promoting commercialization, three of 
which are of particular importance in outlining a duty to 
commercialize. The first of these relevant objectives, “to promote 
the utilization of inventions arising from federally-supported 
research or development,” indicates the intent of Congress to 
ensure that promising research results are put to productive use. 
The second objective, “to protect the public against nonuse 
or unreasonable use of inventions,” supports the first objective and 
further demonstrates Congress’s intent to ensure that publicly-
funded inventions reach the public. Furthermore, it reflects the 
government’s right to enforce the commercialization provisions of 
Bayh-Dole.  The third key objective, “to promote collaboration 
between commercial concerns and nonprofit organizations, 
including universities,” explicitly partners academia and industry, 
providing a pathway for academic interests to comply with the 
Act’s duty and ultimately effectuate the Act’s goals. (Henderson et 
al 2002). 
CATEGORIZATION  OF NANOTECHNOLOGY ACTIVITY AT  
MULTINATIONAL LEVELS
Denominating national engagement in NanoS&T 
development by means of assessment of country participation in 
innovation, Barker et al. suggest that “most government 
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investments are aimed at improving national corporate 
competitiveness in nanotechnology”. Roco believes some 
governments are focussing efforts towards nanotechnology 
because they have recognised lost opportunities at the dawn of 
earlier technologies such as the Human Genome Project, ICT and 
biotechnology.
Whilst global government spending on nanotechnology is 
relatively evenly split between North America (inclusive of Canada)
($1.6 billion), Asia ($1.6 billion) and Europe ($1.3 billion) 
(President’s Council of Advisors on S&T, 2005). 
Categorization of general level on NT activity of the 
country is performed according to the degree of government 
support for NT, as well as on level of industry involvement and the 
amount of internet accessible  NT research from academic 
institutions and research groups (Court et al 2004). 
Category Requirements To Fulfil The Category 
National
Activities or 
Funding
Either: 
1. A national strategy for nanotechnology; 
2. Nationally co-ordinated nanotechnology 
activities; 
Table 1. Denomination by categorization of country 
activity in NanoS&T. 
3. Government funding for nanotechnology 
research 
Individual or 
Group Research 
Project
At least one individual or group currently 
conducting work identified as 
‘nanotechnology research’ 
Country Interest 
An expression of interest from country 
governments,  representatives or delegates 
The Lux Research data included U.S. State funding in the 
total for North America and incorporated figures from associated 
and acceding EU countries in the European estimate. The 
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remaining governments, not covered above, contributed $133 
million.  Funding among nations varies greatly. In Russian 
Federation 2007 year was nominated under the hallmark of 
nanotechnology innovation. 20 billion is spent each year. By the 
year 2015 is launched federal program for the development of 
nano-industry. For example, whilst both the U.S. and Thailand 
have national nanotechnology programs, established in 2000 and 
2003, respectively, Thailand’s program receives approximately $2 
million per year (Changsorn, 2004) compared with 2005 annual 
funding for the U.S. National Nanotechnology Initiative (NNI), set 
at $982 million (Office of S&T Policy, Executive Office of the 
President, 2005).  At 25th of November 2006 Arab News reports, 
that the King of Saudi Arabia is putting the equivalent of about 
US$9.6 million into nanotechnology at Saudi universities. 
U.S. CURRENTLY LEADS THE WORLD IN GOVERNMENT R&D 
INVESTMENT, WITH A LITTLE OVER 25% OF THE TOTAL19
National Nanotechnology Initiative supported by U.S. 
government holds Worldwide Leadership in Nanotechnology 
Research. At the White House, at the 3rd of December, 2003, the 
President George W. Bush signed into law the “21st Century 
Nanotechnology Research and Development Act”. This legislation 
puts into law programs and activities supported by the National 
Nanotechnology Initiative (NNI), one of the President's highest 
multi-agency R&D priorities. The Act aims to cement U.S. 
economic and technical leadership by assuring stable, long-term 
support for nanotechnology research.
The U.S. is the world leader in generating knowledge and 
performing creative interdisciplinary research. 
19 Source: Jim Murday. NanoBusibess Aliance Analysis, in “Nanotechnology 
and Energy. Be a Scientist –Save the World!” by Adams, W., Jaffe, A., Smalley, 
R. (2005). In memoriam of R. Smalley. 
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Funding for the National Nanotechnology R&D 
Program is one of the Administration's top multi-agency 
priorities.
The National Nanotechnology R&D Program involves 10 
federal agencies and continues to be a high priority of both the 
Administration and the Science Committee. Between FY 2001 and 
FY 2005, spending on federal nanotechnology R&D more than 
doubled, rising from $464 million in FY01 to $982 million in 
FY05. The FY06 budget requests an estimated $1.05 billion for the 
program in FY06, an decrease of $27 million, or 2.5 percent, over 
the estimated FY05 level. Requested funding for the five agencies 
authorized in the 21st Century Nanotechnology Research and 
Development Act (P.L. 108-153) is $665 million, and remains 
significantly below the $890 million authorized for these agencies 
for FY06 in the Act.  
Nanotechnology promises to be both evolutionary and 
revolutionary-improving and creating entirely new products and 
processes in areas from electronics to health care.  Nanotechnology 
can help provide clean energy. Nanotechnology is expected to have 
a broad and fundamental impact on many sectors of the economy, 
leading to new products, new businesses, new jobs, and even new 
industries (Rejeski, 2006). 
Figure 2. Share of Global Investment in NanoS&T by 
Leading Countries. 
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Lux Research, Inc., expects sales of products that 
incorporate emerging nanotechnology to rise from less than 0.1% 
of global manufacturing output today to 15% in 2014, for a total of 
$2.6 trillion annually - a value that approaches the size of the 
information technology and telecom industries combined and is 10 
times larger than biotechnology revenues.  
Figure  3. More good newa: U.S. corporate investment is 
significant  ($ Billions).
THE SIXTH FRAMEWORK PROGRAMME OF THE EUROPEAN 
COMMISSION
Nanotechnology initially was the priority of material 
sciences and began it’s start-up mainly in materials production 
industry. Nanotechnology is providing a critical bridge between 
the physical sciences and engineering, on the one hand, and 
modern molecular biology on the other. Materials scientists are 
learning the principles of the nanoscale world by studying the 
behavior of biomolecules and biomolecular assemblies. In return, 
engineers are creating a host of nanoscale tools that are required to 
develop the systems biology models of malignancy needed to 
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better diagnose, treat, and ultimately prevent cancer (NIH 
Publication, 2004).
The Sixth Framework Programme of European Community 
predominantly covers  activities in the field of NT research, 
technological development and demonstration (RTD) for the 
period 2002 to 2006. The data collected are gathered in a 
knowledge database, which gives the possibility to obtain specific 
technology roadmaps depending from the branches and the 
industrial applications. The results have been published in different 
reports, one of them is “European survey on success factors, 
barriers and needs for the industrial uptake of nanomaterials in 
SMEs” (Small and Medium Sized Enterprises survey). SMEs 
account for around two-thirds of employment in Europe, it is 
evident that more effort is needed to encourage the creation of new 
and innovative enterprises (Commission of the European 
Communities, 2004). 
Figure 4. Sector specific distribution of application field of 
companies’ products. 
In order to remain competitive on these markets, companies 
have to integrate these new results in their commercial vision for 
future products. Within the survey the situation for companies 
working in the branches medical & health, energy, automotive and 
aeronautics has been examined in detail. 39% of the enterprises 
(not mainly pharmaceutical)  specified “Medical & Health” as 
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main application field of their products and/or parallel  among their 
basic productions. 
HEALTH-RELATED NANOTECHNOLOGY PATENT ACTIVITY AND 
RELEVANCE OF INDUSTRIAL IMPLICATION
The U.S. National Institutes of Health counts nanomedicine 
as one of its top five priorities, the National Cancer Institute 
committed $144 million to nanotechnology research in October 
2004. Yet major pharmaceutical companies are committing almost 
no money or people to nanotechnology research – exposing them 
to strategic risks (Lux Research, 2005). 
Between 1996 and 2001 among all of NT patents medical 
applications were filed most often, both in United States and 
Europe according to comparison of nanopublications and 
nanopatents, seems that specialization in pharmaceutics tends to be 
reflected in a relatively high share of patents for medical purposes 
(Heinze, 2004).
However, as of mid-2006, 130 nanotech-based drugs and 
delivery systems and 125 devices or diagnostic tests are in 
preclinical, clinical or commercial development. The combined 
market for nanoenabled medicine (drug delivery, therapeutics and 
diagnostics) will jump from just over $1 billion in 2005 to almost 
$10 billion in 2010 and the US National Science Foundation 
predicts that nanotechnology will produce half of the 
pharmaceutical industry product line by 2015. Nanomedicine will 
help big pharma extend its exclusive monopoly patents on existing 
drug compounds and on older, under-performing drugs. Analysts 
suggest that nanotech-enabled medicine will increase profitability 
and discourage competition. (The ETC Group, 2006)  
Despite the promise of nanotechnology, experts of Lux 
Research, Inc., mention, that the big pharmaceutical companies are 
'flat-footed' in their nanotech initiatives, while medical device 
firms are more advanced in their race to develop nanotechnologies, 
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with major players such as Baxter International Inc., Medtronic 
Inc., and Guidant Corporation all pursuing nanobiotech R&D," 
says Lynn Yoffee, associate publisher of NanoBiotech News, 
which produced the 2005 Nanomedicine, Device & Diagnostic 
Report.
It is tentative for belief, that transfer from S&T sector to 
industry is somehow  delayed. When matching performed for 
revealing confluence of publications and patents, in order to reflect 
flow rate of science to technology, Meyer observed, that 
knowledge transfer from science to technology is most prominent 
within the academic sector, rather than from academe to industry 
(Meyer, 2001). 
Coleman (2003) brings suggestions, that medical and 
healthcare sectors takes only 
8% in whole nanotechnology 
industry (Fig. 5.). Opposite 
data are proposed  according 
to US National 
Nanotechnology Initiative 
report nanotechnology 
involvement by 20% of 
companies focused on 
medical applications.    
It’s noteworthy to mention the case study (Borreguaro et al, 
1994) from marketing manual, which is depicted, that one of the 
Hispanic homeland medium-sized textile enterprise “Industrias 
Beltran”  was considered as market leader with ownership of only 
7% share of total textile market in the country. The total market 
share of materials’ production and informational technologies are 
much more prevailing, compared with medical & healthcare 
industrial market in general. So even in case of merely 8% 
involvement for NT investment in medical & healthcare sector 
could be accepted as substantial impact for advance in innovative 
technology implication. 
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“Nanotech presents many opportunities to pharmaceutical 
giants, ranging from better delivery of existing drugs to entirely 
new therapies based on nanomaterials,” said Lux Research Vice 
President of Research Matthew M. Nordan. “But big pharma is not 
investing in nanotech 
today. If this trend 
continues, nanotech 
will play out in 
pharmaceuticals just 
as biotechnology did, 
with major 
pharmaceutical 
companies leaving 
money on the table 
and allowing new 
competitors to take root.” Lux Research bases its conclusions on 
in-depth interviews conducted with individuals accountable for 
nanotechnology at 33 global corporations with annual revenues 
exceeding $5 billion. The interview data reveals that: 
- No life sciences interviewee rates NT as a high corporate 
priority, as opposed to 78% of interviewees in electronics and 
materials;  
- Only one out of six life sciences respondents claims to 
have an explicit strategy for nanotechnology, compared with two-
thirds of those in other electronics and materials; 
- Big pharma companies on average commit 16 people and 
less than half of one percent of R&D spending to nanotechnology 
research, whereas like-sized electronics and materials firms 
commit more than 100 people and more than 8% of R&D. 
Lux Research’s analysis finds that large drug 
manufacturers pay little attention to nanotechnology for three 
reasons: organization, history, and hubris. First, big pharma 
companies typically entrust accountability for nanotechnology to 
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an executive responsible for drug discovery, pharma’s biggest cost 
driver – but nanotech’s big near-term impact is in drug delivery. 
Second, big pharma companies learned during the biotech 
revolution that they could avoid their own investment and instead 
in-license drugs from start-ups at a late stage – but greater pressure 
on big pharma’s drug pipelines today gives nanotech start-ups a 
negotiating advantage. Finally, many big pharma executives claim 
they’ve been “doing nanotech” for years by developing small-
molecule drugs or engineering proteins – however, few can claim 
the materials science expertise that truly novel nanotech 
innovations depend on. Pharmaceutical companies’ laissez-faire 
attitude towards nanotech will have consequences. “Big pharma 
will have to contend with a new wave of superbranded generics 
that will erode market share. This trend began with the approval of 
American Pharmaceutical Partners’ nano-enabled ABRAXANE 
cancer therapy this February, 2005” said Nordan. “On the other 
hand, opportunity exists for a forward-thinking drug manufacturer 
to go on the offensive and acquire competitive capabilities by 
picking up a nanoscale reformulation specialist, as mid-cap pharma 
manufacturer Elan and medical devices leader Baxter already 
have.” Even with big pharma companies largely sitting on the 
sidelines, start-up companies are surviving and even thriving and 
new start-ups emerging nearly every month (Powers, 2006). 
Welland challenges the contemporary belief that drug research has 
to be capital intensive, claiming that pocket-sized, drug factories 
“could theoretically end the control of large companies over 
manufacturing” (Mantell, 2003).  
PATENT PROTECTION BECOMES INCREASINGLY CRITICAL FOR 
INVESTMENT
Successful researchers are frequently turning into 
entrepreneurs by launching start-up companies. Out of the 
hundreds of such companies founded in recent years, one-half are 
57
located in the USA compared with one-quarter in the EU (De 
Francesco, 2003).
"For start-ups especially patents are absolutely critical," 
says Leon Radomsky, a patent attorney with US law firm Foley & 
Lardner. "Their assets are based on their intellectual property and 
this is what they are selling to the venture capitalists (VCs) and to 
the larger companies when they are planning their exit routes." He 
says that for investors, who were hit badly by the dotcom 
meltdown, patents covering technologies with applications in 
potentially huge markets are just the kind of tangible asset they are 
looking for. And companies clearly realize this. According to the 
2001 Business of Nanotechnology Survey, the smaller nanotech 
businesses are attracting record levels of venture capital interest 
with 53 funds in the US now actively investing in the sector. For 
2002, the total amount invested by venture and private equity is 
forecast to come in at $1 billion, with a growth rate of 20% per 
year for both 2003 and 2004 as technologies and products begin to 
have an impact in various market places. Between them, the three 
strands of the nanotech revolution are expected to spend $2 billion 
to $3 billion on research and development over the next 12 months. 
And as more and more money is poured into R&D activities, so the 
importance of patents is on the increase.   
Banks and venture capitalists are very selective when 
offering risk capital, in particular, for areas that are perceived by 
them to have a high technical risk, uncertain time-to-market, or 
could have negative ethical, health or environmental consequences. 
Patents are normally needed to prove ownership of the knowledge 
and new entrepreneurs need not only to be at the forefront of 
nanotechnology but to combine this with management and 
business strategy acumen. New entrepreneurs often complain that 
they are offered credit (instead of risk capital) and that they receive 
no support in management - this increases their exposure and 
perception of risk. Despite technological success, start-ups may fail 
due to lack of financial breakeven – the so-called “death valley”. 
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This problem can be acute for nanotechnology, where the R&D 
process necessitates a long-term commitment. In this context, the 
European Investment Bank (EIB) can play an important role in 
providing loans and strengthening the capital base for 
nanotechnology enterprises (Commission of the European 
Communities, 2004). 
FOCUSED RECOMMENDATIONS FOR NT COMMERCIALIZATION
National Science Foundation (NSF) predicts that the world 
market for goods and services using nanotechnologies will grow to 
$1 trillion by 2015. Lux Research calculates that in 2004 there was 
$13 billion worth of products in the global marketplace 
incorporating nanotechnology (Lux Research, 2004). Worldwide 
about $9 billion annually is being spent by governments and the 
private sector on nanotechnology research and development.  Any 
government program, policy, or strategy must work for our small 
businesses; they are the heart of the nanotech revolution and will 
remain so into the foreseeable future. According to the 2003 Small 
Tech CensusTM research, nearly 72% of 300,000 manufacturing 
entities in the United States have less than 20 employees and 92% 
of manufacturing companies have less than 100 employees.
Additionally, the Small Business Administration estimates that 
there were approximately 22.9 million small businesses in the U.S. 
in 2002 and that small businesses provide approximately 75% of 
the net new jobs added to the economy, represent 99.7% of all 
employers, and represent 97% of all U.S. exporters (Small 
Business Administration 2006). 
Nanotechnology is no longer just a large government 
science research project. In the long run, key social and economic 
benefits will only occur if we succeed in bringing innovations to 
 http://www.luxcapital.com/nanotech_report_b.htm (June 30, 2004). 
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market. To do that, we need to place new people, resources, and 
ideas behind an expanded national nanotechnology initiative.
NANO T&S PATENT OWNERSHIP BY MEDICAL & HEALTHCARE 
SECTOR
With respect to medical-healthcare sectoral ownership, 
77% of patents are held privately, 16% by universities, 5% by 
government and 2% by independent, not-for-profit organizations. 
The U.S. remains the leader in terms of the shear number (75%) of 
nano-based medical products in development, and of the 25% of 
drug and device candidates being developed outside of the U.S., 
Canada, Australia and Israel are working on 43% of the total 63 
drugs and devices in the works around the world. 
Table 2. Distribution of health-related nanotechnology patent 
activity by sectors for 2004. Source: Maclurcan, D.,C. (2005). 
Sector Share (%) 
Private
Company 
Individual
54
23
University 16
Government 5
Independent, Not-For-Profit 2
U.S. government added financial muscle to nanobiotech 
development in 2005, with major capital infusions through the 
National Cancer Institute’s Alliance for Nanotechnology in Cancer 
and the National Institutes of Health’s Program of Excellence in 
Nanotechnology.
Nanomedicine started out with a bang in 2005, with the 
U.S. Food and Drug Administration’s (FDA) approval of 
ABRAXANE in February, considered a seminal event by industry 
experts. And experts predict 2006 will be another good year for 
nanomedicine. In fact, this year may bring several new nano-based 
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drug approvals and the continued rapid evolution of tools and 
enabling technologies that are propelling the development of 
drugs, delivery vehicles, diagnostics, and medical devices. 
According to data compiled by NarwBiotech News in the 2006 
Nanomedicine, Device & Diagnostic Report, more than 130 nano-
based drugs and delivery systems and 125 devices or diagnostic 
tests have entered preclinical, clinical, or commercial development  
- up from 61 drugs and 91 devices and diagnostics the previous 
year, meaning the clinical pipeline has grown 68% since last year 
at this time (Powers, 2006). 
CONCLUSIONS  
1. Activity in nanoscience is determined by increase of 
publications and patent applications. So patent submission data and 
bibliometric analysis are the most useful investigational tools for 
assessing global engagement with nanotechnology. 
2. Identifying research creativity by means of counting top 
scientists, who are prize winners and owners of awards, gained for 
high level NT discoveries. 
3. Flexible and smart interaction and collaboration within 
Academia-Industry-Government nexus is essential contributor for 
faster advance in NanoS&T developments.  
4. One of the marker and indicator of strength in NT development 
of the country is government’s involvement in investment.  
5. The U.S. is the world leader in generating knowledge and 
performing creative interdisciplinary NanoS&T researches.  
6. However both in United States and Europe according to 
comparison of nanopublications and nanopatents, pharmaceutics 
tends to be reflected in a relatively high share of patents for 
medical purposes, medical and healthcare sector takes less than IT 
in whole nanotechnology industry. 
7. In medical-healthcare sector 77% of patents are held privately, 
16% by universities, 5% by government, and 2% by independent 
not-for-profit organizations . 
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8. Advancement of NT involvements in pharmaceutical industry is 
more expected to be promoted by privately held small and medium 
sized companies rather, then by government. So focus group for 
implementation of strategic plan for new drug promotion  will be 
private sector.
9. It’s essential to raise stakeholders interest in emerging and fast 
racing field of NT, convincing them to make steps for NT 
commercialization  of their companies’ propriety products.  
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CHAPTER THREE
SOCIAL SCIENCE RESEARCH METHODS FOR TECHNOLOGY 
ASSESSMENT IMPLICATING  SOCIETAL DIMENSIONS OF 
NANOS&T
INTRODUCTION
Research into nanotechnology’s impact on any societal 
implication, as ethical, environmental, economic, legal aspects, 
must try to keep pace with the technological progress that has been 
made. Otherwise, the technological progress will slow down 
(Mnyusiwalla et al, 2003). This will be one of the first times in 
history that social scientists have such a participatory role in 
nanotechnology’s development. Research methods in the 
economic, social, and behavior science will allow social sciences 
to evaluate nanotechnology developments, as well as government 
funding for research provides input toward the improvement of 
potential applications. To have such a role, social scientists need to 
proceed beyond the data in econometric studies in order to get 
inside the research and development processes as they occur. The 
techniques of interpretive social research (e.g. interviews and focus 
groups), as well as original data collection with surveys will 
enhance our ability to understand societal and economic effects 
much more than archival data (Mihail Roco and Marie Thursby, 
2003)20.
Technology and society evolve together. Nuclear weapons 
joined with U.S. and Soviet hegemonies to constitute a prime 
determinant of geopolitical evolution after World War II. Cars, 
television, air conditioning, and birth control likewise arose in 
20
Ten Research and Policy Themes, in the report of NNI workshop: 
‘Nanotechnology – Societal Implications – Maximizing Benefits for Humanity. 
Edited by Roco, M.C., Bainbridge W. S.  
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particular social contexts and contributed to the remaking of 
everyday life  (Daniel Sarewitz and Edward Woodhouse, 2003). 
No one can fully understand the long-term implications of 
such advances, emerging under the heading of nanotechnology - 
“the art and science of building complex, practical devices with 
atomic precision,” with components measured in nanometers, 
billionths of a meter.  The essence of the nanotechnology story is 
the continuation of a fifty-year trend of machine miniaturization 
culminating in the rise of design control at the molecular level. 
Nanotechnology is not confined to a single area of innovation; 
“smallness” is its unifying attribute. Researchers in a number of 
technical fields are keenly interested in manipulation of matter at 
the nanoscale, and funding is assured because many of the research 
forefronts hold promise for business and military applications. 
(Sarewitz, D. and Woodhouse, E. 2003). 
In an ideal world, scientists would communicate scientific 
knowledge clearly and effectively to laypersons, who would then 
understand the knowledge and use it to make sound judgments 
about science policy. After Hiroshima and Nagasaki, scientists 
made a great effort to explain the atom to the public, thereby 
preparing the public to accept nuclear plants to generate electricity. 
During the 1950s and ‘60s, NASA and the media presented the 
basics of space science in a friendly way which enabled millions to 
understand it, at least at a rudimentary level. Currently the Human 
Genome Project devotes at least 3% of its budget to ethical, legal 
and social issues, including public understanding. In these three 
examples, scientists and science teachers have aspired to an ideal 
model of communication and understanding. In many other cases, 
however, the world is far from ideal. Certain cultural values, 
including strong hopes and deep fears, are likely to shape public 
understanding of nanotechnology. To paraphrase Rosenberg, 
nanotechnology will be appreciated or feared, not because of its 
scientific merits, but because of pre-existing extrascientific values. 
Nanophilic hopes and nanophobic fears will not wait until after 
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scientific work is completed, assessed and disseminated. The 
tangible results of nanotech will be selectively appreciated and 
interpreted in accordance with those hopes and fears (Toumey, 
2004).
Nanotechnology must be developed in a safe and 
responsible manner. Ethical principles must be adhered to and 
potential health, safety or environmental risks scientifically 
studied, also in order to prepare for possible regulation. Societal 
impacts need to be examined and taken into account. Dialogue 
with the public is essential to focus attention on issues of real 
concern rather than “science fiction” scenarios (Commission of the 
European Communities, 2004).  
EXPLORING IMPORTANCE OF TECHNOLOGY ASSESSMENT 
Scientific and technological innovation continually 
remakes society. Technology Assessment (TA) can significantly 
enhance the societal value of research-based innovation. 
A half-century ago, philosopher and skeptics critic of 
technology, Jacques Ellul (1967)  argued that the rise of 
technology leads to the decline of traditional spirituality, as man 
transfers “his sense of the sacred … to technique itself.” We 
develop a “worship of technique,” Ellul said, and we associate our 
technology with a “feeling of the sacred.” 
According to skeptics point of view Jacques Ellul, 
technology perhaps is the most pervasive and potentially 
dehumanizing product of modern life (1967, 1980). 
Selected questions adapted from the Jacques Ellul Society’s 
Seventy-Six Reasonable Questions to Ask About Any Technology 
(International Center for Technology Assessment, 2002) were used 
specifically to stimulate debate and analysis in the ethics seminars. 
The following questions were used: 
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Ecological: Does it preserve or reduce ecosystem integrity? 
How much, and what kind of waste, does it generate? Does it 
incorporate the principles of ecological design? 
Social: How does it affect our way of seeing and 
experiencing the world? Does it serve to commodify knowledge or 
relationships? To what extent does it redefine reality? 
Moral: What values does its use foster? What is gained by 
its use? What are its effects on the least advantaged in society? 
Ethical: What does it allow us to ignore? Can we assume 
personal or communal responsibility for its effects? Can its effects 
be directly apprehended? What behavior might it make possible in 
the future? What other technologies might it make possible? 
Political: Does it concentrate or equalize power? Does it 
require or institute a knowledge elite? Does it require military 
defense? Does it enhance or serve military purposes? How does it 
affect warfare? Is it consistent with the creation of a global 
economy? Does it empower transnational corporations? What kind 
of capital does it require? 
According to Ellul, technology ultimately acts to isolate 
people from each other and from the natural environment, and 
despite the (usual) benignity of its intended consequences, there 
always are unforeseen negative consequences. Most provokingly, 
Ellul (1980) also suggested that technological development will 
soon reach a point at which direct human control will no longer be 
necessary or possible.21 (Sweeney et al. 2003). 
Eric Drexler’s the author of “Machines of Creation” and 
who was awarded an interdisciplinary degree, the world’s first 
doctorate in nanotechnology, noted that nanotechnology is 
21 Sweeney A.E., Seal, S.  (2003),  The Promises and Perils of Nanoscience and 
Nanotechnology: Exploring Emerging Social and Ethical Issues, Nanoscience 
and nanotechnology, bulletin of science, technology & socienty .No 8, pp. 236-
245. 
67
perfectly suited to arouse religious enthusiasm, it involves 
incredible, invisible powers (Keiper, 2003).
Richard Smalley, Nobel Prize winner, claims in the 
introductory part of a public speech about his very specific work 
on the use of carbon nanotubes for energy storage, that, the list of 
things you could do with such a technology [nanotechnology] 
reads like much of the Christmas Wish List of our civilization 
(Smalley, 1995). 
The starting points with the development of 
nanotechnology needs to develop approaches and methodologies 
that can address doubly “fictional” character of technology
assessment of nanotechnology. Many of the envisaged uses of 
nanotechnology are still science fiction, and the study of possible 
impacts is therefore  social science fiction (Rip, 2005).
Headlines about e.g. self-replicating nano-robots (M. 
Crichton, Prey), that are well beyond our present capability but are 
often presented as an immediate risk, demonstrate that there is an 
urgent need to provide information about present-day 
nanotechnology research and its possible applications 
(Commission of the European Communities, 2004). 
 “Real time” TA has been proposed by Sarewitz and 
Guston (now at Arizona State University). Further development of 
such approaches and methods is important, including ways of 
‘public engagement’ as it is now called in the UK (Report of the 
Royal Society, 2004). However, methods development should be 
embedded in understanding of innovation dynamics and the 
embedding of technology in society (Rip, 2005). 
Public reactions to nanotechnology in the U.S. are more 
difficult to envision this way because there has been practically no 
history of public awareness, let alone public reaction (!) to it. In 
lieu of such information, we need to turn to past episodes of the 
arrival of new forms of science and technology, and public 
reactions to them: atomic energy, space science, cold fusion, stem 
cell research, remediation of environmental disasters, genetically 
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modified foods, and so on. American society has had many 
experiences with the arrival of new technologies, and perhaps 
comparisons and analogies with some of them will help us 
anticipate public reactions to nanotechnology. The following 
general statements describe numerous episodes of the arrival of 
new technologies presented here as the these and anti-these 
(Toumey, 2004). 
NEW TECHNOLOGIES PERCEPTION BY SOCIETY
THESE ANTI-THESE
1A. When a new technology 
arrives, it will be so expensive 
that only the very wealthy can 
afford it, thereby exaggerating 
class differences. [Think of the 
initial days of cell phones, hand-
held calculators, and air bags in 
cars, for example.] 
1B. Shortly after a new 
technology arrives, mass 
production will great reduce the 
cost, thereby democratizing its 
availability. [Think of the 
second phase of cell phones, 
hand-held calculators, and air 
bags in cars.] 
2A. If a new technology 
involves profound changes in 
health or medicine, some people 
will object that scientists and 
doctors are playing god. [Here 
one might recall organ 
transplants, tissue transplants 
and technology-assisted 
reproduction.]
2B. If a new technology 
involves profound changes in 
health or medicine, some people 
[including patients, their 
doctors, and their families, plus 
administrators, investors and 
manufacturers] will fervently 
advocate for its use, on the 
grounds that patients should not 
suffer or die needlessly. [Here 
one might recall organ 
transplants, tissue transplants 
and technology-assisted 
reproduction.]
3A. The best way to 
nurture an expensive new 
technology is to consign it to 
3B. The best way to 
nurture an expensive new 
technology is through public 
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processes of proprietary 
capitalism, centered on patents 
and copyrights, because no one 
else besides proprietors and 
their investors will have the will 
or the resources to develop it, 
and because this will protect it 
from political interference. 
[Currently this argument is 
made on behalf of 
pharmaceutical research.]  
funding and government 
regulation, so that potential 
dangers can be closely 
monitored, and the benefits of 
the new technology will become 
available to the largest possible 
number of people. [Here a good 
example is the Human Genome 
Project.]
4A. As Dorothy Nelkin 
pointed out, the media usually 
embrace a new technology 
enthusiastically and emphasize 
its promises and supposed 
advantages (Nelkin 1987). 
[Perhaps you can recall the 
initial accounts of cold fusion 
from 1988.] 
4B. As Dorothy Nelkin 
pointed out, the media often 
denounce a new technology 
when it is seen to be imperfect, 
that is, when it fails to fulfill 
utopian expectations, even 
though the exact same media 
may have previously 
exaggerated its promises and 
supposed advantages (1987). 
[No doubt you can recall the 
later accounts of cold fusion.] 
SURVEY REVEALS  PUBLIC ATTITUDES TO NANOS&T
Recent (Jan/Feb 2005) survey on Europeans’ experience 
and perception of science and technology includes some questions 
regarding nanotechnology: 
- ca. 20% not at all interested in general S&T (U.S. ca. 
10%);
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- Among those interested, NT receives by far the lowest 
rate of interest; 
- Developments in medicine are by far the field in which 
respondents are the most interested in (W 73%, M 50%), and the
second most mentioned item is the environment. 
High interest in medicine and environment can be 
explained: Both areas are linked to health issues – public health 
issues S&T area with highest interest (also in the U.S.) Positive 
effect on our way of life in the next 20 years are especially 
expected from new medical and energy technologies, though 
people are not interested in NT so far (lowest numbers 8%  and 
high ‘no-response’ rate).22
Scientific literacy for nanotechnology is practically 
nonexistent and general scientific literacy in this country is very 
poor. Trends seem to be similar in U.S. and Europe. 
General public does not know very much about 
nanotechnology:
- GB 2004: 29% have heard about NT, 19% can give some 
kind of definition; 
- D 2004: 30% have heard about NT, 15% can link it to 
specific developments; 
- USA 2004: >80 % had heard “little” or “nothing” about 
NT, most could not correctly answer factual questions about it. 
- Majority (~90%) is not interested in NT (or does not 
care);
- Nanotechnology is perceived as a ‘fuzzy’ concept; 
- Positive expectations prevail over negative; 
- The higher the (subjective) level of information and the 
level of education, the lower the ‘fear of risk’. 
22
Data: Special Eurobarometer 224 & 225 / Wave 63.1 2005; NSF Science& 
Engineering Indicators, (2004). 
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To summarize attained results of this survey that reveals  
‘no attitudes’.  Since qualitative judgments about NT mainly 
similar to general attitudes to S&T. 
CONCEPTUAL FOCUS OF TECHNOLOGY ASSESSMENT
Technology assessment (TA) developed as a scientific and 
societal reaction to the problem of how to deal with complex side 
effects and uncertainties in science and technology.(Grunwald et 
al, 2004 – 2006).
The main questions defined to be answered by TA:  
- whether and how knowledge of side-effects can already 
be integrated into decision-making processe; 
- the problem of dealing with the inevitable uncertainties of 
knowledge.
- the unintended side-effects of science, technology and 
technological advance can be experienced in modern age. 
The respective concepts offered by TA to society and 
politics are strongly dependent on the context – and require 
continued modernization if these contexts are subject to rapid 
changes in a dynamically developing global society (Grunwald et 
al, 2004-6). 
Technology assessment is dedicated to help business, 
government and the public anticipate and manage possible health 
and environmental implications of nanotechnology (Rejeski D. 
2006).
It is therefore important that, in parallel with technological 
development, appropriate R&D is undertaken to provide 
quantitative data on toxicology and ecotoxicology (including 
human and environmental dose response and exposure data) to 
perform risk assessments and, where necessary, to enable risk 
assessment procedures to be adjusted. Scientific investigation and 
assessment of possible health or environmental risks associated 
with nanotechnology need to accompany the R&D and 
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technological progress. Addressing the potential risks of 
nanotechnologies to public health, the environment and consumers 
will require evaluating the possible re-use of existing data and 
generating new, nanotechnology-specific data on toxicology and 
ecotoxicology (including dose response and exposure data). This 
also calls for examining and, if required, adjusting risk assessment 
methods. In practice, addressing the potential risks associated with 
nanotechnologies necessitates that risk assessment be integrated 
into every step of the life cycle of nanotechnology-based products  
(Commission of the European Communities). 
Nanotechnologies present new challenges also for the 
assessment and the management of risks. We need formal risk 
analysis because risk is one of the most important ethical and 
social issues we could imagine (Smith, 2001). 
PUBLIC UNCERTAINTY OF NT BENEFITS V. RISKS PERCEPTIONS 
ON HEALTH AND ENVIRONMENT
Nanotechnology could ultimately turn out to be risky, but 
the prudent way to assess the risks is not the abandonment of the 
field. Society needs formal risk analysis because risk is one of the 
most important ethical and social issues. Just as fear of cloning 
could slow efforts in biomedicine and fear of genetically modified 
foods could contribute to hunger, fear of futuristic nanobots 
running amok could delay the benefits offered by nanotechnology. 
When discourse is founded on emotional prejudices, its 
unreasonableness discredits the legitimate need to identify and 
assess risks  (Smith, 2001). 
Health risks of nanoparticles may link NT to areas of 
greater public attention. Proven health risks, or uncertainties, may 
link NT debates with historical technology debates (hazardous 
chemicals, GMO). (Fleischer, 2005). 
Science & Engineering typically assume probabilities and 
consequences of adverse events, and hence the “risks,” as to be 
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objectively quantified by risk assessment. Social Science analysis 
rejects this notion. It focuses instead on the effects that risky 
outcome distributions have on the people who experience them. 
Risk is seen as inherently subjective (Paul Slovic and Elke Weber). 
TWO ASPECTS OF RISK:
Characterisation of risk has both quantitative and qualitative
components: 
a) Risk can be technically defined, e.g.: 
Risk = Hazard x Exposure (health risk) 
Risk = Damage x Probability of Occurrence (insurance) 
b) Risk can be culturally defined: 
“A thread to that which we value”; 
“The probability of loss of that which we value” risk.
“Perceptions of risk play a prominent role in the decisions people 
make, in the sense that differences in risk perception lie at the heart 
of disagreements about the best course of action” (P. Slovic). 
“It is not the things themselves that disturb us but our views of 
them.” (Epiktet).  
THE RISK DEBATE (Fleischer et al, 2005): 
x Risks of visions: Visions show real consequences 
regardless of their seriousness; 
x Risks of unknown material properties at the nanoscale; 
x Risks of (failed) communication and of public engagement. 
TA could include a ‘vision assessment’ that aims to achieve 
transparent, knowledge-based discussion about imaginations of the 
future. Vision assessment within a TA process could prevent ‘fear 
of fears’ and help to avoid damages for the development of S&T 
and for the culture of democratic decisions. 
Visions (positive and negative) are an important topic in 
the public communication of NT (‘Bill Joy-Debate’, visualizations 
in magazines, popular culture: ‘Prey’, ‘Matrix’, …). Visions may 
shape acceptance and further development of this field. Visions are 
ambivalent: high potentials often include high risks. 
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Challenging issues that may arise associated with the risks 
of new material properties:  
- New (surprising and partially still unknown) properties of 
materials at the nanoscale. (E.g. Behaviour of nanoparticles 
in the human body and the environment needs extensive 
research, though already on the market); 
- NanoToxicology – first results, knowledge still insufficient, 
challenges for conventional methods of toxicological 
research; 
- „New forms of known chemicals“ or „new chemicals 
because of different chemistry“? 
Recommendations for policymakers for public involvement 
in dialogue and risk evaluation: to incorporate views from the 
general public in decision-making; improve the knowledge base 
and quality of decisions establish trust and legitimacy; identify 
issues, mediate and resolve conflicts, reduce risk of rejection; 
educate and inform.  
TA provides procedural knowledge on risk communication 
and experiences from public and political debates about other ‘risk 
technologies’ (nuclear, genetic, …). TA as a process contributes to 
societal opinion forming, addresses public concerns, supports 
public understanding of science and technology. TA provides 
knowledge and methods to avoid mistakes, to reduce uncertainties 
and support diffusion of  NT (Fleischer et al, 2005).
In light of this perception of potential danger, the Foresight 
Institute (nonprofit educational organization established to help 
society prepare for advanced technologies) has drafted a set of 
guidelines  for the ethical development of nanotechnology. These 
include the banning of free-foraging self-replicating 
pseudoorganisms on the Earth's surface, at least, and possibly in 
other places. 
A fear exists that nanomechanical robots, if achieved, and 
if designed to self-replicate using naturally occurring materials (a 
difficult task), could consume the entire planet in their hunger for 
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raw materials, or simply crowd out natural life, out-competing it 
for energy. Some commentators have referred to this situation as 
the "grey goo" or "ecophagy" scenario. K. Eric Drexler considers 
an accidental "grey goo" scenario extremely unlikely and says so 
in later editions of Engines of Creation. The "grey goo" scenario 
begs the Tree Sap Answer: what chances exist that one's car could 
spontaneously mutate into a wild car, run off road and live in the 
forest off tree sap? 
ENFORCEMENT VISIONS OF NANOTECHNOLOGY - STRENGTH IN 
SCIENCE, SOUND ETHICS
"The best defense against nanotech misuse is good 
nanotechnology.". 
"Any powerful technology can be abused." (G. Reynolds, 2001)  
It would be difficult to deny the potential benefits of 
nanotechnology and stop development of research related to it 
since it has already begun to penetrate many different fields of 
research. However, nanotechnology can be developed using 
guidelines to insure that the technology does not become too 
potentially harmful. Technology assessment recognizes the fact 
that scientists normally are not trained ethicists themselves and 
accordingly ought to be very careful when passing ethical 
judgment on their own, or their colleagues´, new findings, projects, 
or work in progress.
As with any new technology, it is impossible to stop every 
well funded organization who may seek to develop the technology 
for harmful purposes. However, if the researchers in this field put 
together an ethical set of guidelines (e.g., Molecular 
Nanotechnology Guidelines, Foresight Institute, 2000) and follow 
them, then we should be able to develop nanotechnology safely 
76
while still gathering its promised benefits. Recent technical 
proposals for Molecular Nanotechnology (MNT) nanofactories do 
not include self-replicating nanobots, and recent ethical guidelines 
prohibit self-replication. MNT nanofacturing is popularly linked 
with the idea of swarms of coordinated nanoscale robots working 
together, as proposed by Drexler in his 1986 popular discussions of 
the subject in the “Engines of Creation”. It is proposed that 
sufficiently capable nanobots could construct more nanobots.
New scientific discoveries and the ensuing technologies are 
often accompanied or followed by utopian or dystopian visions 
about the future of humankind under their new dominance. These 
visions can be found in science communication, literature ('high' 
and 'low' level), in popular science, in newspaper articles, books, 
cinema and TV series, Internet and also in more or less arcane 
religious sects. This especially holds for current themes around 
nanotechnology. What effects do such visions have on society and 
back on the further development of nanoscience? (Stefan et al. 
2005).
What are the chances and what are the risks of the 
fictionalisation of nanotechnology? Nanoscience and 
nanotechnology are among today's most promising fields of 
research. As NT quickly develops, the ethical evaluation of such a 
development has yet to begin. If their full potential is to be 
realized, we need to attend along the way to key ethical issues. But 
ethics should not be grounded in exaggerations, either positive or 
negative; hyperbole just obscures important issues (Stefan et al. 
2005).
To what extent does this already influence the 
interpretation of facts and the visions of future development?  "The 
need for special ethical principles in a scientific society is the same 
as the need for ethical principles in society as a whole. They are 
mutually beneficial. We must become competent in dealing with 
moral concerns related to all new technologies. And remember that 
a code of ethics will not solve all ethical problems.  "We must 
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remember that good laws, if they are not obeyed, do not constitute 
good government. Hence there are two parts of good government; 
one is the actual obedience of citizens to the laws, the other part is 
the goodness of the laws which they obey..." (Aristotle, Politics 
1294a3-6).
In 1980s, when nanotech pioneer and Foresight Institute’s 
founder and Chairman up to 2003, K. Eric Drexler considered 
keeping his thoughts quiet, rather than risk opening a Pandora’s 
box of new technology with threats that could include a range of 
microscopic terrors. But in the end Drexler and his colleagues 
reached a simple conclusion: "If you don’t discuss it, someone else 
would come along and develop it. And their intentions might not 
be as good".(Caroll, 2001).
K. Eric Drexler, author of Engines of Creation, has begun 
to develop guidelines for the use of NT, particularly concerning 
self-replication, but also issues such as wealth distribution and 
environmental protection (Mnyusiwalla et al, 2003). (see. 
Foresight Guidelines for Responsible Nanotechnology 
Development.)  
The ethical issues associated with NT fall into a variety of 
categories including: 
1) Equity: NT does not stand to help developed countries 
only, but also (and perhaps mainly) developing countries. For 
example, third world countries suffer most from things that can be 
improved upon from advancements made in NT. For instance, 
providing cleaner water, developing cheaper energy, and also the 
enormous health benefits to be reaped from NT are all aspects of 
NT that could have a dramatic impact on third world countries. A 
global opinion-leaders network for social and ethical implications 
ought to be established so that third world countries may be 
involved.
2) Privacy and security: While NT could dramatically 
improve surveillance systems and would undoubtedly have 
numerous military applications, some are left wondering how 
78
personal privacy would be affected. Questions concerning the 
regulation of this new technology are arising without many 
answers being offered. As nanotechnology begins to deliver new 
and improved weapons, secrecy will eventually mask important 
research work.
The first round of nanotech-inspired materials, for example, 
is likely to find an active suitor within the U.S. defense industry – 
particularly for radar-resistant, lighter and much more durable 
materials. And as the first weapons to use nanotechnology go into 
development, secrecy is likely to follow.  
For now nanotechnology doesn’t have any applications in 
the war on terrorism because it’s still too young. Nanotechnology 
lurks between five and ten years into the future. 
3) Environment: The effects of NT materials on the 
environment. The funding have to increased to study the effects of 
NT on the environment. 
4) Human or machine? How far are humans willing to go 
with replacement of human parts with replacement robot parts? 
Some avenues of research in NT include the incorporation of 
artificial materials or machines into human systems, as is 
beginning to happen with implanted computer chips. The 
modification of living systems is met with great skepticism by 
much of society. How acceptable will technologies such as 
implantable cells and sensors be for the general population? What 
are its implications and what are our limits? (Mnyusiwalla et al, 
2003).
ROLE OF TECHNOLOGY ASSESSMENT FOR RESPONSIBLE 
DEVELOPMENT OF NT
Ethical principles must be respected and, where 
appropriate, enforced through regulation. These principles are 
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embodied in the European Charter of Fundamental Rights23 and 
other European and other international documents24. The opinion 
of the European Group of Ethics (EGE)25, who are examining the 
ethical aspects of medical applications related to nanotechnologies, 
should also be taken into account. (Commission of the European 
Communities, 2004). 
If it is difficult to predict the future direction of 
nanoscience and nanotechnologies and the timescale over which 
particular developments will occur, it is even harder to predict 
what will trigger social and ethical concerns. In the short to 
medium term concerns are expected to focus on two basic 
questions: ‘Who controls uses of nanotechnologies?’ and ‘Who 
benefits from uses of nanotechnologies?’ These questions are not 
unique to nanotechnologies but past experience with other 
technologies demonstrates that they will need to be addressed 
(Report of the Royal Society). 
Apart from denying society the possible benefits, it may 
lead to the constitution of “technological paradises”, i.e. where 
research is carried out in zones without regulatory frameworks and 
is open to possible misuse. Our consequent inability to follow 
developments and intervene under such circumstances could lead 
to even worse consequences. The Precautionary Principle, as used 
up to now, could be applied in the event that realistic and serious 
risks are identified. (Commission of the European Communities, 
“Communication from the Commission on the Precautionary 
Principle” COM(2000) 1.). 
Given the huge uncertainties about the future social impacts 
of nanotechnology, we ought to think of the unfolding revolution 
as a grand experiment—a clinical trial—that technologists are 
23 See http://www.europarl.eu.int/charter/default_en.htm
24 See http://europa.eu.int/comm/research/science-
society/ethics/legislation_en.html
25 See http://europa.eu.int/comm/european_group_ethics/index_en.htm
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conducting on society. From this perspective, we can reflect upon 
the robust societal consensus that demands prior informed consent 
as a basis for participation in scientific experiments. This 
consensus is formally codified in the World Medical Association’s 
Helsinki Declaration, strengthened most recently in 2000, and 
reinforced in the public consciousness by the memory of, for 
example, the Tuskegee experiments, where African American 
males with syphilis were left untreated as part of a “control group,” 
despite the existence of treatments known to be efficacious. In the 
United States, every publicly funded research project involving 
human subjects is monitored by an institutional review board 
(IRB) that must approve the research before it can be conducted. 
Every university, independent laboratory, and private-sector lab 
receiving federal funding for human subjects research has an IRB; 
there are thousands of boards operating in the United States, nearly 
800 in California alone. These boards demonstrate that 
comprehensive governance is a reasonable goal, and while IRBs 
certainly impose a cost in terms of the efficiency of conducting 
research, they are an accepted element of a scientific infrastructure 
that respects human dignity. Similar commitments of the entire 
research enterprise to larger democratic strictures occur in 
experiments with animals and in compliance with environmental 
health and safety regulations. Comprehensiveness, in other words, 
is possible, when the stakes are high and societal intent is clear. 
(Daniel Sarewitz and Edward Woodhouse, 2003). 
Some of the basic ethical values include: the principle of 
respect for dignity; the principle of individual autonomy; the 
principle of justice and of beneficence; the principle of freedom of 
research; and the principle of proportionality. The relevance of 
such principles towards human and non-human applications of 
nanotechnology should be understood. In addition, certain 
applications, e.g. miniaturised sensors, may have specific 
implications for the protection of privacy and personal data 
(Commission of the European Communities, 2004). 
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POTENTIAL ANALYSIS FOR TECHNOLOGY ASSESSMENT 
 
Since NanoTA deals with emerging enabling technologies, 
novel methodical approaches are needed as a tool to link R&D 
activities with visions for applications and as a ‘support layer’ for 
the technological interpretation of (political) scenarios including 
future technology options. 
Science & Technology Roadmapping methodology can be 
adapted for TA for emerging enabling technologies. When 
integrated into a TA process, roadmapping may serve as a 
powerful tool to provide empirical and structural knowledge and to 
produce consensus on strategies. Traditionally used to gather, 
structure and communicate information about technologies and 
products, and to link them to options for the future in companies 
and industries. More recently used as decision aids to design public 
policies related to research and development (de Laat 2004). For 
NT, a number of roadmaps exists - produced by small groups of 
experts with a “technology push” perspective - most remain 
unnoticed or ignored in R&D policies. On June 21, 2005 press 
release was announced in Menlo Park, CA, that Foresight 
Nanotech Institute launched Nanotechnology Roadmap for 
productive nanosystems.  
In 2005-6 series of the Roadmap Reports was made in 
connection with the European project “Development of Advanced 
Technology Roadmaps in Nanomaterial Sciences and Industrial 
Adaptation to Small and Medium sized Enterprizes” 
(“NanoroadSME”) by authorship of René de Groot (Syntens – 
Stiching Syntens, Innovation Network for Entrepreneur, 
Netherland) and Dr. Jonathan Loeffler (Steinbeis-Europa-Zentrum, 
Germany). The project was funded by the European Community 
under the “Sixth Framework” Programme. Expert of technology 
assessment and roadmapping, Ineke Malsch, founder and director 
of Malsch TechnoValuation (Netherland), made contributions to 
reports produced in this EU funded projects (2006).  
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Method of hypothesis used for the acceptance and the 
relevance of a roadmap, process aspects (design, participants, 
modes of communication) are as important as the technical product 
(the roadmap) itself. Variety of technology forecasts, foresight 
reports, market studies – general or sectoral are available 
(Fleischer, 2005). 
 
FORECASTING, SCENARIO-BUILDING AND OTHER TOOLS OF 
FUTURE RESEARCH  
 
Forecasting, scenario-building and other futures research 
tools will help tease out the possible landscapes of the world to 
come.  
Research need to talk directly to and listen to business 
leaders, nanotechnology researchers and nano-product 
development personnel. With respect to studying the possible 
impacts of disruptive technologies on public perceptions, new 
research methodologies are needed (such as “preview” represent 
communities) that can provide prospective information on social 
impacts prior to the mass deployment of the new technology. Most 
NSF (national science Foundation) supported work on the public 
understanding of sciences focuses on attitudes toward science and 
knowledge about science rather than the ends to which science 
could or should be put. Several modes of identifying social needs 
on which to base justifications for advances in S&T have been 
outlined. These include Foresight and Delphi techniques, Charettes 
in city planning, as well as public discussion models from the 
philosophy of science. The identification of technology goals could 
also process from social science research on human needs, e.g. 
Maslow’s hierarchy of goals. Foresight studies attempt to depict an 
image of a possible future using a variety of  techniques. An 
important foresight method is the Delphi survey. A Delphi survey 
basically is a tool to create consensus and detect areas of 
conflicting expert opinions. In a first round, experts are confronted 
  83
with a number of topics they have to evaluate with respect to time 
of realization, implication on wealth creation, quality of life, and 
similar issues. In another round the results of the previous round 
are introduced to the experts who then have a chance to re-evaluate 
the topic (Etzkowitz, 2001).  
 
FUTURE SOCIAL SCENARIOS 
 
Bainbridge and  Kasperson, (2003) performed future social 
scenario analysis, which, can help identify issues and hypotheses, 
and thus is a useful tool of theoretical analysis. This panel puts 
forth two very different scenarios for the coming 10 to 20 years, in 
order to help clarify both the issues related to nanotechnology that 
policy makers will face, and the knowledge that needs to be gained 
through research. In one scenario, the transition will he smooth 
and benign, whereas in the other scenario the transition will be 
rough and marked by many different kinds of harm and conflicts 
with social values and institutions. 
Smooth transition: In this optimistic scenario 
nanotechnology produces clear, demonstrable benefits and 
solutions for real-world problems, and management strategies for 
threats. For example, it will enable low-cost energy production 
with minimal impact on the environment, as well as achieving 
greater efficiency in energy use. It will help prevent and cure 
disease, and will provide many rewarding jobs. It will contribute to 
applications that strengthen the nation’s defense capabilities 
without unduly burdening the privacy of citizens, while also 
reducing the incidence of terrorist activity and strengthening the 
cause of peace worldwide. In this scenario, early applications 
stress positive effects on publicly valued areas, such as health, 
energy and food development, pollution abatement, and 
environmental protection. 
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Importantly, the smooth transition scenario assumes that 
nanotechnology development will benefit from strong public 
involvement.  
Rough Transition: This scenario could lead eventually to a 
happy situation Like that described in the smooth scenario, hut 
only after a longer period of delay and with very substantial human 
costs. Clearly unmanaged or unanticipated risks become evident 
with this scenario. At the extreme, it could lead to the near-
permanent abandonment of some forms of nanotechnology and 
thus to a failure to take advantage of their benefits. 
Societal institutions and the general public would not he 
effectively involved in the policy-setting process. Perhaps 
nanotechnology-enabled weaponry would be used in such a way as 
to increase rather than decrease fatalities, ultimately leading to 
reduced security. The public would perceive that industry and 
scientists are concerned only with their own profits and careers, 
causing widespread apprehension and mistrust. There could be 
irrational fads leading to government regulation that was either too 
rigid or too lax, and a tremendous loss of investment coupled with 
tragic failures to realize the greatest benefits of nanotechnology. 
There are parallels in previous technology revolutions or 
evolutions that can inform us about the future of nanotechnology. 
Genetically modified organisms, stem cells, and nuclear power 
exemplify the rough transition scenario. Indeed, one of the more 
disturbing possibilities is that policy makers and leaders of social 
movements may respond to nanotechnology not as it actually is, 
but in terms of false analogies. 
Research and Evaluation Methodologies 
Scenario analysis, as mentioned earlier, can help identify 
issues and hypotheses, and thus is a useful tool of theoretical 
analysis. A worthwhile variant of scenario analysis is backcasting, 
the mirror image of forecasting, which specifies an outcome and 
tries to identify the steps that might lead to it. Scenarios are an art 
form, akin to brainstorming, but there are ways to render them 
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more rigorous. For example, acknowledged experts can be asked to 
write the scenarios, and their output can he harmonized with 
known facts (such as demographic data or statistics on availability 
of natural resources). Even when they are not fully rigorous, 
scenarios can help policy makers and ordinary citizens alike to 
imagine possible futures, both to prepare responses to anticipated 
problems and to set goals for positive accomplishments. Ideas 
generated through scenarios can become the focus of more 
rigorous methods of empirical research. 
Multi-agent modeling is akin to scenarios, but is carried 
out through computer simulation. An agent is a dynamic computer 
representation of an individual person, organization (such as a 
corporation), sector of the economy, or other social unit. Among 
the most intellectually influential examples is a study by political 
scientist Robert Axelrod (1984), in which a computer modeled the 
interaction of a number of individual people, who followed various 
strategies in their economic dealings with each other. The point of 
the study was to see if these agents could learn to cooperate, 
despite the fact that each was programmed to seek his or her own 
best selfish interests, and indeed they could. The relevance to real 
people was that the study showed that cooperation between 
humans was logically possible even without shared social values, 
religion, or any of the other sophisticated cultural factors that are 
often assumed to help humans he reliable partners. For 30 years, 
agent-based and other computer simulations have contributed to a 
greater understanding of issues, such as the ways a society may 
affect the natural environment and the ways social movements may 
organize around a variety of issues (Bainbridge, 1987, Forrester, 
1971, Meadows et al. 1974).   
Axelrod’s simulations employed game theory; it is also 
possible to use pure mathematical methods in this way of 
conceptualizing human relations in terms of strategic interactions 
for personal gain.  
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The case study method is an important qualitative research 
approach that can be practiced somewhat rigorously, either with 
historical or ethnographic data. Given that nanotechnology is quite 
recent, historical studies will have to rely upon carefully drawn 
analogies with earlier technologies. For example, an extensive 
literature already exists on the often-rocky adoption of new 
medical technologies, as some excellent therapies and diagnostic 
tools are ignored while others spread rapidly throughout the 
medical community despite lack of evidence for their value 
(Bunker et al. 1977, Howell, 1995) . The challenge is how to 
identify close analogies between past cases and particular 
nanotechnology applications. The ethnographic approach avoids 
this problem through direct observation of a specific emerging 
nanotechnology in the laboratory or in the wider organization of 
which it is a part. Ethnography is not well suited for 
prognostication, however, because it focuses on the present and 
very recent past. Potentially, the combination of history (to get the 
time perspective that reveals outcomes) and ethnography (to 
determine the nature of an innovation to support appropriate 
analogies) could he more powerful than either alone. 
New technologies do not merely have an impact upon 
society. Rather, they interact with society and their impact is a 
result of technical facts with social factors. Thus, public opinion 
surveys and methods like market testing are important ways to 
chart the changing meaning of nanotechnology. Focus groups can 
provide insights in to how to intervene and how to get information 
across. The research method must be tailored to the particular 
population under study. For example, young people may not 
respond well to formalized questionnaires, so it may he best to 
conduct listening tours in high schools to examine youth culture 
and understanding. Content analysis (obtained by looking at 
media, popular culture, and Hollywood) could be integrated with 
surveys of audiences for analysis of the social values that 
nanotechnology may affect. 
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Finally, it will be important to collect solid facts about the 
institutions and individuals that are most involved in the 
development and application of nanotechnology. An inventory 
should be undertaken of existing institutions and assessment of 
how they cope with change and uncertainty. Also valuable would 
he research to develop a future nanotechnology-skills inventory for 
identifying best-of-breed competencies that will enable jobs, career 
development and competitiveness. 
 
THE RESPONSIBLE DEVELOPMENT OF NANOTECHNOLOGY 
 
While the phrase ‘responsible innovation’ occurred 
occasionally, it is now becoming more common, especially in 
nanotechnology. Examples are the USA Centre for Responsible 
Nanotechnology (with links to the Drexlerian “social world”), and 
the International Dialogue on Responsible Research and 
Development of Nanotechnology, recently started up by Mihael 
Roco (US National Nanotechnology Initiative), include attempts at 
interactive TA from CSPO at Columbia University (Rip, 2005). 
If still unformed, however, there is reason to believe that 
public debate about nanotech is about to take off - with two just 
founded new nanotech organizations. The Center for Responsible 
Nanotechnology, run by a social activist and a nanosystems 
theorist, Chris Phoenix, one of the Center’s founders says, “What 
we want, is to see molecular nanotechnology policy developed and 
implemented with a care appropriate to its powerful and probably 
transformative nature.” And two Washingtonians—a futurist,  Eric 
Drexler and an antitrust lawyer, Chris Phoenix —are in the process 
of launching the Nanotechnology Policy Forum to improve the 
quality of public discourse about nanotech. They intend to host 
events every few months, and to stay scrupulously evenhanded: the 
advisory panel planned for the organization will include both 
friends and foes of nanotech - as well as present and former 
congressmen (Keiper, 2003). 
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TECHNOLOGY ASSESSMENT FOR THE EUROPEAN PARLIAMENT 
EUROPEAN TECHNOLOGY ASSESSMENT GROUP (ETAG) 
 
Since October 2005 a group of five European scientific 
institutes - with the Institute of Technology Assessment and 
Systems Analysis (ITAS), Research Centre Karlsruhe, Germany as 
the leading partner - has been providing scientific services for the 
European Parliament on social, environmental and economic 
aspects of new technological developments (Chatzimarkakis, 
2006). 
Initially for a period of three years, the European 
Technology Assessment Group (ETAG; www.itas.fzk.de/etag) will 
carry out TA studies on behalf of the STOA Panel. Apart from 
being leading institutions in the field of Technology Assessment 
(TA) in their home countries all members of the group have long-
term experience in policy consulting for parliamentary bodies. The 
group is made up of the following organizations: 
1 Institute of Technology Assessment and Systems Analysis 
(www.itas.fzk.de), which operates the Office of 
Technology Assessment at the German Parliament, 
2 Danish Board of Technology, which provides consultancy 
services for the national parliament (www.tekno.dk), 
3 Flemish Institute for Science and Technology Assessment 
(viwTA), the TA-institution of the Flemish parliament 
(www.viwta.be), 
4 Parliamentary Office of Science and Technology (POST) 
of the British Parliament 
(www.parliament.uk/post/home.htm),  
5 Rathenau Institute, the central TA institution in the 
Netherlands working for the Dutch parliament 
(www.rathenau.nl). The ongoing work programme funded 
from the 2005 STOA budget consists of a set of 10 projects 
dealing with a broad range of subjects from various sectors 
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of policy making, such as R&D, ICT, environment, health 
and energy. 
6 Institute of Technology Assessment of the Austrian 
Academy of Sciences in Vienna. 
 
ESSENTIAL QUESTIONS CONCERNING ETHICAL, 
ENVIRONMENTAL, ECONOMIC, LEGAL AND SOCIAL 
IMPLICATIONS OF NT 
 
1. Main task of nanotechnology assessment (TA) is to foster 
principles of ethical governance, maintenance balance of 
fundamental human rights and responsibilities of government 
regarding to emerging enabling nanotechnology. 
2. What are linked with the new opportunities of NT: possible 
technological, ethical, environmental, societal, economic and 
health risks? What are the actual barriers to be overcome these 
risks in the corresponding sectors? To what uncertainties may 
lead illiteracy of public in NT? 
3. The main purpose is not only defining opportunities or threats, 
but  perform sound  comparisons balancing supposed benefits 
and risks of NT. If ‘threats’ and ‘risks’ overwhelm the 
‘strengths’ and ‘opportunities’, societal attitude obviously may 
be rejection.  
4. Investigate and study environmental, health and socio-
economic impact of NT: Where do nanomaterials go when they 
enter the environment and what are their effects? There are 
always possibilities for environmental or health harms. Address 
forecasting and roadmapping for future implications and 
determining the role of NT in economical development. 
5. Create code of ethics concerning NT utilization in country. 
Design principles to discourage unethical or accidental misuses 
of nanotechnology, versus, encourage and advocate friendly 
‘green’ NT; As the science of NT leaps ahead, so the ethics 
lags behind; Either the ethics of NT will catch up, or the 
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science will slow down. NT may have devastating 
consequences, including public fear and rejection of NT 
without adequate study of its ethical and social implications. 
6. Public engagement, involvement of NGO and promote decision 
making activities at governmental and international levels. 
Mass media need to be involved in the early stages of NT since 
they have an important influence on public perceptions.  
7. Increase awareness and ferry appropriate overview information 
(chemo/bio – nano threats and defense) to concerning 
authorities about national security issues. As said Glenn 
Reynolds, a law professor and longtime nanotech expert at the 
University of Tennessee: "Any powerful technology can be 
abused." NT is capable of dramatically improving surveillance 
devices, and producing new weapons. Will these new 
technologies increase security or add to the arsenal of bio- and 
techno- or even nano-terrorism? Who will regulate the 
direction of research in defensive and offensive military NT? 
How much transparency will be necessary in government and 
non-governmental NT initiatives to avoid misuses? 
8. Promote NT education in secondary schools and universities. 
To emphasize that this multidisciplinary subject is gaining 
priority. Schools and universities could discuss the issue in 
depth, as well, could include exhibits on NT… 
 
CONCLUSIONS 
 
The aim of Technology Assessment is to measure benefit to risk 
ratio. The purpose of TA is to study ethical controversies in 
societal prism. Technology Assessment determines public 
perception. TA establishes visionary attitude. 
Technology Assessment Alleviates: 
o to highlight creativity of field  (Nobel Prize winners,  different 
awards and grants); 
o to define unequivocal ethical and legislative statements; 
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o to find out readiness for investments by venture capitalists 
(VC); 
o to recognize stakeholders willingness to benefit from 
technology; 
o to involve equally all layers of society: government-academy-
society-industry; 
o to maintain balance between  benefits & risks of technology. 
o to match convergence with simultaneously emerging enabling 
technologies (cogno-nano-info-bio). 
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CHAPTER FOUR 
REVIEW  OF NANOTECHNOLOGY APPLICATIONS  IN 
PHARMACEUTICAL INDUSTRY
NANOTECHNOLOGY  - A POWERFUL RESEARCH ENABLER
Nanotechnology is providing a critical bridge between the 
physical and chemical sciences and engineering, on the one hand, 
and modern molecular biology on the other. Materials scientists are 
learning the principles of the nanoscale world by studying the 
behavior of biomolecules and biomolecular assemblies.  
In return, engineers are creating a host of nanoscale tools 
that are required to develop the systems biology models of 
malignancy needed to better diagnose, treat, and ultimately prevent 
cancer.
Nanotechnology is the science of building devices at the 
molecular and atomic level. For example, a single data bit might be 
represented by only one atom some time in the future.  
Beyond being used in computers and communications 
devices, nanotechnology could be used extensively in 
biotechnology to build devices, fight disease, and change the 
properties of materials. 
Nanotechnology will serve as a versatile development 
platform that will be able to quickly turn biological insights into 
clinically useful products.

Presented summary is performed mainly based on SWOT analysis of 
Concerning the Use of Nanomaterials in the Medical and Health Sector, 6th FP 
of European Committee (courtesy of authors René de Groot and Dr. Jonathan 
Loeffler); Cancer Nanotechnology Plan of NCI and NSF of U.S., and press 
releases of interrelated information from  pharmaceutical drug manufacturers, 
compiled together. 
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FIGHTING CANCER WITH NANOTECHNOLOGY
By the year 2015 National Cancer Institute plan to meet the 
goal of eliminating death and suffering from cancer. 
The National Cancer Institute is engaged in efforts to 
utilize the power of nanotechnology to radically change the way 
we diagnose, image, and treat cancer. 
The US National Science Foundation (NSF) expects 
nanotechnology to account for around half of all pharmaceutical 
industry sales by 2010.
As part of NCI mission to accelerate the application of 
nanotechnology to the major challenges in clinical oncology and 
basic cancer research, the NCI Alliance for Nanotechnology in 
Cancer is dedicating $144.3 million as part of a 5-year initiative for 
nanotechnology in cancer research. Main goal is to foster the 
development of nanoscale devices that can identify the early 
molecular signatures of cancer and deliver therapeutic or 
preventive agents that can intervene in the cancer process at this 
early stage. 
NANOTECHNOLOGY  - STRATEGIC IMPLICATION IN ONCOLOGY
Thirty years ago, cancer was a poorly understood and 
usually deadly disease. This is no longer the case.  
Eliminating suffering and death from cancer requires an 
unprecedented collaborative effort that leverages resources from 
government, industry, and academia.  
Nanotechnology will revolutionize the very foundations of 
cancer treatment, prevention and diagnosis.  
Nanoscale devices have the potential to radically change 
cancer therapy for the better and dramatically increase the number 
of highly effective therapeutic agents. Nanoscale constructs can 
serve as customizable, targeted drug delivery vehicles capable of 
ferrying large doses of chemotherapeutic agents or therapeutic 
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genes into malignant cells while sparing healthy cells, greatly 
reducing or eliminating the often unpalatable side effects that 
accompany many current cancer therapies. 
Nanoscale particles and devices are similar in size to 
biomolecules and can easily enter most cells. Our ability to 
manipulate the physical, chemical, and biological properties of 
these particles affords researchers the ability to engineer and use 
nanoparticles for drug delivery, as image contrast agents, and for 
diagnostic purposes. 
Nanotechnology refers to the interactions of cellular and 
molecular components and engineered materials—typically 
clusters of atoms, molecules, and molecular fragments—at the 
most elemental level of biology. Such nanoscale objects—
typically, though not exclusively, with dimensions smaller than 
100 nanometers—can be useful by themselves or as part of larger 
devices containing multiple nanoscale objects.  
Nanotechnology is the development and engineering of 
devices so small that they are measured on a molecular scale. This 
emerging field involves scientists from many different disciplines, 
including physicists, chemists, engineers, information 
technologists, and material scientists, as well as biologists. 
Nanotechnology is being applied to almost every field imaginable, 
including electronics, magnetics, optics, information technology, 
materials development, and biomedicine. 
At the nanoscale, the physical, chemical, and biological 
properties of materials differ fundamentally and often 
unexpectedly from those of the corresponding bulk material 
because the quantum mechanical properties of atomic interactions 
are influenced by material variations on the nanometer scale. In 
fact, by creating nanometer scale structures, it is possible to control 
fundamental characteristics of a material, including its melting 
point, magnetic properties, and even color, without changing the 
material’s chemical composition. For instance, opaque substances 
become transparent (copper); inert materials become catalysts 
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(platinum); stable materials turn combustible (aluminum); 
insulators become conductors (silicon). Much of the fascination 
with nanotechnology stems from these unique quantum and surface 
phenomena that matter exhibits at the nanoscale. A material such 
as gold, which is chemically inert at normal scales, can serve as a 
potent chemical catalyst at nanoscales. One hundred and fifty years 
after one of the founders of chemistry Michael Faraday in 1850s 
(Thomas & Kulkarni 2003) first created gold nanoparticles and 
observed that these nanoparticles absorbed light, researchers have 
created a 21st century version that absorbs light so efficiently that 
a mere flash of light can cause the particles to melt. This ability to 
efficiently turn light into extreme heat could prove useful for 
creating nanoscale thermal scalpels capable of killing cancer cells.
Used in manufacturing for many years, nanotechnology 
enables scientists to build devices and materials one atom or 
molecule at a time, creating tightly packed structures that take on 
new properties by virtue of their miniature size.  
EXPLORING NANOTECHNOLOGY IN CANCER
NANOTECHNOLOGY PLATFORMS FOR CANCER RESEARCH
A nanometer is one-billionth of a meter(10-9), or about 
100,000 times smaller than the width of a human hair. Most animal 
cells are 10,000- 20,000 nanometers in diameter, so nanoscale 
devices are tiny enough to enter cells and analyze DNA and 
proteins, potentially identifying and treating cancerous cells at 
much earlier stages than currently possible.
They are smaller than human cells and organelles and 
similar in size to large biological macromolecules 
("biomolecules") such as enzymes and receptors— hemoglobin, 
for example, is approximately 5 nm in diameter, while the lipid 
bilayer surrounding cells is on the order of 6 nm thick. Nanoscale 
devices smaller than 50 nanometers can easily enter most cells, 
while those smaller than 20 nanometers can move out of blood 
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vessels as they circulate through the body. As a result, nanoscale 
devices can readily interact with biomolecules on both the cell 
surface and within the cell, often in ways that do not alter the 
behavior and biochemical properties of those molecules. From a 
scientific viewpoint, the actual construction and characterization of 
nanoscale devices may contribute to understanding carcinogenesis. 
Because of their small size, nanoscale devices by gaining 
access to so many areas of the body, they have the potential to 
detect disease and deliver treatment in ways unimagined before 
now. Since biological processes-including events that lead to 
cancer-occur at the nanoscale at and inside cells, nanotechnology 
offers a wealth of tools that are providing cancer researchers with 
new and innovative ways to diagnose and treat cancer. 
PRIMARY ASPECTS OF NANOTECHNOLOGY IN MEDICINE
Today, cancer-related nanotechnology is proceeding on two 
main fronts: laboratory-based diagnostics and in vivo diagnostics 
and therapeutics. 
Work is currently being done to find ways to safely move 
these new research tools into clinical practice. But there are 
already examples in clinical use that show the promise of 
nanotechnology.
x Nanotechnology has been used to create new and improved 
imaging techniques to find small tumors. Researchers have 
shown that incredibly small iron oxide particles 
(nanoparticulates) can be used with magnetic resonance 
imaging (MRI) to accurately detect cancers that have 
spread to lymph nodes, without requiring surgery.
x Nanoscale drug delivery devices are being developed to 
deliver anticancer therapeutics specifically to tumors. 
Liposomes are one such "first generation" nanoscale 
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device. Liposomal doxorubicin26 is used to treat specific 
forms of cancer, while liposomal amphotericin B treats 
fungal infections often associated with aggressive 
anticancer treatment. Recently, a nanoparticulate 
formulation of the well-known anticancer compound taxol 
was submitted as a new treatment for advanced stage breast 
cancer.
x In the near future, nanoscale devices may lead to detection 
of the earliest stages of cancer while simultaneously 
delivering anticancer agents to the tumor. Early research 
has shown that nanoparticulate sensors can detect the cell 
death that occurs when a cancer cell succumbs to the 
effects of an anticancer drug. As a highly sensitive means 
of determining if a therapy is working, this application of 
nanotechnology could save a patient from months of 
ineffective medication and debilitating side effects, 
allowing a switch to a potentially more effective course of 
treatment. In addition, such a sensor could greatly 
accelerate clinical trials of new anticancer agents, again by 
demonstrating very early signals of the effectiveness of a 
drug.
The NCI envisions over the next five years that 
nanotechnology will result in significant advances in early 
detection, molecular imaging, assessment of therapeutic efficacy, 
targeted and multifunctional therapeutics, and the prevention and 
control of cancer. 
26
ALZA Corporation's STEALTH® liposomal technology, developed for state-
of-the-art intravenous drug delivery, is the basis for the anticancer agent Doxil® 
(doxorubicin HCl liposome injection). The proprietary STEALTH® liposomes 
evade recognition by the immune system because of their unique polyethylene 
glycol (PEG) coating. 
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RELEVANT NANOTECHNOLOGY EFFECTS FOR APPLICATIONS IN 
THE MEDICAL & HEALTH SECTOR27
Nanoparticles are especially relevant for the Medical & 
Health sector, because they are in the same range of dimension 
than biomaterials (Table 1).  
Table 1. Dimensions of biomaterials  
Biomaterials Size (about)
Atoms  - 0,1 nm 
Nitrogenbases DNA molecules 
(A,G,T,C)
0,1 nm 
Genes 0,1 nm 
DNA molecules  1 – 2 nm 
Small molecules  1 nm 
Peptides (part of enzymes)  1 – 4 nm 
Proteins 2 – 8 nm 
Enzymes (proteins)  2 – 8 nm 
Hormones (proteins)  2 – 8 nm 
Lipids (cholesterol, part of cell 
membrane)  
10 nm 
Nucleus of cell  40 nm 
Viruses 50 – 100 nm 
Vaccines  50 – 1000 nm (0,005 – 1 μm) 
Cell (human, animal)  2000 – 10000 nm (2 – 10 μm) 
Antibody  2000 – 10000 nm (2 – 10 μm) 
Bacteria 5000 – 1000 nm (0,5 – 1 μm) 
27 Groot de, R., Loeffler, J., (2006). Roadmap Report Conserning the Use of 
Nanomaterials in the Medical and Health Sector. The Sixth Framework 
Programme of European Community.
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Nanotechnology is already impacting drug delivery. The 
use of nanostructured materials for drug delivery is an area with a 
great deal of activity that could have a major impact on the medical 
and pharmaceutical industry. Nanotechnologies dedicated to 
biology are called nanobiotechnologies. Nanobiotechnology refers 
to the ability to create and manipulate biological and biochemical 
materials, devices and systems at atomic and molecular levels. 
A key area of research is targeted drug delivery.
Nanotechnology offers the promise of delivery of the right drug in 
the right place at the right time. Some approaches use 
nanoparticles or nanocapsules to deliver drugs through the skin, 
lungs, stomach and eyes already. These approaches offer numerous 
advantages such as increased solubility, resistance to gastric 
enzymes, controlled release or the ability to direct the drug through 
various means to the very place where it is needed. 
The nanostructured materials for drug delivery are 
presented by different methods: 
x Oral delivery. 
x Pulmonary / inhaling systems. 
x Implantable / injectable polymer systems. 
x Transdermal systems. 
x Liposome delivery systems. 
x Needle free injection systems. 
Formulating drugs with nanoparticles can also improve 
their solubility (because many drugs are not water-soluble). 
A key area of research is targeted drug delivery to 
individual cells within the body. Nanotechnology offers the 
promises of: 
x New formulations and routes for drug delivery to 
previously inaccessible sites in the body. 
x The delivery of the right drug in the right place at the right 
time. 
x Personalized drugs. 
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Also some approaches talk about nano pumps and valves, 
nano MEMS devices (NEMS), nano needles and stents to deliver 
nano-litres or nano-quantities of chemical substances. 
Nanomaterials presently used in clinical or pre-clinical 
trials are for example: 
x Nanoparticles.
x Nanocapsules (inclusive liposomes). 
x Nanoshells.
x Fullerenes. 
x Nanotubes.
x Nanoporous materials. 
x Nanocrystals (quantum dots). 
x Dendrimers. 
x Nanomagnets. 
x Calcium Phosphate (CAP) Vaccins. 
x CAP nanoporous particles. 
For drug delivery, these nanomaterials combine the 
advantages of high surface area, improved interfacial properties 
and size confinement to deliver drugs that have increased efficacy, 
offer more convenient dosing of regimens and have improved 
toxicity profiles compared to their micron-sized predecessors. With 
nanoparticles, it is possible that drugs may be given better 
solubility, leading to a better absorption. Also, drugs may be 
contained within a molecular carrier, either to protect them from 
stomach acids or to control the release of the drug to a specific 
targeted area, reducing the likelihood of side effects. These 
nanoparticles could also contain a slowly-released drug payload, 
be radioactive, or enhance the heating effects of a laser shone 
through the flesh to destroy tissue. 
For example, inhalation of sub-micrometer diameter 
particles may offer an efficient route for the administration of 
therapeutic substances: these particles can be deposited deep 
within the lungs, whence, with a thin blood-gas barrier and copious 
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blood supply, they can be absorbed rapidly into the body. Ultra 
fine particles individually contain very little mass, but if present in 
extremely large numbers can disperse significant amounts of 
material deep in the lung. Once there, their very large cumulative 
surface area may assist their dissolution. 
It is hypothesized that engineering inhaled drug particle 
sized down to ultra fine particle levels will produce effective 
“vectors” for respiratory and other drugs, by virtue of their large 
numbers (and hence potential area coverage) and their penetrative 
and deposition properties. In order to prove that, a size-controlled 
ultra fine aerosol delivery system has been developed for human 
volunteer studies and will be used to determine the clinical efficacy 
of a given dose of drug administered in a variety of particle sizes. 
An added benefit would be a reduction in deposition to the mouth 
and throat, reducing some of the adverse side effects seen with 
current inhaled drug delivery systems. Such drugs are already 
beginning pre-clinical or clinical trials, adhering to the strict 
regulatory requirements for new pharmaceuticals. 
Regarding oral drug delivery, factors that affect the 
efficacy of a drug include the solubility, bioavailability, biological 
half-life, dose and dosing regimen and shelf-life. 
Technologies that can improve oral delivery of drugs by 
controlling the release and absorption in the gastro-intestinal tract 
are in great demand and improved powder processing is one 
strategy that can overcome these obstacles. Indeed, in vivo studies 
have shown sustained-release and improved bioavailability of 
pressed powders for improved tablet processing of next generation 
pharmaceuticals. For example, the company Nanotherapeutics has 
developed a system based on nanoparticles that enables oral 
delivery of macromolecules (peptide/protein) and improves the 
oral bioavailability of insoluble and poorly absorbed drugs that 
require injection (e.g. antibiotics, antivirals, anti-inflammatories). 
Nanoparticle suspensions also offer an advanced approach 
in the delivery of insoluble drugs for injectable delivery. Indeed, 
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nanoparticles for injectable delivery offer several advantages 
including low excipient loads/smaller dose volumes, better control 
of particle size and dispersion efficiency, controlled release-rates, 
increased efficacy and systemic bioavailability. 
As has been described nanotechnology is already impacting 
drug delivery, however this will continue apace. In the future, 
nanoparticles will contain far more intelligence than the entire 
current system of drug delivery. These will be able to target and 
deliver therapeutics to specific tissues and cells with no side 
effects. For example a nanoparticle taken orally, that passes 
undisturbed through the stomach and small intestine and into the 
colon, where it homes in directly on the tumour cells and releases a 
powerful anticancer drug that destroys just the cancerous cells, 
could soon be a reality. In this respect antibodies that bind 
exclusively to cancerous cells could be attached to nanoshells and 
injected into patients. 
Following infrared irradiation of the nanoshell-targeted 
tumour the resultant heat would destroy the cancer cells (Virginia 
Commonwealth University). The same directions are conducted by 
French company Nanobiotix. Clinical tests are starting within 2 
years.
 Another possible targeted drug delivery system involves 
the use of nanomagnets that can be directed to specific sites within 
the body using external magnetic fields. These magnets could be 
attached to drugs, modulated field could release drug from 
particles, that treat specific cellular structures. (Biophan 
Technologies, Inc.)
A drug payload is not even necessary: the material could 
just produce high temperature under heat or light to destroy the 
targeted cells. The advantage of such a system is that it allows very 
focused and intense treatment of diseased cells without harming 
cellular structures of non-interest. Nanotubes may one day be used 
in transdermal drug delivery patches as nanoscale needles that can 
inject substances into the body. In fact, developing nanotubes as 
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nanoscale, intravenous or intradermal, drug delivery devices is 
medically significant because  
a) it increases the mechanical and sensing functionality of 
the resultant nanoneedle, which makes it precise. 
b) it is a less invasive and less painful drug administration. 
Nanotubes offer the potential of targeted drug delivery, for 
example to muscles, with molecular amounts of material, which 
maximizes efficiency by permitting lower doses, thereby 
minimizing possible toxicity and harmful side effects. 
The following examples of potential applications can be 
given.
Nanotubes could even be used as nanoneedles that inject 
drugs directly into individual cells, as developed at Purdue 
University. Indeed, many drugs destroy infectious bacteria by 
poking holes in their cellular membranes and leaking out their 
nutrients, just like pricking a hole in a balloon. The nanotubes 
developed by Purdue University could also act in this manner, but 
in addition, they can be targeted and thus lure bacteria with “a 
bait” that guides the nanotubes to the bacterial cell membrane 
where they can start destroying the cell. 
Nanoparticles such as fullerenes28 (molecules based on a 
60 carbon atom cage) and quantum dots (complexes of semi-
conductor material that have unique fluorescent properties) are 
being exploited in many areas including imaging (e.g. 
enhancement of magnetic resonance imaging [MRI] and 
28 Fullerenes, which are made of 60 linked carbon atoms, or C60 made a splash 
in the scientific world when they were unveiled in 1985 by chemists Robert Curl 
and Richard Smalley (1943-2005) at Rice University and Sir Harry Kroto at the 
University of Sussex. The trio won the Nobel Prize in chemistry in 1996 for 
their discovery. They proved that fullerenes were a third form of carbon, after 
graphite and diamond, and named the molecules buckminsterfullerenes because 
they resembled the geodesic dome invented by Buckminster Fuller. Buckyballs 
and another form of fullerene called carbon nanotubes are expected to become 
key ingredients in some nanotech products. 
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ultrasound) and drug delivery (e.g. a modified fullerene is entering 
clinical trials as an anti-HIV agent). 
Other nano-devices will allow the continuous monitoring of 
the level of various biochemicals in the bloodstream and in 
response could release appropriate drugs. For example, an insulin-
dependent diabetic could use such a device to continuously 
monitor and adjust insulin levels autonomously. 
On the other hand drugs can be inhaled in a foggy form 
instead of applied by injection. 
Nektar Therapeutics at the 8th of September, 2005, reported 
that Pfizer Inc and the Sanofi-Aventis Group said that a U.S. Food 
and Drug Administration (FDA) advisory committee panel has 
recommended the approval of Exubera®,   rapid-acting, insulin 
[rDNA origin]),dry powder for oral inhalation for the treatment of 
adults with type 1 and type 2 diabetes. Companies leading 
technology  is advanced PEGylation. 
Nanocrystalline sun blocker (protection) cream that possess 
zinc-oxide, offer the best protection against skin cancer because it 
stops both UVA-beams (cause of sun burn) andUVB-beams 
(penetrate deeper in the skin). BASF developed a very pure 
nanocrystalline zinc-oxide what makes the sun cream colourless 
and silk-soft. The nanocrystalline zinc-oxide is used in the 
SunSense SPF 30 suncream of NuCelle. 
NanoCrystal™ Technology has developed for poorly water 
soluble compounds, Elan's proprietary NanoCrystal technology can 
enable formulation and improve compound activity and final 
product characteristics. The NanoCrystal technology can be 
incorporated into all dosage forms both parenteral and oral, 
including solid, liquid, fast-melt, pulsed release and controlled 
release dosage forms.29
29
In July,2006 Elan Corp. filed a lawsuit against Abraxis BioScinece Inc. 
alleging patent infringement in relation to ABRAXANE and asserting that 
ABRAXANE uses technology protected by two Elan-owned patents. Abraxis is 
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A surgical intracavitary application of paclitaxel and 
carboplatin encapsulated by liquid crystalline cubic phases are 
examined in a pilot study. Cubic phases consist of curved 
biocontinuous lipid bilayers, separating two congruent networks of 
water channels. Used as a host for cytotoxic drugs, the gel-like 
matrix can easily be applied to the walls of a surgical resection 
cavity. The authors have an intracavitary developed Nanocarrier 
system of biodegradable liquid crystalline cubic phases 
encapsulating carboplatin and paclitaxel.30
confident in the integrity of its patents and believes that ABRAXANE does not 
infringe on the patent rights of Elan. The company intends to vigorously defend 
against this lawsuit to protect its patent rights. (Press Release of Abraxis 
BioScience Inc. from Aug. 3, 2006, (NASDAQ:ABBI)). 
30 von. Eckardstein, K. L., Reszka, R., Kiwit, J. C. W. ( 2005 ). Intracavitary 
Chemotherapy (Paclitaxel/Carboplatin Liquid Crystalline Cubic Phases) for 
Recurrent Glioblastoma – Clinical Observations. J. Neuro-Oncology. 305 - 309 . 
von. Eckardstein, K. L., Patt, S., Kratzel, C., Kiwit, J. C. W., Reszka, R. (2005). 
Local chemotherapy of F98 rat glioblastoma with paclitaxel and carboplatin 
embedded in liquid crystalline cubic phases. J. Neuro-Oncology. 209 - 215. 
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Medical coatings are also an area of application where 
much is expected. On this moment you can see much effort in the 
research and development of coatings with nanomaterials with 
depending on the specific application properties and characteristics 
like anti-bacterial, non toxic, stimulation of tissue growth, 
biocompatibility, good attachment to surfaces and sustainability. 
Nanocomposites of titanium alloys, for example, can be 
used to improve the biocompatibility and longevity of surgical 
devices and implants. 
Nanostructuring surfaces can improve cellular attachment 
(e.g. etching surfaces with nanoscale grooves or using instruments 
such as an AFM to imprint surfaces with cell attachment 
molecules), and direct cells to grow into defined structures. By 
incorporating biodegradable polymers to act as a scaffolding, these 
structures can be assembled into dimensional “tissues”. 
Nanostructuring can also be used to provide an anti-microbial 
coating on implants. 
Another area of application with high expectations is the 
imaging of molecules. It is expected that the application of 
nanoparticles (for example with gold, iron, fluorine, manganese 
quantum dots) could be extremely important for the development 
of contrast agents for almost all imaging techniques (magnetic 
resonance, ultrasound, optical, nuclear). 
Quantum dots, nanometer sized crystals of a semiconductor 
material such as cadmium selenide, (CdSe), cadmium sulfide 
(CdS) or cadmium telluride (CdTe) with an inert polymer coating, 
are another promising nanoscale tool for laboratory diagnostics. 
The color of a quantum dot depends on its size. These quantum 
dots emit across the entire visible spectrum even though all are 
irradiated with white light. 
The semiconductor material used for the core is chosen 
based upon the emission wavelength range being targeted: CdS for 
UV-blue, CdSe for the bulk of the visible spectrum, CdTe for the 
far red and near-infrared, with the particle’s size determining the 
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exact color of a given quantum dot. Because of the multitude of 
colors with which they can emit light, quantum dots can be 
combined to create assays capable of detecting multiple substances 
simultaneously. Due to their tiny size they are traced in dividing 
cells versus other fluorescent dyes. The polymer coating 
safeguards cells from cadmium toxicity but also affords the 
opportunity to attach any variety targeting molecules, including 
monoclonal antibodies directed to tumor-specific biomarkers. In 
one demonstration, researchers were able to simultaneously 
measure levels of the breast cancer marker Her-2, actin, microfibril 
proteins, and nuclear antigens.
Because of their small size, quantum dots can function as 
cell- and even molecule-specific markers that will not interfere 
with the normal workings of a cell. In addition, the availability of 
quantum dots of different colors provides a powerful tool for 
following the actions of multiple cells and molecules 
simultaneously. 
In August 2004, researchers announced the successful 
preparation of water-soluble gold quantum dots that can also be 
constructed to emit light at a variety of wavelengths. These 
polymer-coated quantum dots may prove to be more suitable for 
use in human clinical applications. 
BIO-NANOTECHNOLOGY BREAKTHROUGH: RNA COULD FORM
BUILDING BLOCKS FOR NANOMACHINES
Eventually, it should be possible to mix and match 
anticancer drugs with any one of a number of nanotechnology-
based delivery vehicles and targeting agents, giving researchers the 
opportunity to fine-tune therapeutic properties without needing to 
discover new bioactive molecules. A good example from the 
biological world is a virus capsule, made from a limited set of 
proteins, each with a specific chemical functionality, that comes 
together to create a multifunctional nanodelivery vehicle for 
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genetic material. In fact, at least one research group is using the 
empty RNA virus capsules from cowpea mosaic virus and 
flockhouse virus as potential nanodevices. 
Purdue Universitie’s researchers developed some of their 
RNA-manipulation techniques in 2003 by building an RNA 
nanomotor.  
Peixuan Guo, professor of molecular virology at Purdue 
University, has found that a virus known as Bacteriophage Phi 29 
uses six RNAs strung together in the shape of a hexagon to create a 
motor that transports DNA in the virus.  
Guo's findings represent the first example of a hexagonal-
shaped RNA complex. It is also the first example of transportation 
vehicles using RNA as building blocks. 
The motor measures about 25 nanometers long, which is 
less than one hundredth the size of a red blood cell. It is made from 
six strands of RNA surrounding a center strand of DNA. In the 
presence of ATP, the RNA strands push the DNA axle in 
succession, spinning it around. This produces 50 to 60 
piconewtons, or trillionths of a newton of force. A falling apple 
exerts about one newton of force.
Professor Guo's team created their nanoparticles by linking 
together different kinds of RNA, sorted through a variety of RNA 
forms that have shown promise for disease treatment and found 
three that could perform each of the desired tasks. One is "small 
interfering RNA," or siRNA, which deactivates certain genes in 
cells. The anothers are RNA aptamers, which bind to cancer cell 
surface markers, and the last are ribozymes, which can be designed 
to degrade specific RNA in cancer cells or viruses. 
The successful use of small RNA for therapeutic purposes 
requires a safe and efficient delivery system capable of targeting 
specific cells. These protein-free 25-nm nanoparticles will allow 
for repeated and longterm administration escaping 
immunoresponse and avoid the short retention time of smaller 
molecules and the undeliverability of larger molecules. 
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The nanoparticles have already proven effective against 
cancer growth in living mice as well as lab-grown human 
nasopharlyngeal carcinoma and breast cancer cells.  [Shu, D., 
Moll, W.-D., Deng, Z., Mao, C., and Guo, P. (2004). Nano Lett. 
4:1717–1724]
"This is an incredible accomplishment that points to the 
versatility and potential medical value of these nanoparticles." said 
Jean Chin, a scientist at the National Institute of General Medical 
Sciences, which is part of the National Institutes of Health. 
UTILIZATION OF BIODEGRADABLE POLYMERS FOR 
CONTROLLABLE DRUG RELEASE
While such work with naturally existing nanostructures is 
promising, chemists and engineers have already made substantial 
progress turning synthetic materials into multifunctional 
nanodevices.
Over the past decade for development of nano and 
microparticles are investigated biodegradable polymers, as 
effective drug delivery systems (DDSs) for the most urgent areas 
of medicine, particularly for chemotherapy, vaccines, and anti-
infectious agents.  
Life is polymeric in its essence, as the most important 
components of living cells (proteins, carbohydrates and nucleic 
acids) are polymers. Polymers are natural and synthetic in origin. 
Most essential polymers could possess such important 
features as  biodegradability, biocompatibility and capability of 
sustained intracellular delivery of multiple classes of cargoes, so to 
be a suitable system for intracytoplasmic delivery of drugs, 
proteins, or genes.
Already, some dendrimer-based constructs are making their 
way toward clinical trials for treating a variety of cancers. 
Dendrimers are of particular interest for cancer applications 
because of their defined and reproducible size, but more 
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importantly, because it is easy to attach a variety of other 
molecules to the surface of a dendrimer.
Dendrimers are 1- to 10-nanometer spherical polymers of 
uniform molecular weight made from branched monomers, are 
proving particularly adept at providing multifunctional modularity.  
A dendrimer is a tree-like highly branched polymer 
molecule (Greek dendra = tree). Dendrimers are synthesized from 
monomers with new branches added in discrete steps 
("generation") to form a tree-like architecture. A high level of 
synthetic control is achieved through step-wise reactions and 
purifications at each step to control the size, architecture, 
functionality and monodispersity. Several different kinds of 
dendrimers have been synthesized utilizing different monomers 
and some are commercially available. This picture shows a "3rd 
generation" polyamidoamine (PAMAM) dendrimer.  
The guest molecules, which are hydrophobic when trapped 
into the suitable sites of dendrimers, are becoming soluble in 
aqueous solution. Such molecules could include tumor-targeting 
agents (including but not restricted to monoclonal antibodies), 
imaging contrast agents to pinpoint tumors, drug molecules for 
delivery to a tumor, and reporter molecules that might detect if an 
anticancer drug is working. In one elegant demonstration, 
investigators attached the anticancer drugs methotrexate or 
paclitaxel to a single dendrimer. 
ANTICANCER DRUG DELIVERY  BY POLYMER -BASED 
NANO/MICROSPHERES
Although, the drug delivery system (DDS) concept is not 
new, great progress has recently been made in the treatment of a 
variety of diseases. Targeting delivery of drugs to the diseased 
lesions is one of the most important aspects of DDS. To convey a 
sufficient dose of drug to the lesion, suitable carriers of drugs are 
needed. Nano/microspheres carriers have important potential 
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applications for the administration of therapeutic molecules. The 
research in this area is being carried out all over the world at a 
great pace. Research areas cover novel properties that have been 
developed increased efficiency of drug delivery, improved release 
profiles and drug targeting.
Nano and microspheres for their attractive properties 
occupy unique position in drug delivery technology. Nano/micro- 
particles and spheres attained much importance, as the different 
dosage forms reported. One of the current trends in this area will 
be discussed, particularly PGLA nano/microspheres utilization as 
DDS.
The term nano/microcapsules and nano/microspheres are 
defined, as a spherical particles with the size varying in between 50 
nm to 2 mm containing a core substance. Due to attractive 
properties and wider applications of nano/microcapsules and 
nano/microspheres, a survey of the applications in controlled drug 
release formulations is appropriate. 
One way to overcome side effects of anticancer drags and 
resolve these problems is to encapsulate the drug in polymer 
matrix. Commercially available best known class of biodegradable 
materials for controlled release are the poly L lactide (PLA),  
poly(D,L-lactide-co-glycolide)s (PLGAs), poly ethylene glycol 
(PEG) and etc. Various drug release profiles can be achieved by 
varying the molecular weight, copolymer ratio, drug loading, 
microspheres size and porosity, and the fabrication conditions. The 
fabrication technique chosen should be based on the nature of the 
polymer, the drug, its intended use and the duration of the therapy. 
The research report from Singapore National University31
describes the in vitro release of Paclitaxel from PLA-based 
31 Reports are presented by the group of authors, from the Department of 
Chemical and Biomolecular Engineering, National University of Singapore:  
[1] Lee, LY., Smith, K. A., Wang, CH., (2005). Fabrication of micro and 
nanoparticles of paclitaxel-loaded Poly L Lactide for controlled release using 
supercritical antisolvent method: Effects of Thermodynamics and Hydrodynamics. 
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nano/microspheres fabricated using the modified SASEM process 
was further evaluated for their suitability for controlled release 
applications. The encapsulation and sustained release of a 
hydrophobic anticancer drug, paclitaxel, was employed to 
characterize the properties and release from PLA micro and 
nanoparticles. Paclitaxel is a promising anticancer drug with 
efficacy against a wide variety of carcinomas. However, its clinical 
application has been limited due to its hydrophobic nature. One 
method to overcome the problems brought about by Cremophor® 
EL is to encapsulate paclitaxel in biodegradable polymers such 
PLA or poly (DL lactic-co-glycolic acid) (PLGA) in micro and 
nanoparticles. These biodegradable polymeric particles also have 
the advantage of providing sustained release of paclitaxel for 
chemotherapy.32, .33
[2] Xie, J., Wang, CH., (2004).Paclitaxel-loaded Biodegradable Nanoparticles 
Developed by Dialysis and ElectroHydrodynamic Atomization Methods. 
[3] Xie, J., Wang, CH., (2005). Micro- and Nano-Particles Developed by 
Electrohydrodynamic Atomization for the Sustained Delivery of Paclitaxel to Treat 
C6 Glioma. 
[4] Lee, L. Y., Smith, K. A., Wang, C. H., (2005).Fabrication of controlled release 
devices using supercritical antisolvent method. 
[5] Xie, J., Wang,  C. H. (2005). Self-Assembled Biodegradable Nanoparticles 
Developed by Direct Dialysis for the Delivery of Paclitaxel. 
32 L. Mu, S.S. Feng, “Fabrication, characterization and in vitro release of paclitaxel 
(Taxol ®) Poly (DL-lactic-co-glycolic acid) microspheres prepared by spray drying 
technique with lipid/ cholesterol emulsifiers”. J. Control. Rel. 76, pp 239 – 254, 
2001.
33[1] L. Mu, S. S. Feng, PLGA/TPGS Nanoparticles for controlled release of 
paclitaxel, Pharma. Res. 20, pp 1864 – 1972, 2003 
[2] L. Mu, S. S. Feng, “A novel controlled release formulation for the anticancer 
drug paclitaxel (Taxol®): PLGA nanoparticles containing vitamin E TPGS”, J. 
Control. Rel. 86 (2003) pp 33 – 48, 2003 
[3] S. S. Feng, L. Mu, K. Y. Win, G. Huang, “Nanoparticles of biodegradable 
polymers for clinical administration of paclitaxel”, Curr. Med. Chem. 11, pp 413 – 
424, 2004 
[4] J. Wang, C. W. Ng, K. Y. Win, P. Shoemakers, T. K. Y. Lee, S. S. Feng, C. H. 
Wang, “Release of paclitaxel from polylactide-co-glycolide (PLGA) microparticles 
and discs under irradiation”, J. Microencapsulation. 20, pp 317 – 327, 2003. 
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APPLIED NANOTECHNOLOGY FOR PACLITAXEL 
DRUG DELIVERY COULD BE THE SOLUTION 
As terrible as cancer can be, chemotherapy treatments can 
make one think that the disease might be the lesser of two evils. 
The basic premise behind chemotherapy is to poison the patient’s 
system with a cocktail of drugs. Not only does the cancer get 
attacked but so too does the entire body. 
If the drugs aren’t water soluble the need to be dissolved in 
another solvent so they can be injected. Often this solvent is highly 
toxic and causes strong side effects. American Pharmaceutical 
Partners have announced that its cancer-fighting drug 
ABRAXANE™ (consisting of 130-nanometer spheres of protein 
and paclitaxel) has demonstrated greater tumour reduction and 
fewer side effects when compared to a solvent-dissolved 
equivalent.
For the first time, the anticancer drug Paclitaxel can now be 
delivered using the body's transport protein, human serum albumin 
rather than a chemical solvent. As a solvent-free chemotherapy 
agent, ABRAXANE™ increases the convenience of 
administration.  
ABRAXANE™ (Paclitaxel) was approved in February 
2005 by the FDA.  ABRAXANE™ launched by Abraxis 
Oncology, the proprietary drug division of (APP) American 
Pharmaceutical Partners, Inc. Abraxane™ is trademark of 
BioScience, Inc.(USA). 
ABRAXANE™ - for Injectable Suspension is the first and only 
approved taxane for the treatment of metastatic breast cancer in a 
new class of albumin-bound nanotechnology that is free of 
solvents. As a solvent-free chemotherapy agent, ABRAXANE™ 
increases the convenience of administration. 
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ABRAXANE™ - FINANCIAL PERFORMANCE OVERVIEW  OF 
MARKETING  FOR 2005-200634
"This has been an exciting year of growth for the company. 
We have exceeded, for the first time, half a billion in net 
sales supported by the approval and successful launch of 
ABRAXANE™ and the stability of the base business," 
said, Patrick Soon-Shiong, APP's president and chief 
executive officer.
Current overview is made based on press releases of APP and 
Abraxis Inc. Assuming that unless marked as Company 
Confidential, all information has been made punlic. This 
presentation provides an overview of financial performance 
American Pharmaceutical Partners, Inc. is a specialty drug 
company that develops, manufactures and markets injectable 
pharmaceutical products, focusing on the oncology, anti-infective 
and critical care markets. Abraxis Oncology, the proprietary 
division of APP, is devoted entirely to developing and promoting 
innovative, next-generation cancer therapies such as 
ABRAXANE™. 
AMERICAN PHARMACEUTICAL PARTNERS REPORT RECORD FOR 
2005 SALES AND NET INCOME
Full year net sales increased 28% to $518.8 million and net income 
increased 52% to $86.4 million; 
ABRAXANE™ brings of 11 months net sales following launch to 
$133.7 Million; 
For the full year, gross margin was 56.5%, versus 53.3% in 2004. 
34 ABTAXIS BIOSCIENCE, INC.
AMERICAN PHARMACEUTICAL PARTNERS
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ABRAXANE™ revenue for the 3rd quarter 2006 increased to 
$52.3 million, which includes $40.2 million of net sales, versus net 
sales of $32.1 million in the same period last year. Net sales in the 
third quarter of 2006 represent a 25% increase. 
Ź ABRAXANE™ shows a positive trend in market 
penetration for metastatic breast cancer. According to IMS 
data, for the period between February 2006 and September 
2006 versus the same period last year, there was a 64% unit 
growth in ABRAXANE™ versus an 11% increase in the 
overall taxane market. At the beginning of the third 
quarter, an expanded team of 172 oncology specialists 
began selling ABRAXANE™ throughout the U.S. This 
team now consists of the original ABRAXANE™ sales 
force as well as the added AstraZeneca oncology 
specialists. 
Ź It’s five and a half year U.S. co-promotion of 
ABRAXANE™. This agreement effectively doubles the 
sales force and promotional investment in ABRAXANE™. 
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CYTIMMUNE - PEGILATED GOLD NANOPARTICALS -
A NOVEL VECTOR FOR TUMOR DIRECTED DRUG DELIVERY
In 2000, CytImmune discovered that pegylated colloidal 
gold nanoparticles bind anti-cancer therapeutics on their surface 
and carry these drugs safely through the blood stream.   
Thiolated forms of small molecule therapeutics, such as 
paclitaxel, TNF, bind directly to the surface of colloidal gold 
nanoparticles.
With tumor targeting 
resulting in increased drug 
levels in the tumor and reduced 
drug uptake by healthy organs, 
the technology improves 
efficacy and reduces toxicity. 
Polyethylene glycol (PEG) 
masks particles from immune 
recognition preventing uptake 
by liver and spleen. Nanoparticles exit circulatory system only at 
the tumor neovasculature due to leakiness of blood vessels 
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Particles too large to exit circulation elsewhere TNF targeting 
molecule on particle’s surface binds to receptors causing rapid 
absorption of drug in and around tumor. 
ACUSPHERE Inc.  
ACUSPHERE Inc. is a specialty pharmaceutical company 
that develops new drugs and improved formulations of existing 
drugs using its proprietary porous microparticle technology.  
AI-850, our initial product candidate utilizing our HDDS 
technology, is a readily dissolving formulation of the hydrophobic 
drug, paclitaxel, the active ingredient in the cancer drug, Taxol. To 
dissolve paclitaxel, Taxol contains Cremophor, which is believed 
to cause severe hypersensitivity reactions, such as an extreme 
allergic reaction called anaphylaxis. Therefore, Taxol is typically 
administered using pre-medications and by long infusions to 
patients with cancer. By putting nanoparticles of paclitaxel into 
sponge-like microparticles, is created a paclitaxel formulation that 
is free of Cremophor and consists of paclitaxel nanoparticles in a 
porous, hydrophilic matrix, composed primarily of a sugar that has 
been proven to be innocuous in other injectable drugs. 
NEOPHARM - DRUG DELIVERY PLATFORM - NEOLIPID®
NeoPharm  is a biopharmaceutical company dedicated to 
the research, discovery, and commercialization of new and 
innovative cancer drugs for therapeutic applications. NeoPharm 
has built its drug portfolio based on its two novel proprietary 
technology platforms: a tumor-targeting platform and the 
NeoLipid® drug delivery system. 
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NeoLipid® technology entraps anticancer agents inside 
liposomes, which are microscopic membrane-like structures 
created from lipids. Because tumor cells need to consume large 
amounts of fats to sustain their rapid growth, they eat the liposome, 
while at the same time absorbing the anticancer agents. LEP-ETU 
embedded paclitaxel enters II phase of clinical trials. 
BIODELIVERY SCIENCES INTERNATIONAL, INC.
BDSI Technology is patented and proprietary drug delivery 
technologies: Bioral® and BEMA™ technologies.
The Bioral® drug delivery technology encapsulates the 
selected drug in a nanocrystalline structure termed a “cochleate” 
cylinder.  All of the components of the cochleate cylinder are 
naturally occurring substances. Cochleate cylinder provides an 
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effective delivery mechanism without forming a chemical bond, or 
otherwise chemically altering, the selected drug.
The BEMA™ drug delivery technology consists of a 
dissolvable, dime-sized polymer disc for application to mucosal 
(inner lining of cheek) membranes.  BEMA™ discs deliver a rapid, 
reliable dose of drug across mucous membranes for time-critical 
conditions like breakthrough cancer pain, or trauma cases where 
intravenous lines or injections are unavailable or not practical. 
Bioral paclitaxel is available for licensing. 
Drug Indication Status
Emezine Nausea/Vomiting Partnered
BEMA Fentanyl Breakthrough pain Proprietary 
Bioral Amphotericin 
B
Fungal infections Proprietary 
Bioral NSAID Pain Licensed
Bioral paclitaxel Oncology Avail. for Licensing
Bionasal
Amphotericin B
Chronic
rhinosinusitis
Partnered
Biorazyme Gauchers Disease Avail. for Licensing
Bioral siRNA Infectious
disease/cancer 
Avail. For Licensing
APHIOS CORPORATION
Aphios Corporation is developing enhanced therapeutics 
for health maintenance and the treatment of human diseases with a 
focus on infectious diseases, cancer and quality-of-life medicines
Aphios has utilized its patented SuperFluids™CFN 
technology to form nanosomes (small, uniform liposomes) of 
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paclitaxel. Liposomes are microscopic vesicles of phospholipid 
bilayers comprised of single or multiple lipid bilayers. Most 
liposomes are non-toxic, non-antigenic and biodegradable in 
character since they have the molecular characteristics of 
mammalian cell membranes. Hydrophobic compounds are trapped 
inside the lipid bilayers, masking the toxic nature paclitaxel and 
permitting a biocompatible formulation to be administered.  
Aphios has developed and patented a nanosomal 
formulation of Paclitaxel, Taxosomes.™ The formulation is 
Cremophor-free and produced by Aphios’ patented phospholipid 
nanosomes technology [U.S. and European Patents, 1995, 1997, 
1998 and 2002]. Harvard Medical School researchers have 
demonstrated that Taxosomes™ is much less toxic in vitro than 
Taxol,® while being twice as effective in the in vivo treatment of 
nude mice with breast cancer xenografts. 
NANOMED PHARMACEUTICALS, INC.
NanoMed has developed a scaleable nanoparticle 
manufacturing technology (Nanotemplate Engineering) to deliver 
small molecules, peptides, proteins, plasmid DNA, and diagnostic 
agents.
NanoMed has developed a scaleable nanoparticle 
manufacturing technology (Nanotemplate Engineering) to deliver 
small molecules, peptides, proteins, plasmid DNA, and diagnostic 
agents. The company is utilizing this novel platform technology to 
develop new and improved formulations for two approved 
chemotherapeutic drugs -- paclitaxel (Paclitaxel NP™) and 
doxorubicin (Doxorubicin NP™) -- and a new indication for a 
third approved therapeutic agent for use as a novel anti-cancer drug 
(NAC NP). The therapeutic focus is breast, lung, and colorectal 
cancer.
122
SONUS PHARMACEUTICALS
The Company's lead product candidate is TOCOSOL® 
Paclitaxel, an injectable, ready-to-use formulation of the widely 
prescribed anti-cancer drug paclitaxel.
The product is administered to patients in a short 15-minute 
infusion compared to the prolonged three-hour infusion required 
with Taxol. TOCOSOL Paclitaxel has been designed to overcome 
the limitations associated with Taxol® and generic paclitaxel-
based chemotherapy, including time consuming and expensive 
preparation of the products prior to administration, long infusion 
times and undesirable or treatment-limiting side effects.  
Sonus has completed patient enrollment in Phase 2a studies 
of TOCOSOL Paclitaxel in non-small cell lung, bladder and 
ovarian cancers, and Phase 2b studies are ongoing in bladder and 
breast cancers. In addition, the U.S. Food and Drug Administration 
has completed a Special Protocol Assessment (SPA) for the pivotal 
Phase 3 trial of TOCOSOL Paclitaxel, which Sonus expects to 
initiate in 2005.
The TOCOSOL® technology uses vitamin E and vitamin E 
derivatives to solubilize, stabilize and formulate drugs with the 
goal of enhancing their delivery, safety and efficacy. The 
Company’s development strategy is: 
Develop proprietary formulations of therapeutic drugs 
utilizing the TOCOSOL technology platform; and identify and 
acquire additional therapies and technologies in oncology and 
related fields in order to expand product pipeline and corporate 
capabilities.
SPHERICS, INC – FEASIBILITY  STUDY OF ORAL NANOPARTICLE 
FORMULATION PACLITAXEL
Paclitaxel exists in several states, e.g., semicrystalline, 
dehydrate and amorphous and is generally supplied in the semi-
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crystalline state. A micronization method that could reduce particle 
size and reduce crystallinity of paclitaxel would increase 
absorption of both particulate and soluble drug. 
The paclitaxel nanoparticle formulations in the present 
study were prepared using a proprietary phase-inversion 
precipitation technique, to produce discrete particles of amorphous 
paclitaxel in the size range of 300 nm. The oral pharmacokinetics 
of the PNF were evaluated after single and repeat dosing in fasted 
mice. Paclitaxel nanoparticles were fabricated via a phase 
inversion technique.
NANOTECHNOLOGY FORECASTING
PIRIBO provides informational databases and performs 
information about products, including market research, covering 
the Drug Delivery Industry, including latest technologies, company 
profiles, biopharmaceuticals, market data and information covering 
Europe, the UK, North America and Asia. PIRIBO performs “Drug 
Delivery Market Research, Intelligence and Forecasts.” There are 
presented 183 biotechnology and 164 drug delivery companies. 
GREYSTONE ASSOCIATES is a medical technology 
consulting firm and offers forecasts and projections cover the 
period from 2004 to 2008. “Nanoparticle Drug Delivery, 
Technology, Therapies, and Prospects”. 
Nanotechnology first successfully developed in chemical 
and material production industry. Later some major companies 
commercialize their developments and start to sale production 
mostly to leading pharmaceutical companies, such as Jonson & 
Jonson, Bristol Mayerr Squibb, Roche, Sanofi-Aventis and so on. 
For example - Nektar Therapeutics (UK) is a leader drug delivery 
company. They have partner collaborations with more than 25 
pharmaceutical and biotechnology companies, including Pfizer, 
Roche, Amgen, Bristol-Myers Squibb, Scherig-Plough, UCB 
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Pharma, Chiron, InterMune, Serono. This technologies are 
essential to six drugs approved in the United States and/or Europe. 
The combination of technology leadership and 
development expertise allows Netar to capitalize on the rapidly 
expanding market for drug delivery solutions, which is estimated 
to grow from $50 billion in 2000 to more than $100 billion by 
2005.
Recently, a nanoparticulate formulation of the well-known 
anticancer compound taxol was submitted by as a new treatment 
for advanced stage breast cancer.
Pharmaceutical market is partially traversed by 
nanotechnology based medications. However, most clinical reports 
in the nanotechnology are of phase 1 and phase 2 trials.
To conclude, nanotechnologies have already begun to 
change the scale and methods of drug delivery. 
Nanotechnology can provide new formulations and routes for 
drug delivery that broaden their therapeutic potential 
enormously by effecting delivery of new types of medicine to 
previously inaccessible sites in the body. 
The use of nanocapsules and nanoparticles for drug 
delivery is an area with a great deal of activity that could have 
a major impact on the medical and pharmaceutical industry. 
Some of the technologies are relatively developed but will be 
affected by the notoriously long timescales needed for clinical 
testing. The eventual success of nanotechnology in areas of 
medicine will require patient acceptance and careful 
consideration of the social and economic consequences of 
genetic testing and therapy. 35
35 Groot de, R., Loeffler, J., (2006). Roadmap Report Conserning the Use of Nanomaterials in the Medical and 
Health Sector. The Sixth Framework Programme of European Community. 
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CHAPTER FIVE
INVENTION OF NOVEL DRUG DELIVERY SYSTEMS FOR 
IMPROVEMENT AND ENHANCEMENT OF CHEMOTHERAPY 
NANOPARTICLES OF BIODEGRADABLE  POLYMERS FOR NEW-
CONCEPT CHEMOTHERAPY
36
Clinical trials are the most important step for any medical 
product to be approved for clinical use. Pharmacology of 
experimental animals could be very different from that of humans, 
and interpatient and intrapatient differences also exist. Few reports 
of clinical trials can be found from the literature for nanoparticles 
of biodegradable polymers for chemotherapy, although some 
preclinical guidelines have been provided. Chemotherapy plays an 
important role especially when surgery and radiotherapy fail to 
cure the patients, who have only a 10% chance of cure by other 
therapies. 
While the effort to find medical solution should be contin-
ued, new hope will most likely come from emerging technology, 
especially nanobiotechnology, which can be defined as 
chemotherapeutic engineering37. The situation for the emerging 
chemotherapeutic engineering looks similar to that for tissue 
engineering 30 years ago. Chemotherapeutic engineering will be 
well defined and begin to play a necessary and important role in 
the fight against cancer and other fatal diseases in the next 5 years.
It has been shown by the marvelous progress in the past 
decades in molecular biology, materials science and nanoparticle 
technology, that nanoparticles of biodegradable polymers have 
36 Feng S. S. (2004). Nanoparticles of Biodegradable polymers for new-concept 
chemotherapy.  Expert Rev. Medical Devices 1 (1), pp.115-125. 
37 Feng SS, Chien S. (2003), Chemotherapeutic engineering: application and 
further development of chemical engineering principles  for chemotherapy of 
cancer and other diseases. Invited review. Chem. Engr. Sci. 58, 4087-4114. 
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great potential to provide an ideal solution for most of the major 
problems encountered in chemotherapy and with further 
development, to promote a new concept of chemotherapy, which 
may include sustained chemotherapy controlled and targeted 
chemotherapy, personalized chemotherapy, chemotherapy across 
various physiological drug barriers such as the GI barrier for oral 
chemotherapy and the BBB for treatment of brain tumors and other 
CNS diseases, and eventually, chemotherapy at home. 
Chemotherapy will become safer, more efficient and eventually 
under full control. The quality of life of the patents can then be 
greatly improved. While tissue engineering is thought to be likely 
to change the traditional concept of surgery, chemotherapeutic 
engineering should be of potential to substantially change the 
current practice of internal medicine. 
Development of effective carriers for both existing and 
newly developed anticancer drugs may be as important as the 
discovery of new anticancer drugs. 
There has been intense research over the past decade into 
the development of nanoparticles of biodegradable polymers as 
effective drug delivery systems for chemotherapy. Progress in 
nanoparticle technology, material science and engineering, and 
cellular and molecular physiology and pathology has contributed to 
the advancement in nanopsrticle technology for chemotherapy. The 
polymers used are biocompatible and biodegradable, either 
synthesized or natural, which are subject to FDA approval. The 
drug can either be dispersed in the polymeric matrix, or 
conjugated/attached to the polymer molecules. Following 
administration, the drug can be released from the nanoparticles. 
The drug release mechanism can be diffusion, polymer matrix 
swelling, polymer erosion and degradation. For most FDA-
approved biodegradable polymers, which have bulk erosion 
properties, drug diffusion and polymer matrix swelling play a 
major rule since the degradation of these polymers is relatively 
slow, often occurring over a year or so. However, more and better 
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polymers of surface erosion properties or hydrophilic components 
are being developed, where polymer erosion/degradation can play 
a primary role. No other adjuvant is required. The drug 
encapsulated in the nanoparticles will gradually be released from 
the polymer matrix, which will eventually be degraded into 
harmless molecules such as hydrogen, nitrogen and water. 
Nanoparticles of biodegradable polymers can be made adequately 
small to allow intracapillary or transcapillary passage and can be 
appropriately coated to escape elimination by the 
reticuloendothelial system, as well as to promote adhesion to and 
uptake by cancer cells. Nanoparticles for cancer chemotherapy 
have been extensively investigated in the past decade, including, 
but not limited to, paclitaxel, doxorubicin and 5-FU. 
In addition to drug formulation, nanoparticles of biodegrad-
able polymers can be employed to solve other problems in 
chemotherapy such as pharmacokinetics, drug toxicity and drug 
resistance.
Polymeric nanoparticles can be prepared either by 
dispersion of the polymers or by polymerization of monomers; 
both approaches involve the use of chemical engineering 
techniques. Various FDA-approved biodegradable and 
biocompatible polymers such as polylactic acid (PLA), polylactic-
co-glycolic acid (PLGA) and polyepsilon-caprolactone (PCL) are 
available for this purpose. 
NEW DRUG DISCOVERY  - BIRTH OF A DRUG
From the time it leaves the discovery laboratory until it is 
cleared by the U.S. Food and Drug Administration, a new drug 
typically follows a series of well-defined steps. Here is an 

Roche Pharmaceuticals in U. S. (2002). Innovative Research and Development 
-  Birth of a Drug.  
Elan Corporation, (2001- 2004). Benefits of Drug Delivery. Dublin, Ireland. 
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overview of the process that all pharmaceutical companies must 
follow to file a new compound in the United States.
Development of new treatments in medicine is made 
possible by the design, conduct and reporting of prospective 
clinical trials. There are number of early stage and internal 
development projects for each of the technology platforms which 
are shown below: 
¾ Feasibility – In vitro (laboratory) feasibility study to determine 
whether, under laboratory conditions, the formulation of the 
product candidate can be achieved. Laboratory and animal 
studies are conducted to evaluate the safety and efficacy of the 
new compound in lower animals, to determine its toxicity and 
clinical effects.   
¾ Investigational New Drug Application (IND) – to receive
permission in the U.S. to test the drug on humans, companies, 
show the results of previous series of animal testing. Further 
pharmacological and pharmacokinetic experiments then 
attempt to elucidate the method of action of the drug and 
suggest appropriate doses for administration to humans. 
¾ Phase I - Also called pre-clinical, where batches are 
manufactured for in vivo studies (in humans) in healthy 
volunteers. This phase involves testing on 20 to 80 normal, 
healthy volunteers to determine a safe dosage and how the drug 
is absorbed and metabolized in the human body. Some 
preliminary dose proportionality data may be obtained. At this 
phase, the drug development group may set about developing 
an appropriate dosage form for administration to humans. 
¾ Phase II – Also called pre-pivotal trials. Additional in vivo 
testing my be performed involving in small patient population. 
In phase II clinical trials, patients, affected by the disease for 
which the therapeutic indication is being sought, are recruited 
to gain information on the dose proportionality of the drug, and 
preliminary efficacy data. It is at this phase that a dosing 
schedule is usually determined. 
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¾ Phase III – Also called pivotal trials. Phase III clinical trials 
are larger programs in which the product is administered to an 
expanded patient population typically at dispersed sites. All of 
the improved outcome or new products under development 
require a phase III trial. To assess the drug’s effectiveness, 
studies are conducted with 1,000 to 3,000 patients, with the 
disease that the drug has been designed to treat. Physicians 
monitor patients closely to confirm the drug’s efficacy and 
identify adverse reactions. The purpose is to determine the 
safety and effectiveness of the drug when compared with a 
placebo or an established product on the market. 
¾ Commercial Manufacturing - In parallel with Phase II and 
Phase III trials, development work is usually undertaken to 
scale up the production of the prototype dosage forms 
developed in the laboratories.
¾ New drug Application (NDA) – Filed. Data from all phases 
are analyzed and findings (if positive) are compiled and filed 
with the FDA. Company (which initially develops original 
production) file for regulatory approval in jurisdiction in which 
it is intended that the product will be marketed. For example, in 
USA, this will require filing with the FDA. 
¾ FDA Advisory Review - An independent panel of experts 
appointed by the FDA reviews the NDA, considers 
presentations by company representatives and FDA reviewers, 
then makes a recommendation to the FDA. The FDA may or 
may not follow that recommendation. 
¾ Labeling Discussions -Companies work with the FDA on the 
specific wording for the product label, which provides the 
essential information needed by a physician to prescribe a drug 
properly.
¾ Registration - Information collected throughout the discovery 
and development process is forwarded to a government 
regulatory agency (FDA, in the United States) for a complete 
review. The agency determines, sometimes with the help of a 
132
committee of experts, whether the company submitting the file 
has made a case for use of the drug in patients for specific 
diseases. In particular, the FDA will look for statistical and 
clinical evidence that the drug is effective, often compared to 
drugs currently used in the market, and most importantly, that 
it is safe for use in the indication which has been studied. If the 
company has shown this convincingly, the drug will then be 
approved.
¾ Approval– Approved by the relevant regulatory authority. 
¾ Phase IV – Marketed. Product is available in the market. 
Once a drug has been cleared for marketing, the new medicine 
is made available to physicians to prescribe. Once marketed, 
further clinical studies may be undertaken to compare the 
market potential or cost-effectiveness of the new drug with 
established market leaders, or in other therapeutic areas for 
which marketing claims are not sought. These studies are 
usually termed "Phase IV trials," and they are used to position 
the product in the marketplace and facilitate acceptance of the 
new drug among the medical community. Phase IV studies are 
often undertaken to answer questions posed by regulatory 
authorities and thought leaders. The company must continue to 
submit periodic reports to FDA, including any cases of adverse 
reactions.
DRUG DELIVERY SYSTEMS
Devices capable of bypassing biological barriers to deliver 
therapeutic agents with accurate timing and at locally high 
concentrations directly to cancer cells will play a critical role in the 
development of novel therapeutics. 
Drug delivery and targeting systems under development 
aim to minimize drug degradation and loss, prevent harmful side 
effects and increase the availability of the drug at the disease site. 
Drug carriers include micro and nanoparticles, micro and 
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nanocapsules, lipoproteins, liposomes, and micelles, which can be 
engineered to slowly degrade, react to stimuli and be site-specific. 
Targeting mechanisms can also be either passive or active. An 
example of passive targeting is the preferential accumulation of 
chemotherapeutic agents in solid tumors as a result of the 
differences in the vascularization of the tumor tissue compared 
with healthy tissue. Active targeting involves the chemical 
‘decorating’ of the surface of drug carriers with molecules 
enabling them to be selectively attached to diseased cells. 
The controlled release of drugs is also important for 
therapeutic success. Controlled release can be sustained or 
pulsatile. Sustained (or continuous) release of a drug involves 
polymers that release the drug at a controlled rate, by diffusion out 
of the polymer or by degradation of the polymer over time. 
Pulsatile release is often preferred, as it closely mimics the way by 
which the body naturally produces hormones such as insulin. It is 
achieved by using drug-carrying polymers that respond to specific 
stimuli (e.g. exposure to light, changes in pH or temperature). 
Other nano-based approaches to drug delivery are focused 
on crossing a particular physical barrier, such as the blood-brain 
barrier; or on finding alternative and acceptable routes for the 
delivery of a new generation of protein-based drugs other than via 
the gastro-intestinal tract, where degradation can occur. 
Nanoscience and nanotechnology are thus the basis of innovative 
delivery techniques that offer great potential benefits to patients 
and new markets to pharmaceutical and drug delivery companies. 
For over 20 years, researchers in Europe have used 
nanoscale technology as the basis of vast improvements in drug 
delivery and targeting, and Europe is now well placed to build on 
this body of knowledge38.
38
European Technology Platform on NanoMedicine. Nanotechnology for 
Health. Vision Paper and Basis for Strategic Research Agenda for 
NanoMedicine. European Commission. September 2005.
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BENEFITS OF DRUG DELIVERY
There is enormous potential for nanotechnology to be 
applied to gene and drug delivery. The vehicle might be a 
functionalized nanoparticle capable of targeting specific diseased 
cells, which contains both therapeutic agents that are released into 
the cell and an on-board sensor that regulates the release. Different 
stages of this approach have already been demonstrated, but the 
combined targeting and controlled release have yet to be 
accomplished. In this event the way will be opened up for initial 
trials, and the eventual approval of such techniques will be fully 
regulated as for any new pharmaceutical. 
A related approach already in use is that of polymer-based 
drug therapies: they include polymeric drugs, polymer–drug 
conjugates, polymer–protein conjugates, polymeric micelles to 
which the drug is covalently bound, and multi-component 
complexes being developed as non-viral vectors for gene therapy. 
Many of these materials are now undergoing clinical trials for a 
variety of disease states39.
Polymeric nanoparticle have advantages over liposomes 
and micelles and the polymer-based drug delivery systemss (DDS) 
have relatively shorter history . It is thus clear that more and better 
results for polymer synthesis nanoparticle formulation and 
characterization and in vitro and in vivo experiments, are needed 
for nanoparticles of biodegradable polymers to be approved for 
clinical trials as a DDS for chemotherapy of cancer and other 
diseases such as cardiovascular restenosis. It is most likely that 
clinical trials of nanoparticles for chemotherapy could be approved 
and would be under intensive investigation if and only if close 
collaborations between oncologists and biomedical engineers have 
39
The Royal Society & The Royal Academy of Engineering (2004), 
Nanoscience and nanotechnologies: opportunities and uncertainties, Bulletin: 
Nanoscience and nanotechnologies. 
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been established. It is probable that nanoparticles of biodegradable 
polymers will become commercially available as a medical device 
in the next 5-10 years40.
HISTORICAL PERSPECTIVE OF DRUG DELIVERY SYSTEMS41
The concept of polymeric DDS was first introduced in the 
early 1960s by Folkman and Long42. In the 1970s, the long-term 
controlled release of contraceptive steroids, narcotic antagonists, 
local anesthetics, antimalarial and anticancer agents were mainly 
investigated to attain potentiation of the pharmacological activities 
and elimination of the inconvenience of repeated injections. 
Thereafter, in the late 1980s, biodegradable polymers were 
investigated intensively for those peptides and proteins to both 
achieve satisfactory efficiency and increase patient compliance. 
Primarilyin vitro studies DDS investigated for various applications. 
Brem et al.43 reported the delivery of nitrosourea carmustine 
(BCNU) from biodegradable polyanhydride disks. The DDS can 
be either biodegradable by using degradable polymers such as 
poly(lactide-co-glycolide) (PLGA),44, , , , 45 46 47 48 fibrin,49 and 
40 Feng S. S. (2004). Nanoparticles of Biodegradable polymers for new-concept 
chemotherapy.  Expert Rev. Medical Devices 1 (1), pp.115-125.
41 Cao, X. (1997). Delivery of Neuroactive Molecules from Biodegradable 
Microsperes. M.A. Sc. Degree thesis. University of Toronto.
42 Juliano, R.L ., (1980).Drag delivery systems: characteristics and biomedical 
applications, Oxford University Press. 
43 Brem, H., Tamargo, R. J., Olivi, A., Pinn, M., Weingart, J. D., Wharam,  M., 
Epstein, J.I. (1994). Biodegradable polymers for controlled delivery of 
chemotherapy with and without radiation therapy in the rnonkey brain, J. 
Neurosurg., 80,283-290. 
44 Okada, H., Doken, Y., Ogawa, Y., Toguchi, H. (1994). Sustained suppression 
of the pituitary-gonadal axis by Leuprorelin three month depot microspheres in 
rats and dogs, Pharmaceutical Res., 11,1199-1103. 
45 Yamakawa, I., Tsushima, T.,  Machida, R., Watanabe, S. (1992). In vitro and 
in vivo release of poly (DL-lactic acid) microspheres containing neurotensin 
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bovine serum albumin; or biostable by using non-biodegradable 
polymers such as poly(ethylene oxide) (PEO) and ethylene-vinyl 
acetate copolymer (EVAc). Injectable and biodegradable 
microspheres appear to be a particularly ideal delivery systems 
because they are small and they degrade, obviating the necessity to 
remove the device after the drug supply is exhausted. 
Microspheres and microcapsules 
Microspheres are fine spherical particles that contain drugs 
that can be divided into two categories: (i) homogeneous or 
monolithic microspheres in which the drug is dissolved or 
dispersed throughout the polymer matrix and (ii) reservoir-type 
microspheres in which the drug is surrounded by the polymer 
matrix in a mononuclear state. Particles belonging to (i) and (ii) are 
referred to as microspheres and microcapsules, respectively. There 
is, however, no clear-cut between these two, because the 
morphological structures are sometimes mixed. For example, in 
some systems, most of the drug core is surrounded by the polymer 
but some drug molecules are dispersed separately or adsorbed on 
the surface of the polymer.  
Types of Copolymers -  Poly (lactide/glycolide). Linear
polyesters of lactide (PLA) and glycolide (PGA) have been used 
analogue prepared by novel oil-in-water solvent evaporation method, J. Pham. 
Sci., 81, 808-811. 
46 Gupta, P.K., Johnson, H., Allexon, C.  (1993). In vitro and in vivo evaluation 
of clarithromycin/poly(1actic acid) microspheres for intramuscular drug 
delivery, J. Controled Release, 26, 229-238. 
47 Arshady, R. (1991). Preparation of biodegradable microspheres and 
microcapsules. 
Polyactides and related polyesters, J. Controlled Release, 17, 1-22. 
48 Arshady, R. (1990). Biodegradable microcapsular drug delivery systems: 
manufacturing methodology, release control and targeting prospects, J. 
Bioactive Compatible Polymers, 5, 315-342. 
49 Ho, HO., Hsiao, CC., Sokoloski, T. D., Chen, CY., Sheu, MT. (1995). Fibrin-
based drug delivery systems, the evaluation of the release of macromolecules 
from microbeads, J. Controlled Release, 34, 65-70. 
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for more than three decades for a variety of medical applications50.
They were among the first synthetic degradable polymers to find 
application as surgical suture materials, controlled drug release 
devices, as well as orthopedic and reconstructive implants51. Low 
molecular weight PLA and PGA are prepared by the direct 
condensation of lactic acid and glycolic acid, respectively, whereas 
poly(lactide-co-gtycolide) (PLGA) is obtained by the condensation 
of both lactic and glycolic acids with or without catalysts. High 
molecular weigh polymers are produced by the ring opening 
method with a catalyst such as dialkyl zinc. Having an asymmetric 
carbon atom, lactic acid has two optical isomers. Therefore, its 
polymer consists of L-, D- and D, L- lactic acid in which the L- or 
D-polymers have a crystalline form and D, L- polymers are 
amorphous and more rapidly degraded. 
Degradation of PLA, PGA, PLGA copolymers has been 
studied extensively both in vitro and in vivo. Degradation can be 
followed by changes in mass, molecular weight, morphology, 
mechanical strength. It has been shown that the degradation of 
PLA, PGA, PLGA is due to the hydrolysis of the ester bonds along 
the backbone of the polymer chains, and the degradation products 
are carboxylic acids and alcohols. 
Once a polymer device is immersed into water, the first 
event that happens is water uptake. This results in the bulk water 
penetration throughout the polymer’s amorphous domains whereas 
crystalline domains remain intact because they are less accessible 
to water. Due to the hydrolysis of the ester bonds along the 
polymer chain, the molecular weight of the degrading polymer 
decreases. As the degradation time increases, some of the degraded 
50 Domb, A. J. (1994). Implantable biodegradable polymers for site-specific 
drug delivery in "polymeric site-specific pharmacotherapy" (A.J. Domb, Ed.), 
John Wiley & Sons Ltd.  
51 Menei, P., Benoit, J. P., Boisdron-Celle, M., Fournier, D., Mercier, P., Guy, 
G. (1994). Drug targeting into the central nervous system by stereotactic 
implantation of biodegradable microspheres, Neurosurgery, 34, 1058-1064.
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polymers are cleaved so small that they eventually become water 
soluble and leach out of the polymer matrix, resulting in the mass 
loss of the degrading device. Random scission of the ester bonds 
also results in a mechanical strength decay. The water 
impermeable domains, however, degrade much more slowly, 
giving rise to a multimodal molecular weight distribution as 
observed by gel permeation chromatography (GPC) for a 
degrading semi-crystalline polymer. 
In general, factors that affect water uptake and hydrolysis 
reaction of the ester bond will affect the degradation of polymers, 
i.e. chemical structures, degree of crystailinity, molecular weight, 
degradation conditions (e.g. pH and temperature) and the size of 
degrading device. 
Furthermore, two phenomena are of critical importance in 
considering the degradation of PLGA. First, degradation causes an 
increase in the number of carboxylic acid chain ends that are 
known to autocatalyse the ester bond hydrolysis. Second, only 
oligomers which are water soluble in the surrounding aqueous 
medium can escape from the matrix. It therefore can be predicted 
that during degradation, soluble oligomers that are close to the 
surface can leach out once they are produced, whereas those which 
are located well inside the matrix may remain entrapped and 
contribute to the autocatalytic effect. The autocatalytic effect, in 
turn, results from the production of the carboxylic acid groups, 
resulting in faster degradation. This ultimately results in a steep 
mass loss observed in the PLGA degradation profile. A subsequent 
sudden release of degradation products in vivo, can render a 
sudden local environment acidic and induce an inflammatory 
reaction or even tissue necrosis. Recum et al. successfully 
employed a blend of different molecular weight PLAs to address 
this problem. 
Biocompatibiliiy
PLA, PGA, PLGA have good biocompatibility and now are 
being used clinically in human therapy, such as sutures and bone 
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fracture devices. Visscher et al. studied the tissue reaction to 
PLGA (50:50) microspheres by injecting the microspheres 
intramuscularly. There was no inflammatory reaction to the 
microspheres after 56 days of injection when microspheres were 
completely absorbed, although a few foreign body cells and the 
encapsulation of microspheres by immature fibrous connective 
tissue were observed in the first several days after injection. It was 
concluded that PLGA (50:50) is a biocompatible material. Another 
experiment was conducted by Menei et al. in an attempt to extend 
the application of degradable PLGA polymers into neurosurgery. 
The brain tissue’s reaction to the injected PLGA (50:50) 
microspheres was investigated. PLGA (50:50) microspheres were 
stereotactically injected into the rat brain. An astrocytic 
proliferation, which is typically found following damage to the 
CNS was observed, and some foreign-body giant cells were also 
found. However the inflammatory and macrophagous reaction 
decreased dramatically after 2 month and almost disappeared after 
2 months when the microspheres were totally degraded. They 
concluded that PLGA (50:50) is a biocompatible material for 
implantation in the brain. 
CHEMICAL SYNTHESES OF BIODEGRADABLE  POLYMERS 52
One of the strategies to solve problems of global 
environmental pollution with fossil resources wasted products is 
thorough recycling of polymeric materials. In such cases it would 
be indispensable to use biodegradable polymers, one way of their 
recycled is by microorganisms without consumption of thermal 
energy.
52 Okada, M. (2002). Chemical syntheses of biodegradable polymers. Progress 
in Polymer Science N 27, p. 87-133.
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Biodegradable polymers are defined as polymers that are 
degraded and catabolized, eventually to carbon dioxide and water, 
by microorganisms (bacteria, fungi, etc.) under natural 
environment. These polymers, when they are degraded, should not 
generate any substances that are harmful to the natural 
environment. Biodegradable polymers are classified into three 
major categories: (1) polyesters produced by microorganisms, (2) 
polysaccharides and other biopolymers, (3) synthetic polymers, 
particularly aliphatic polyesters. Synthetic biodegradable polymers 
have a great advantage, since recent advances in polymer science 
and technology have made it possible to design and synthesize at 
will a great variety of polymers with desirable properties. 
Furthermore, they are adaptable for mass production. As to 
synthetic biodegradable polymers, aliphatic polyesters are the 
representatives. Nowadays, aliphatic polyesters such as 
poly(epsilon caprolactone), poly(L-lactide), poly(butylene 
succinate) are commercially produced, and their output continues 
to increase.
Polyesters from lactides 
Polylactides are widely used for medical purposes  such as 
sutures, fracture fixation, oral implant, and drug delivery 
microspheres. Polylactides including polyglycolide are hydrolyzed 
at a relatively high rate even at room temperature and neutral pH 
without any help of enzymes if moisture is present, are   
hydrolyzed in our body to the respective monomers and oligomers 
that are soluble in aqueous media, and hence they are often called 
bioabsorbeble polymers rather than biodegradable polymers. 
Poly(lactic acid)  (PLA) and its copolymer with glycolic acid 
(PLG) have increasing importance also as materials for the 
preparation of microspheres. The knowledge of their degradation 
process is important to prepare microparticulate delivery systems 
with suitable drug release rates. Giunchedi et al.53 studied the 
53 Giunchedi P, Coni B, Scalia S, Conte U. J. (1998). Controlled Release; 56:53. 
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degradation of a poly(D,L-lactide-co-glycolide) (50:50) (PLGA). 
They showed that the preparation methods play an important role 
in determining the degradation behavior of microspheres: the 
unloaded spray-dried particles were characterized by a higher 
monomer release rate than the microspheres obtained by solvent 
evaporation.
MARKET VIEW OF COMMERCIALLY AVAILABLE 
BIODEGRADABLE POLYMERS 54
The Roadmap Report was made in connection with the 
European project “Development of Advanced Technology 
Roadmaps in Nanomaterial Sciences and Industrial Adaptation to 
Small and Medium sized Enterprizes” (“NanoroadSME”) by 
authorship of René de Groot (Syntens – Stiching Syntens, 
Innovation Network for Entrepreneur, Netherland) and Dr. 
Jonathan Loeffler (Steinbeis-Europa-Zentrum, Germany). The 
project was funded by the European Community under the “Sixth 
Framework” Programme (Contract No MP4-CT-2004-505857). 
In this Roadmap the focus is on the actual State of the Art 
and the future use of  nanomaterials in the Health & Medical 
Systems sector. It will give to small and medium sized enterprises 
(SMEs) a good tool to have a concise description of the 
development in this sector and to make choices for their strategy. 
This roadmap report has the main purpose to help SMEs which are 
in the process of looking for new materials with improved 
properties to be integrated in their new products and to give them a 
first list of relevant nanomaterials they should consider depending 
on the industrial applications foreseen, the time to market and the 
R&D capacity of the company. 
54 Groot, de R., Loeffler, J., Sutter. S., (2006). Roadmap Report Concerning the 
Use of Nanomaterials in the Medical and Health Sector. The Sixth Framework 
Programme of European Community. 
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The results of the roadmap are based on a database with 
information about more than 100 nanomaterials, which was 
developed in the frame of the EC-funded project NanoRoadSME. 
The database and the linked roadmapping tool were structured 
taking into account the results of a European Survey on more than 
300 European SMEs, the results of several R&D surveys and 
industrial SWOT analysis as well as workshops and experts’ 
interviews.  
The report is structured in domains of applications in which 
nanomaterials have the potential to play an important role in the 
future in the Medical&Health sector. 
Presentation of relevant nanomaterials are presented by 
drawing 4 tables, which represent the nanomaterial roadmap for 
the specific domain of application and which give the following 
information: the level of development of the nanomaterials and a 
prognosis of its evolution in the next 15 years; the timeframe of 
possible industrial applications in this domain at short (0-2 years), 
middle (3-5 years) and long term (6-10 years); the nanomaterial 
costs and its possible evolution at short, middle and long term 
(when available); the market size of the nanomaterials (when 
available).
For each relevant nanomaterial, detailed information like a 
short material description, improved properties, 
advantages/disadvantages of the nanomaterial, barriers for the 
development as well as specific applications for each category are 
given.  Finally a list about companies and organisations (if 
available) active in the specific areas is presented. 
In order to have a quick overview of the development stage 
of the different nanomaterials and its evolution, five different 
levels of development were defined: 
1. Scientific result / technology invention ; 
2. Laboratory prototype; 
3. Industrial demonstrator; 
4. Industrialization; 
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5. Market entry (ME) – the final stage in the development 
process. The material is now ready available for the end consumer, 
probably still not everywhere and at a rather higher price. 
These stages of development have different order of 
importance for SMEs depending to their position in the supply 
chain of nanomaterials. Three main categories can be defined: 
developer of nanomaterials; producer of nanomaterials; user of 
nanomaterials. 
Marketing description of poly-lactic-co-glycolic acid 
(PLGA) nanofibers 
Polymer nanofibers, nanocapsules and nanofilms with good 
chemical and mechanical properties, used for tissue engineering 
and drug delivery. 
Description of material properties which have been 
improved: 
The morphology of the electrospun nanofibers can change 
with the spinning conditions, forming droplets when the 
concentration of the polymer solution is low. 
Advantages: biodegradable; biocompatible; flexibility for 
nanofibers and nanofilms, nanostructured PLGA enhances cell 
proliferation and adhesion. 
Disadvantages: high collagen type I proliferation but not 
so high with collagen type II or III; fabrication of PLGA 
complexes is needed in these cases. 
Barriers for the development: 
1. Technology - PLGA based materials should be further 
developed for specific tissues to enhance its properties. 
2. Market - Many other new materials with similar 
applications. 
3. Regulatory - Investigation in different mammals must be 
done before using any products in humans, although many other 
PLGA experiments have already been done. 
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4. Environmental impacts - Effects of small nanoparticles 
entering the human body and accumulating in the cells of the 
respiratory or other organ systems are yet unknown.  
Table 1. Level of development of the PLGA  and a prognosis of its 
evolution in the next 15 years in the drug delivery and tissue 
engineering sectors. 
Short term 
2006-2012
Middle term 
2013
Long term 
2014-2020
poly-lactic-co-
glycolic acid 
(PLGA) 
nanofibers
Market Entry 
Table 2. Possible industrial applications of the PLGA in the drug 
delivery and tissue engineering sectors in dependence of a short (0-
2 years), mid (3-5 years) and long term (5-10 years) view. 
Unspecified 0 -2 years 3 -5 years 6 -10 years 
poly-lactic-
co-glycolic 
acid
(PLGA)
nanofibers 
drug 
delivery 
nanocapsules 
and
nanospheres, 
nanofibers 
scaffold
nanofibers 
hoses 
Table 3. Expected market size and material costs until poly-lactic-
co-glycolic acid (PLGA) nanofibers 2015.
Short term Middle term Long term 
2006 2007 2008 2009 2010 2011 2012 2013 2014 
Market size 
poly-lactic-co-
glycolic acid 
(PLGA) nanofibers 
a250 tons/year a500 tons/year a2500 tons/year 
Material costs 
poly-lactic-co-
glycolic acid 
(PLGA) nanofibers 
a37000 Euro per Kg a33000 Euro per Kg a29000 Euro per Kg 
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NANO- AND MICROPARTICLES AS CONTROLLED DRUG DELIVERY 
SYSTEMS 55
Nano- and micro- particles and microspheres for their 
attractive properties occupy unique position in drug delivery 
technology. Some of the current trends in this area will be 
discussed.
The solvent evaporation process is commonly used to 
encapsulate drugs into poly(lactide-co-glycolide) microparticles 
(PLGA) [56]. It is well known that the candidate drugs must be 
soluble in the organic phase. In the case, where the active 
ingredient is not oil soluble, other alternative can be considered. 
The W/O/W-multiple emulsion method is particularly suitable for 
the encapsulation of highly hydrophilic drugs. For drugs which are 
slightly water soluble, like IdUrd (2mg/ml), other approaches must 
be investigated to achieve significant encapsulation: dissolution of 
the drug in the organic phase through the use of a cosolvent or 
dispersion of drug crystals in the dispersed phase. In the latter case, 
it is often admitted that the suspension of crystals in the organic 
phase can lead to an initial drug release, which is difficult control 
[57, 58]. To reduce IdUrd particle size, two-grinding processes 
55 Ravi Kumar, M. N. V. (2000). Nano and Microparticles as Controlled Drug 
Delivery Devices, J Pharm. Pharmaceut. Sci, 3(2):234-258. 
56 Benoit, J. P., Marchais, H., Rolland, H. and Van de Velde, V. (1996). 
Biodegradable microspheres: advances in production technology. In: Benoit, S. 
(Ed.), Microencapsulation methods and industrial applications, Marcel Dekker, 
New York, pp. 35-72.  
57 Bodmeir, R., Chen, H., Davidson, R. G. W. and Hardee, G. E. (1997). 
Microencapsulation of antimicrobial ceftiofur drugs. Pharm. Dev. Technol., 2: 
323-334. 
58 Shenderova, A., Burke, T. G. and Schwendeman, S. P. (1997). Stabilization of 
10-hydroxycampto- thecin in poly(lactide-co-glycolide) microsphere delivery 
vehicles. Pharm. Res., 14: 1406-1414.  
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were used, spray-drying and planetary ball milling [59, 60, 61].
The optimal conditions of grinding were studied through 
experimental design and the impact on in vitro drug release from 
PLGA microspheres was then examined. More recently, Geze et al 
[62], studied IdUrd loaded poly(D,L-lactide-co-glycolide) (PLGA) 
microspheres with a reduced initial burst in the in vitro release 
profile, by modifying the drug grinding conditions. IdUrd particle 
size reduction has been performed using spray drying or ball 
milling. Spray drying significantly reduced drug particle size with 
a change of the initial crystalline form to an amorphous one and 
lead to a high initial burst. Conversely, ball milling did not affect 
the initial Id Urd crystallinity. Therefore, the grinding process was 
optimized to emphasize the initial burst reduction. The first step 
was to set qualitative parameters such as ball number, and cooling 
with liquid nitrogen to obtain a mean size reduction and a narrow 
distribution. In the second step, three parameters including milling 
speed, drug amount and time were studied by a response surface 
analysis. The interrelationship between drug amount and milling 
speed was the most significant factor. To reduce particle size, 
moderate speed associated with a sufficient amount of drug (400-
500 mg) was used. IdUrd release from microparticles prepared by 
the O/W emulsion/extraction solvent evaporation process with the 
lowest crystalline particle size (15.3 Pm) was studied to overcome 
59 Gubskaya, A. V., Lihnyak, Y. V. and Blagoy, Y. P. (1995). Effect of 
cryogrinding on physico-chemical properties of drugs.I. Theophylline: 
evaluation of particle sizes and the degree of crystallinity, relation to dissolution 
parameters. Drug Dev. Ind. Pharm., 21: 1953-1964.  
60 Annapragada, A. and Adjei, A., (1996). Numerical simulation of milling 
processes as an aid to process design. Int. J. Pharm., 136: 1-11.  
61 Villiers, V. M. and Tiedt, L. R. (1996). An analysis of fine grinding and 
aggregation of poorly soluble drug powders in a vibrating mill. Pharmazie, 51: 
564-567.  
62 Geze, A., Verier-Julienne, M. C., et al. (1999). Development of 5-iodo-2'-
deoxyuridine milling process to reduce initial burst release from PLGA 
microparticles. Int. J. Pharm., 178: 257-268.  
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burst effect. In the first phase of drug release, the burst was 8.7% 
for 15.3 mm compared to 19% for 19.5 Pm milled drug particles 
(Geze et al). 
In the other procedure, Rojas et al.63 optimized the 
encapsulation of E-lactoglobulin (BLG) within PLGA 
microcaparticles prepared by the multiple emulsion solvent 
evaporation method. The role of the pH of the external phase and 
the introduction of the surfactant Tween 20, in the modulation of 
the entrapment and release of BLG from microparticles, was 
studied. Better encapsulation of BLG was noticed on decreasing 
the pH of external phase to a value close to the PI of BLG, 
however, a larger burst release effect. In contrast, the addition of 
Tween 20 increased the encapsulation efficiency of BLG and 
considerably reduces in the burst release effect. In addition, Tween 
20 reduced the number of aqueous channels between the internal 
aqueous droplets as well as those communicating with the external 
medium. Inventors claimed that these results constitute a step 
ahead in the improvement of an existing technology in controlling 
protein encapsulation and delivery from microspheres prepared by 
the multiple solvent evaporation method (Rojas et al). 
Blanco-Prieto et al.64 studied the in vitro release kinetics of 
peptides from PLGA microspheres, optimizing the test conditions 
for a given formulation, which is customary to determine in 
vitro/in vivo correlation. The somatostatin analogue vapreotide 
pamoate, an octapeptide, was microencapsulated into PLGA 50:50 
by spray drying. The solubility of this peptide and its in vitro 
release kinetics from the microspheres were studied in various test 
media. The solubility of vapreotide pamoate was approximately 
63 Rojas, J., Pinto-Alphandary, H., et al, Optimization of the encapsulation and 
release of E-lactoglobulin entrapped poly(D,L-lactide-co-glycolide) 
microspheres. Int. J. Pharm., 183: 67-71, 1999.  
64 Blanco-Prieto, M. J., Bewsseghir, K., et al. (1999). Importance of the test 
medium for the release kinetics of a somatostatin analogue from poly(D,L-
lactide-co-glycolide) microspheres. Int. J. Pharm., 184: 243. 
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20-40 Pg/ml in 67 mM phosphate buffer saline (PBS) at pH 7.4, 
but increased to 500-1000 Pg/ml at a pH of 3.5. At low pH, the 
solubility increased with the buffer concentration (1-66 mM). Very 
importantly, proteins (aqueous bovine serum albumin (BSA) 
solution or human serum) appeared to solubilize the peptide 
pamoate, resulting in solubilities ranging from 900 to 6100 Pg/ml. 
The release rate was also greatly affected by the medium 
composition. The other results are, m PBS of pH 7.4 only 33+1% 
of the peptide was released within 4 days, whereas, 53+2 and 
61+0.95 were released in 1% BSA solution and serum 
respectively. The type of medium was found critical for the 
estimation of the in vivo release. From their investigations, it was 
concluded that the in vivo release kinetics of vapreotide pamoate 
form PLGA microspheres following administration to rats were 
qualitatively in good agreement with those obtained in vitro using 
serum as release medium and sterilization by J-irradiation had only 
a minor effect on the in vivo pharmacokinetics (Blanco-Prieto et 
al).
In a recent study from England, methods used to 
microencapsulate human serum albumin (HSA) in a biodegradable 
polymer were compared for their effects on the physicochemical 
characteristics of HSA-loaded microparticles and on the release 
and integrity of encapsulated HSA. Postemulsification spray-
drying enables efficient preparation of high-quality PLGA 
microparticles for protein drug delivery 65.
"The polymer used was poly(D,L-lactide-co-glycolide) 
(75:25) (PLGA) (Boehringer Ingelheim, Resomer RG 752, MW 
20,900)," noted M.E. Lane et al. at the University of London. 
"Microparticles were formulated by (i) w/o/w emulsification and 
65 Lane, M.E. et al. (2006). Influence of postemulsification drying processes on 
the microencapsulation of Human Serum Albumin. International Journal of 
Pharmaceutics; 307(1):16-22.
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freeze-drying (EFD) or (ii) w/o/w emulsification and spray-drying 
(ESD)."
In the Department of Chemical and Biomolecular 
Engineering, National University of Singapore, was conducted 
other study: Fabrication of  controlled release devices using 
supercritical antisolvent method66. Supercritical antisolvent with 
enhanced mass transfer (SASEM) method is used to process 
biodegradable and biocompatible polymer PLGA (poly DL lactic 
co glycolic acid) in an attempt to fabricate micro or nano sized 
particles for encapsulation of drugs for purposes of controlled 
release. In this process, an ultrasonic vibrating surface provides the 
liquid atomization in the supercritical fluid medium. The ultrasonic 
vibration also creates turbulence in the supercritical phase and 
enhances the mixing and mass transfer between the organic solvent 
and supercritical antisolvent. The setup has been designed for 
visualization of the liquid atomization and antisolvent process in 
the high pressure vessel. PLGA particles obtained from this 
process are further analyzed using SEM (Scanning Electron 
Microscopy). Experiments were also carried out to study the 
droplet size distribution from ultrasonic liquid atomization using a 
Phase Doppler Particle Analyzer (PDPA). 
DRUG DELIVERY TO THE CNS
Due to poor transport across the BBB, when administered 
by an implantable drug delivery system (DDS) can be delivered 
directly to the CNS. Moreover, the DDS maintained the drug 
dosage within a desired therapeutic range for a pre-determined 
time via a controlled release mechanism. The treatment of 
infiltrating brain tumors, particularly oligodendrogliomas, requires 
66 Lee, L. Y., Smith, K. A., Wang, C. H., (2005). Fabrication of  controlled 
release devices using supercritical antisolvent method.  
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radiotherapy, which provides a median survival of 3.5-11 years67.
Since 5-iodo-21-deoxyuridine (IdUrd) is a powerful radio 
sensitizer68, the intracarnial implantation of IdUrd loaded 
microparticles within the tumor might increase the lethal effects of 
J-radiations of malignant cells having incorporated IdUrd. The 
particles can be administered by stereotactic injection, a precise 
surgical injection technique69. This approach requires 
microparticles of 40-50 Pm in size releasing in vivo their content 
over 6 weeks, the standard period during which a radiotherapy 
course must be applied. 
IN VITRO STUDY AT C6 GLIOMA CELLS OF ANTICANCER DRUG 
DOXORUBICIN IN PLGA-BASED MICROPARTICLES70
Doxorubicin (DOX), also known as adriamycin, is an 
anthracycline drug commonly used in cancer chemotherapy. 
Unfortunately, its therapeutic potential has been restricted by its 
dose limited cardiotoxicity and the resistance developed by the 
tumor cells to the molecule after some time of treatment. Like 
many other drugs used to treat cancer, DOX is a potent vesicant 
that may cause extravasations and necrosis at the injection site or 
any site that the skin is exposed to. One way to overcome these 
problems is to encapsulate the drug in poly (D,L-lactide-co-
67 Daumas-Duport, C., Tucker, M. L., Kolles, J. H., Cervera, P., Beuvon, F. and 
Varlet, P., Oligodendrogliomas. Part II: a new grading system based on 
morphological and imaging criteria. J. Neuro-Oncol., 34: 61-78, 1997.  
68 Djordjevic, B. and Snuybalski, K. (1960). Genetics of human cell lines. 
Incorporation of 5-bromo and 5-iodo-deoxyuridine into the deoxyribonucleic 
acid on human cells and its effect on radiation sensitivity.  J. Exp. Med., 112: 
509-531.  
69 Menei, P., Benoit, J. P., Biosdron-celle, M., Fournier, D., Mercies, P., Guy, G. 
(1994). Drug targeting into the central nervous system by stereotactic 
implantation of biodegradable microspheres. Neurosurgery, 34: 1058-1064. 
70 Lin, R. Ng, LS., Wang, CH., (2005). In vitro study of anticancer drug 
doxorubicin in PLGA-based microparticles. Biomaterials 26, 4476-4485.
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glycolide) (PLGA) microparticles. This paper investigates the 
release characteristics of DOX from polymeric carriers fabricated 
using the spray-drying technique. Finally, a cytotoxicity test was 
performed using Glioma C6 cancer cells to investigate the 
cytotoxicity of DOX delivered from PLGA microparticles.  
PLGAs have different properties according to the variation 
of lactide and glycolide ratio. Accordingly, an increase in the 
lactide/glycolide ratio makes the polymer more hydrophobic thus 
reducing degradation rate. This can be verified by the release curve 
where the initial burst and release rate decreased by approximately 
10% when the lactide/glycolide ratio was increased. Despite the 
slight improvement in the initial burst and release rate, 70% of the 
drug was released within the first day. 
Particle size also affects the initial burst of the drug. When 
particle size increases, the initial burst reduces. This is because a 
smaller particle size has a larger volume-to-surface area. Hence, 
during particles formation, the low solubility of DOX in EA 
resulted in the easy exclusion of the drug from the polymer matrix, 
which resulted in drug accumulation on the particle surface.  
Hence, for a smaller particle, more drug accumulates on a 
smaller surface area hence resulting in a greater initial burst. The 
biconcave morphology was observed to accelerate the drug release. 
The morphology change can certainly affect the surface 
area/volume ratio. Presumably, an increase of this ratio results in 
the observed acceleration of drug release rate. 
CONCLUSIONS
In the study performed in Singapore National University, 
nano/micro-particulate drug delivery devices were developed for 
DOX using spray drying. These devices were fabricated using 
various polymers, namely, PLGA, pluronic and PLLA in the form 
of polymer blends and composite nano/microparticles. The 
polymers were used in different combination with the aim of 
obtaining a device with improved drug release characteristics and 
enhanced cytotoxicity against cancer cells. 
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It has been found that the cytotoxicity of DOX to Glioma 
C6 cancer cells is enhanced when DOX is delivered from PLGA 
polymeric carrier. The use of a biodegradable polymer matrix, 
whith encapsulated DOX, reduces the toxic effects against normal 
cells whilst increasing its therapeutic activity. 
RESULTS OF PHASE II CLINICAL TRIALS WITH USE OF 
IMPLANTABLE 5-FU-BIO-MICROPARTICLES 71, ,72 73
The group of French scientist (Faisant, N., Benoit, J. P., 
Menei, P.) received patent in May, 2006. Title is: “Use of 
Biodegradable Microspheres That Release an Anticancer Agent for 
Treating Gliobastoma”. United States Patent No 7,041,241. United 
States Patent and Trade Mark Office. This is successful 
achievement after conducting of series of experiments during more 
then decade.  
The present invention relates to the use of biodegradable 
microspheres that release a radiosensitizing anticancer agent for 
producing a medicament to be used simultaneously with, 
separately from or spread over time with a radiotherapy, for 
treating glioblastoma. The use of said biodegradable microspheres 
according to the invention results in a patient survival time of at 
71 Menei, P., Venier, M. C., Gamelin, E., Saint-André, J. P., Hayek, G.,  Jadaud, 
E.,  Fournier, D., Mercier, P., Guy, G., Benoit, J. P. (2000). Local and sustained 
delivery of 5-fluorouracil from biodegradable microspheres for the 
radiosensitization of glioblastoma. A pilot study. Cancer V. 86, 2 , P. 325 – 330.
72 Menei, P., Jadaud, E., Faisant, N., Boisdron-Celle, M., Michalak, S., Fournier, 
D.,  Delhaye, M., Benoit, J. P., (2003). Stereotaxic implantation of 5-
fluorouracil-releasing microspheres in malignant glioma. A Phase I study. 
Cancer, V. 100, 2 , P. 405 – 410.
73 Menei, P., Capelle, L., Guyotat, J., Fuentes, S., Assaker, R., Bataille, B.,  
Francois, P., Dorwling-Carter, D. Paquis, P., Bauchet, L., Parker, F., Sabatier, J., 
Faisant, N., Benoit, J. P. (2005). Local and Sustained Delivery of 5-Fluorouracil 
from Biodegradable Microspheres for the Radiosensitization of Malignant 
Glioma: A Randomized Phase II Trial. Neurosurgery. 56(2):242-248.
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least 90 weeks, a therapeutically effective concentration being 
maintained in the parenchymatous area throughout this time. The 
microspheres used preferably contain 5-fluorouracil of the tumor, 
by intratissular injection. The radiotherapy targeting the tumorous 
mass is dosed at 60 Gy over approximately 6 weeks. The invention 
also relates to a method for producing the biodegradable 
microspheres by emulsion-extraction, and to a suspension 
containing the biodegradable microspheres obtained using this 
method (Boisdron-Celle, M., Menei, P., Benoit, J. P. (1995). 
"Preparation and Characterization of 5-Fluorouracil-loaded 
Microparticles as Biodegradable Anticancer Drug Carriers," J. 
Pharm. Pharmacol., 47:108-114.).  
The polymer is preferably poly(D,L-lactic acid-co-glycolic 
acid), or PLGA, which is a biodegradable polymer permitted in the 
formulation of sustained-release galenic preparations. The 
poly(D,L-lactic acid-co-glycolic acid) is preferably 50:50 PLGA 
(i.e. containing an equal amount of lactic acid and of glycolic 
acid).
This study was a phase I/II open pilot clinical trial 
comparing the effect of perioperative implantation of 5-
fluorouracil-releasing microspheres followed by radiotherapy  in 
patients with gross total resection of high-grade glioma.  
RESULTS
The preliminary results regarding survival could not be 
interpreted statistically due to the small number of patients. They 
were, however, very encouraging. At the final assessment, in the 
first group treated (70 mg), the three patients died at 61, 114 and 
125 weeks. It should be noted that the patient who died at 114 
weeks died of pulmonary metastases of the glioblastoma. In the 
second group treated (132 mg), three patients died at 31, 59 and 82 
weeks and two were still in remission at 159 and 172 weeks, at the 
date of drafting of these preliminary results. 
The survival median for the patients is 98 weeks (it is 50.6 
weeks in the literature for patients satisfying the same criteria 
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(Devaux et al, 1993)74. Five out of eight patients, i.e. 62%, were 
alive at 18 months, whereas, in the literature, for patients satisfying 
the inclusion criteria of this study, the survival at 18 months is 
20% (Devaux et al, 1993).
CONCLUSIONS
1. Nanotechnology provides wide opportunities to modify basic 
chemotherapeutic drugs, some of them are under investigation at 
different stages of pre-clinical and clinical trials.  
2. The thorough survey of the appropriate literature revealed, that 
recently has been finished  2nd phase clinical trials in 
neurooncology with the use of 5-FU embedded in PLGA  
microsperes and entering 3rd phase of clinical trials. Scientist from 
France received patent in May 2006 by USPTMO (United States 
Patent and Trade Mark Office).  
GUIDELINES FOR NEURO-ONCOLOGY - STANDARDS FOR 
INVESTIGATIONAL STUDIES - REPORTING OF CLINICAL TRIALS
Most comprehensive and upgrade guidelines for conduction 
of 1 and 2 phase clinical trials in neuro-oncology are presented by 
Chang S. et al (2005)75. Authors present guidelines to standardize 
the reporting of phase 1 and phase 2 neuro-oncology trials. The 
guidelines are also intended to assist with accurate interpretation of 
results from these trials, to facilitate the peer-review process, and 
to expedite the publication of important and accurate manuscripts. 
Our guidelines are summarized in a checklist format that can be 
used as a framework from which to construct a phase 1 or 2 
clinical trial. Development of new treatments in oncology is made 
possible by the design, conduct, and reporting of  prospective 
74
Devaux, B. C., O'Fallon, J. R., Kelly, P. J. (1993). Resection, biopsy and survival in 
malignant glial neoplasms, J. Neurosurg, 78: 767 -775. 
75 Chang, S. M., Reynolds, S. L., Butowski, N., Lamborn, K.R., Buckner, J. C., Kaplan, 
R. S. and Bigner D.D., (2005): GNOSIS: Guidelines for neuro-oncology: Standards for 
investigational studies - reporting of phase 1 and phase 2 clinical trials. J. Neuro-
Oncology, N 7, pp. 425–434.
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clinical trials. The phase 3 randomized,  controlled clinical trial is 
considered to be the “gold  standard” of clinical research, 
providing the most reliable method for comparing standard with 
experimental therapies. However, most clinical reports in the 
neurooncology literature are of phase 1 and phase 2 trials, which 
are required for testing the safety and efficacy of a proposed drug 
before the initiation of a phase 3 study. Incomplete, unclear, or 
inaccurate design, interpretation,  and reporting of the results from 
these vital early phase  trials can hamper timely drug development 
and lead to erroneous conclusions as to efficacy (Mariani and 
Marubini, 200076). Recently, there has been a trend in the scientific 
community toward the creation of guidelines for increasing the 
transparency of clinical study results. Some examples of these 
guidelines include the STARD, or Standards for Reporting of 
Diagnostic Accuracy, statement for reporting studies of diagnostic 
accuracy (Bossuyt et al. 200377), the TREND, or Transparent 
Reporting of Evaluations with Nonrandomized Designs, statement 
for reporting nonrandomized public health interventions (Des 
Jarlais et al., 200478), and most familiar, the CONSORT, or 
Consolidated Standards of Reporting Trials, statement  for the 
reporting of randomized, controlled clinical trials (Altman et al., 
200179). The CONSORT statement has particular relevance to 
neuro-oncology. However, as it deals exclusively with phase 3 
76 Mariani, L., and Marubini, E. (2000) Content and quality of currently published phase 
II cancer trials. J. Clin. Oncol. 18, 429–436. 
77 Bossuyt, P.M., Reitsma, J.B., Bruns, D.E., Gatsonis, C.A., Glasziou, P.P., Irwig, L.M., 
Moher, D., Rennie, D., de Vet, H.C., and Lijmer, J.G. (2003). The STARD statement for 
reporting studies of diagnostic accuracy: Explanation and elaboration. Clin. Chem. 49, 7–
18.
78 Des Jarlais, D.C., Lyles, C., and Crepaz, N. (2004). Improving the reporting quality of 
nonrandomized evaluations of behavioral and public health interventions: The TREND 
statement. Am. J. Public Health 94, 361–366. 
79 Altman, D.G., Schulz, K.F., Moher, D., Egger, M., Davidoff, F., Elbourne, D., 
Gotzsche, P.C., and Lang, T. (2001) The revised CONSORT statement for reporting 
randomized trials: Explanation and elaboration. Ann. Intern. Med. 134, 663–694. 
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trials, it does not address many important issues that arise in the 
reporting of phase 1 and phase 2 neuro-oncology trials.
CONSORT, or Consolidated Standards of Reporting Trials, 
statement is an important research tool that takes an evidence-
based approach to improve the quality of reports of randomized 
controlled clinical trials. Its critical value to researchers, health 
care providers, peer reviewers, and journal editors, and health 
policy makers is the guarantee of integrity in the reported results of 
research. CONSORT comprises a checklist and flow diagram to 
help improve the quality of reports of randomized controlled trials. 
It offers a standard way for researchers to report trials. The intent 
is to make the experimental process more clear, flawed or not, so 
that users of the data can more appropriately evaluate its validity 
for their purposes. 
CONSORT: Checklist of items to include when reporting a 
randomized trial (RCT)
PAPER SECTION 
And topic
ITEM DESCRIPTION
TITLE & 
ABSTRACT 1
How participants were allocated to interventions (e.g., 
"random allocation", "randomized", or "randomly 
assigned").
INTRODUCTION
Background 2
Scientific background and explanation of rationale. 
METHODS
Participants 3
Eligibility criteria for participants and the settings and 
locations where the data were collected. 
Interventions 4
Precise details of the interventions intended for each group 
and how and when they were actually administered. 
Objectives 5 Specific objectives and hypotheses. 
Outcomes 6
Clearly defined primary and secondary outcome measures 
and, when applicable, any methods used to enhance the 
quality of measurements (e.g., multiple observations, 
training of assessors). 
Sample size 7
How sample size was determined and, when applicable, 
explanation of any interim analyses and stopping rules. 
Randomization
--Sequence
generation
8
Method used to generate the random allocation sequence, 
including details of any restrictions (e.g., blocking, 
stratification) 
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Randomization
--
Allocation 
concealment 
9
Method used to implement the random allocation sequence 
(e.g., numbered containers or central telephone), clarifying 
whether the sequence was concealed until interventions 
were assigned. 
Randomization
implementation
10
Who generated the allocation sequence, who enrolled 
participants, and who assigned participants to their groups. 
Blinding
(masking)
11
Whether or not participants, those administering the 
interventions, and those assessing the outcomes were 
blinded to group assignment. When relevant, how the 
success of blinding was evaluated. 
Statistical 
methods
12
Statistical methods used to compare groups for primary 
outcome(s); Methods for additional analyses, such as 
subgroup analyses and adjusted analyses. 
RESULTS 
Participant flow 13
Flow of participants through each stage (a diagram is 
strongly recommended). Specifically, for each group report 
the numbers of participants randomly assigned, receiving 
intended treatment, completing the study protocol, and 
analyzed for the primary outcome. Describe protocol 
deviations from study as planned, together with reasons. 
Recruitment 14 Dates defining the periods of recruitment and follow-up. 
Baseline data 15
Baseline demographic and clinical characteristics of each 
group.
Numbers
analyzed 
16
Number of participants (denominator) in each group 
included in each analysis and whether the analysis was by 
"intention-to-treat".   State the results in absolute numbers 
when feasible (e.g., 10/20, not 50%). 
Outcomes and 
estimation 
17
For each primary and secondary outcome, a summary of 
results for each group, and the estimated effect size and its 
precision (e.g., 95% confidence interval). 
Ancillary 
analyses 
18
Address multiplicity by reporting any other analyses 
performed, including subgroup analyses and adjusted 
analyses, indicating those pre-specified and those 
exploratory. 
Adverse events 19
All important adverse events or side effects in each 
intervention group. 
DISCUSSION 
Interpretation 20
Interpretation of the results, taking into account study 
hypotheses, sources of potential bias or imprecision and 
the dangers associated with multiplicity of analyses and 
outcomes.
Generalizability 21 Generalizability (external validity) of the trial findings. 
Overall evidence 22
General interpretation of the results in the context of 
current evidence. 
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Publish your work 
Have you written a book related to Nanotechnology? Or you intend to write one! Does your book 
cover the different areas of nanotechnology? Does your book have unique and marketable inputs? 
If so, you should consider publishing your book with NSTC, focused on helping you to publish 
your nanotechnology work.
NSTC has designed each of its publishing, distribution, marketing, editorial, and book design 
services to support your sales and marketing efforts for any nanotechnology and its applications 
related book. 
Introduction 
NSTC is a non-governmental, industry managed and promoted organization with a role of 
facilitator for Nano Developmental processes. NSTC by objective associates companies, 
universities, research institutions and work closely for enhancing the opportunities in the area of 
Nanotechnology and emerging new applications for the benefit of human race. 
Nanoscience and nanotechnology comprise one of the fastest-growing research and development 
areas in the world. NSTC works to create an environment conducive for the growth, promotion and 
partnering in the field of Nano science and Technology taking together industries, academics and 
governments through consultative, advisory and educative processes which will provide a growth 
platform for organizations/ Institutions and researchers for harnessing the Nano potential at Global 
level.
We are performing many important activities like “NanoTrends” Journal, NSTC Newsletter and 
“Nano Technology Sensitization Program” for the promotion of nanotechnology.  
We want to encourage the authors who are writing new books on nanotechnology and its 
applications.  
Each book published at NSTC is a special project. Publishing a book is a personal experience and 
should be an enjoyable one. Whether it is a record of your life's work or lecture notes from a 
course, it is important to you and therefore important to us. NSTC is committed to publish high-
quality books of nanotechnology and its applications so that our members and the students & 
scientific community can be benefited with this at affordable prices.
NSTC Goals related to Publications  
1.  To make relevant research results accessible to a broad audience by publishing high-
quality books that explain or apply the results to nanotechnology areas addressed in 
industry and scientific areas consistent with NSTC's membership. This includes the 
publication of books that promote the interdisciplinary interaction between 
nanotechnology and other disciplines such as engineering and science, as well as the 
publication of works in disciplines where nanotechnology is just beginning to develop.  
2. To reach beyond our core membership and encompass the interests of potential 
members such as big corporate / institutions, academicians, scientists working in 
nanotechnology area or related disciplines of nanotechnology such as physics, 
chemistry, biotechnology, materials science etc..  
3. To provide for broad dissemination and exhibition of new ideas in nanotechnology area. 
4. To provide quality publications at prices affordable to individuals. 
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Why Publish with NSTC?
The main reason to choose NSTC as your publisher is the reputation of our association and other 
programs which we are running for the development of nanotechnology. NSTC intends to publish 
quality books related to nanotechnology with practical implementations. Here are some of the other 
advantages to publishing with NSTC:  
Worldwide Distribution and Aggressive Marketing: Because we are an association provides 
consultancy, R&D to corporate and institutions which are our members, publishes books, journals, 
and newsletters, provide academic programs, and we also arrange seminars & conferences on 
Nanoscience and Nanotechnology. So we have many opportunities to market your book to our 
members, students as well as book buyers and NSTC seminars & conference attendees. We also 
use outside publications and mailing lists and have cooperative arrangements for marketing our 
products to other societies around the world.  
Focused Platform: We at NSTC are only focused with Nano sciences, Nanotechnology and its 
applications , so no other publisher or organization can compare with us in terms of focus towards 
the relation towards product and the relevancy with our cause for promoting it.  
Pricing: The books are priced for individuals. We have our members and individuals related to 
nanotechnology and related scientific & engineering communities as our most important asset, and 
we want our publications to be affordable for them.  
Shelf Life: The NSTC book program is a service to our members and the books are available 
whenever they are needed. All books, with the exception of proceedings, remain in print until 
replaced by an updated version.  
Quality Control: Many publishers place the burden of proofreading on the author. Although we 
request that our authors proofread carefully, we also proof read all manuscripts except those for 
proceedings (which come to NSTC in camera-ready form). We have full-time copy editors in 
house who are familiar with nanotechnology and its applications.  
Support of the Profession: When a book is purchased from a consortium like us, the revenue is 
used to foster new programs and products for consortium members. Same we are doing for the 
development of Nanotechnology community.  
Flexibility: Our staff works with authors and editors to accommodate special needs such as 
modified typesetting systems and unusual formatting.  
Distribution: All books are shipped directly from the NSTC office. This means that fulfillment of 
orders takes place within 48 hours of receipt. The orders do not have to be sent to another location 
to be filled.
Special Assistance: Because we intend to publish a modest number of books each year, each 
volume receives the special attention that is often not possible in a large corporation that publishes 
several hundred books each year. Our publications staff is always available to answer questions 
and provide specific guidelines.  
Rapid Publication: Because we work with authors from an early stage, we are often able to 
publish books in a relatively short period of time.  
Author Royalty: Authors are offered a royalty that is competitive with other publishers. In 
addition, authors receive complimentary copies for personal and promotional use. 
If you are serious about marketing your book and about its success and sales, don't wait! Simply 
mail us at info@nstc.in.
